# UNITED STATES OF AMERICA

# CENTERS FOR DISEASE CONTROL

+ + + + +

# NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

+ + + + +

# ADVISORY BOARD ON RADIATION AND WORKER HEALTH

+ + + + +

77th MEETING

+ + + + +

WEDNESDAY MAY 25, 2011

+ + + + +

The meeting convened at 8:30 a.m., Central Daylight Time, in the Crowne Plaza St. Louis-Downtown, 200 North Fourth Street, St. Louis, MO, James M. Melius, Chairman, presiding.

### PRESENT:

JAMES M. MELIUS, Chairman
HENRY ANDERSON, Member
JOSIE BEACH, Member
BRADLEY P. CLAWSON, Member\*
R. WILLIAM FIELD, Member
MARK GRIFFON, Member
RICHARD LEMEN, Member
JAMES E. LOCKEY
WANDA I. MUNN, Member

# PRESENT (continued):

ROBERT W. PRESLEY, Member GENEVIEVE S. ROESSLER, Member PHILLIP SCHOFIELD, Member PAUL L. ZIEMER, Member\* TED KATZ, Designated Federal Official

# REGISTERED AND/OR PUBLIC COMMENT PARTICIPANTS:

ADAMS, NANCY, NIOSH Contractor AL-NABULSI, ISAF, DOE ANDERSON, LOIS\* BURGOS, ZAIDA, NIOSH DAVIES, LOIS\* ELLISON, CHRIS, DCAS FESTER, THOMAS\* FITZGERALD, JOSEPH, SC&A FOULDES, TOM\* FUORTES, LARS GLOVER, SAM, DCAS HINNEFELD, STU, DCAS JOHNSON, MARY\* KINMAN, JOSH, DCAS KOTSCH, JEFF, DOL LEITON, RACHEL, DOE LEWIS, GREG, DOE LIN, JENNY, HHS MAKHIJANI, ARJUN, SC&A McFEE, MATT, ORAU Team NETON, JIM, DCAS RABINOWITZ, RANDY RAFKY, MICHAEL, HHS ROLFES, MARK, DCAS RUTHERFORD, LAVON, DCAS STEINBERG, GARY, DOL STIVER, JOHN, SC&A TAULBEE, TIM, DCAS TRIPLETT, TINA VALERO, OSCAR\* WADE, LEW, NIOSH Contractor WEST, TONY ZINK, BRIAN

<sup>\*</sup>Participating via telephone

1	P-R-O-C-E-E-D-I-N-G-S
2	8:29 a.m.
3	CHAIRMAN MELIUS: Good morning
4	everybody, we'll get started this morning.
5	And we'll start with the usual, general work
6	from Ted here, announcements and so forth.
7	MR. KATZ: Right. Good morning
8	and welcome everybody on the line and in the
9	room, Advisory Board on Radiation and Worker
10	Health. This is the 77th meeting, Day 2.
11	The first announcement to make, I
12	think everyone in the room probably knows, but
13	for people on the line, we have a schedule
14	change today. We, if you see the Agenda, if
15	you don't have the Agenda, it's on the web, on
16	the NIOSH webpage under the Board and under
17	the Meeting Section.
18	We had scheduled for Savannah
19	River Site to be the first item on the Agenda
20	at 8:30, but we've moved that to accommodate a
21	Board Member who's coming in a little late
22	this morning, to 11:00 a.m.

1	And I believe we've gotten a hold
2	of the petitioners on this. So, Savannah
3	River will be 11:00 a.m., and in its place
4	this morning we have a work session from 8:30
5	to 9:30.
6	Let me also note, again, for
7	people on the line, all of the presentations

- 8 should be, for this meeting, should be on the
- 9 web at this point. And they're also at that
- 10 same Board, the Board's section of the DCAS
- 11 web page, under Meetings.
- 12 Last thing, just to note, for
- people on the line again, is please mute your
- 14 phone while you're listening. If you don't
- 15 have a mute button, use \*6.
- 16 And then if you were to address
- 17 the group, you would press \*6 again, to come
- 18 off of mute. There is a public session today,
- 19 it's at 5:30 this evening. And that covers
- 20 the items for the meeting, thanks.
- 21 CHAIRMAN MELIUS: Do you want us
- 22 to check on Board Members --

1	MR.	KATZ:	Yes,	roll	call	for

- 2 Board Members. We have Members in the room I
- 3 can see, but a number of Members are in other
- 4 places. Let me just check and have you speak
- 5 up. Dr. Ziemer, others who might be on the
- 6 line?
- 7 MEMBER ZIEMER: Paul Ziemer is
- 8 here.
- 9 MR. KATZ: Any other Board Members
- 10 on the line?
- 11 (No response.)
- MR. KATZ: Very good.
- 13 CHAIRMAN MELIUS: And we are
- 14 expecting Mark Griffon to be arriving a little
- 15 bit later. He emailed me at 5:00 a.m. to get
- some information about the meeting. I didn't
- 17 answer.
- 18 (Laughter.)
- 19 CHAIRMAN MELIUS: At least, not at
- 20 5:00 a.m. What I thought we'd do this
- 21 morning, up until time for the Sandia
- 22 presentation, is we would go through our Work

- 1 Group reports and Subcommittee reports, at
- least, I think we can get most of them done.
- 3 We do have a few Chairs that are missing so
- 4 we'll have to skip over those.
- 5 And I think the first one is, on
- 6 my list, is Brookhaven.
- 7 MEMBER BEACH: At this time
- 8 there's no change from my last update, other
- 9 than I believe that I reported at the big
- 10 teleconference.
- 11 There is a Work Group meeting
- 12 scheduled, half a day on July 7, for
- 13 Brookhaven.
- 14 CHAIRMAN MELIUS: Okay. Fernald
- we've heard from. Hanford, we talked a little
- 16 bit about, during the public comment period
- 17 yesterday, and we will hear a little bit later
- 18 this afternoon, about the NIOSH Evaluation of
- 19 the most recent petition from Hanford.
- 20 Meanwhile, we've been working,
- 21 SC&A has been working, there's been a number
- of changes in that, so we've sort of regrouped

1	and	identifying	sort	of	key	issues	going
---	-----	-------------	------	----	-----	--------	-------

- 2 forward on that. We'll have to then figure
- 3 out how to handle the new petition also, at
- 4 some point, depending on how we handle that.
- I know, Arjun, do you want to say
- 6 a few words about this?
- 7 DR. MAKHIJANI: Thank you, Dr.
- 8 Melius. Our direction from the Work Group has
- 9 been to review the updated Site Profile from
- 10 2010, of NIOSH from the remaining SEC period,
- 11 because that's where the dose reconstruction
- 12 method is defined.
- So I've gone over the matrix for
- 14 the issues that still need to be resolved and
- 15 I'm preparing a report.
- We've completed the evaluation of
- 17 the completeness and adequacy of the data for
- 18 various radionuclides. And so the report is
- 19 rather long. And, as I mentioned yesterday,
- 20 we've done the interviews for Building 324,
- and are evaluating that for the SEC period.
- 22 CHAIRMAN MELIUS: Good. And so we

_		-				
1	พดเมได	be.	expecting	vour	report.	

- DR. MAKHIJANI: In early June,
- 3 maybe at the end of the first --
- 4 CHAIRMAN MELIUS: Okay.
- DR. MAKHIJANI: In the first ten
- 6 days of June we will send the report for the
- 7 DOE for review. And maybe a Work Group
- 8 meeting in July.
- 9 CHAIRMAN MELIUS: So, Members of
- 10 that Work Group, if you take note and we will
- 11 circulate some dates and set up a meeting
- 12 sometime in July, for that one.
- 13 Thank you, Arjun, for that.
- 14 Idaho, I know, Phil?
- 15 MEMBER SCHOFIELD: We are
- 16 scheduled to meet --
- 17 MR. KATZ: Phil, your mic is not
- 18 on.
- 19 MEMBER SCHOFIELD: We are
- 20 scheduled to meet on June 21st, in Cincinnati
- 21 for a Work Group session.
- 22 CHAIRMAN MELIUS: And are we

1	expecting	all	reports	and	updates	and

- 2 responses from NIOSH and so forth to be ready
- 3 by then?
- 4 MEMBER SCHOFIELD: Yes.
- 5 CHAIRMAN MELIUS: Okay. I
- 6 couldn't quite tell from the schedule and so
- 7 forth. Good, okay. Dr. Ziemer, Lawrence
- 8 Berkeley.
- 9 MEMBER ZIEMER: Nothing to report
- 10 on Lawrence Berkeley.
- 11 CHAIRMAN MELIUS: Okay, thanks,
- 12 sorry to surprise you there. Linde, Gen?
- 13 MEMBER ROESSLER: We're scheduled
- 14 for a Work Group meeting on July 7th. We're
- 15 sharing the day with the Brookhaven Work
- 16 Group. Linde will be meeting in the afternoon
- 17 at 1:00, and we'll begin our deliberations on
- 18 SEC Petition 154.
- 19 And I understand that SC&A will
- 20 have their comments to us in time for that
- 21 meeting.
- 22 CHAIRMAN MELIUS: Okay, thank you.

1	LANL	we'll	have	to	postpone	until	Mark	gets
---	------	-------	------	----	----------	-------	------	------

- 2 here. Mound.
- 3 MEMBER BEACH: At this time there
- 4 is no change for Mound, other than expected
- 5 documents from NIOSH have been pushed back
- 6 until I believe the May time frame.
- 7 So, as soon as we have those in
- 8 hand, there's three outstanding reports we're
- 9 waiting for. They're pretty encumbered,
- 10 they're large reports.
- Once we have the reports we'll
- 12 schedule a Work Group meeting. So hopefully
- 13 before the August meeting.
- 14 CHAIRMAN MELIUS: Good. Pantex,
- 15 Brad isn't here. I think Greg Lewis gave the
- 16 update on that when we had some discussion at
- 17 the time.
- 18 And someone correct me if I'm
- 19 wrong, from the Work Group, but the, there are
- 20 plans for both a meeting in Germantown to go
- 21 over documents, as well as possibly a site
- 22 visit, if I understood correctly, in early

- 1 June?
- 2 MR. LEWIS: Yes, this is Greg
- 3 Lewis. There's a meeting scheduled for I
- 4 think June 16th or 13th --
- 5 CHAIRMAN MELIUS: Yes.
- 6 MR. LEWIS: -- in Germantown. And
- 7 then I believe that SC&A is also going to be
- 8 visiting Pantex sometime in mid June, although
- 9 I'm not certain.
- 10 MEMBER BEACH: The week of the
- 11 20th.
- MR. LEWIS: The week of the 20th,
- 13 okay.
- 14 CHAIRMAN MELIUS: And so forth.
- 15 And, I think, my understanding is that those
- 16 meetings will help to resolve issues related
- 17 to Pantex and so I don't think it's -- it's
- 18 even foreseeable we may have some resolution
- 19 of that for August meeting.
- 20 We'll see. I may be optimistic
- 21 but, I think, they're making significant
- 22 progress, as I understand it.

2	anything to add?
3	MR. FITZGERALD: Not too much. I
4	think we have a lot of activity over the next
5	four to five weeks. We just had a Work Group
6	meeting, SC&A did an onsite classified review.
7	The Board is of course going to do
8	its classified review in a couple of weeks for
9	the onsite at Pantex in three weeks, as Greg
10	noted.
11	And there's a number of documents
12	going back and forth, including updated
13	matrix, so I think there's been a lot of
14	progress over the last month or two.
15	And, as you were saying, I think
16	we're hopeful that in the next month or so, we
17	can kind of get these things to closure.
18	CHAIRMAN MELIUS: Okay. Thanks,
19	Joe. Pinellas, Phil.
20	MEMBER SCHOFIELD: Nothing new at
21	this point. There have been some new
22	documents, but we're having the same issues at

I know, Joe, do you want to have

1

1 Pinellas that we are having at M
------------------------------------

- 2 Since they're already putting,
- 3 SC&A and NIOSH, putting the effort in at
- 4 Mound, it would just be a duplication.
- 5 CHAIRMAN MELIUS: Okay, so, so I
- 6 understand sort of the game plan would be to
- 7 wait for the Mound --
- 8 MEMBER SCHOFIELD: Correct.
- 9 CHAIRMAN MELIUS: Yes, report --
- 10 MEMBER SCHOFIELD: If we can
- 11 settle those issues there, then we can settle
- 12 anything at Pinellas.
- 13 CHAIRMAN MELIUS: Okay, that makes
- 14 sense and so forth. And you're on the Mound
- 15 Work Group. Good, okay. Piqua, Dr. Poston is
- 16 not here, so I don't think we have an update
- on that. Did they meet?
- 18 MR. KATZ: They did meet and they
- 19 did agree on recommendations and so on, so
- 20 that will be ready for August.
- 21 CHAIRMAN MELIUS: Good. Now that
- 22 LaVon has left the room, we can tell him that

1	he'	S	about	to,	don't	do	too	far,	LaVon.

- 2 We go through these reports, we
- 3 may put you on.
- 4 (Laughter.)
- 5 CHAIRMAN MELIUS: I should have
- 6 let him get farther. Portsmouth, Paducah, K-
- 7 25. I think this has a new name.
- 8 MEMBER SCHOFIELD: Yes, that's the
- 9 gaseous diffusion plants and we are scheduled
- 10 to meet on July 6. NIOSH has issued some new
- 11 papers that SC&A still has to respond to.
- 12 CHAIRMAN MELIUS: Okay. I feel
- 13 like we're having a naming contest for that,
- 14 get a new acronym or something for that.
- 15 Rocky, we have to wait for Mark.
- Santa Susana, I don't think, Mike
- 17 Gibson, you're not on the line, are you? I
- 18 haven't heard him, okay. Josie?
- 19 MEMBER BEACH: We have nothing
- 20 planned for Santa Susana, but I believe we
- 21 have documents due some time towards the end
- of the year.

2	DR. NETON: We are working or
3	those and I suspect within the next few weeks
4	or so we'll have a proposition.
5	CHAIRMAN MELIUS: Okay, so we may
6	need a Work Group meeting once those documents
7	are out? Okay.
8	MEMBER ZIEMER: Dr. Melius?
9	CHAIRMAN MELIUS: Yes.
10	MEMBER ZIEMER: Ziemer here. Or
11	Santa Susana, I'm just looking at the DCAS
12	matrix. They have several deliverables that
13	show up for July 11th and 18th.
14	CHAIRMAN MELIUS: Right.
15	MEMBER ZIEMER: So, I think that's
16	what Josie was referring to.
17	CHAIRMAN MELIUS: Yes, and Jin
18	Neton confirmed that. We need to follow up
19	and make sure Mike knows that and we can get
20	that Work Group together at some point.
21	Or I don't know if they're going
22	to want SC&A to review, but I think they

CHAIRMAN MELIUS: Okay.

1

1 probably need to meet first and do that	1	probably	need	to	meet	first	and	do	that
---	---	----------	------	----	------	-------	-----	----	------

- 2 Savannah River we'll hear from in
- 3 a little bit, when Mark Griffon gets here,
- 4 hopefully. And, if Mark doesn't get here,
- 5 we'll hear about it.
- And Science Issues, I don't
- 7 believe this Committee has met. We have a
- 8 charge for that Committee to review and so
- 9 forth.
- 10 Dr. Ziemer, not to put you on the
- 11 spot, I don't know if you were listening when
- we were talking yesterday about CLL, I believe
- 13 you were on the line.
- 14 MEMBER ZIEMER: Yes.
- 15 CHAIRMAN MELIUS: And we wanted
- 16 the Science Work Group to review it. David
- 17 Richardson has a conflict on that. So he
- 18 wouldn't be able to participate.
- 19 Would you be willing to Chair that
- 20 meeting?
- 21 MEMBER ZIEMER: I could do that.
- 22 I heard another pretty good suggestion

	1 ,	yesterday	for	Dr.	Lemen,	but	if	he's	not
--	-----	-----------	-----	-----	--------	-----	----	------	-----

- 2 available, I will do it.
- 3 CHAIRMAN MELIUS: He appears to be
- 4 reluctant.
- 5 (Laughter.)
- 6 MEMBER ZIEMER: Okay, I will work
- 7 with Ted --
- 8 CHAIRMAN MELIUS: Yes, that's what
- 9 I thought. Thank you very much, Dr. Ziemer.
- 10 The Special Exposure Cohort Issues group did
- 11 have a conference call and discussion on
- 12 General Electric, and we'll report on that
- 13 later this afternoon.
- 14 Subcommittee on Dose
- 15 Reconstruction. Mark is not here, so I think
- we'll postpone that.
- I was going to skip over
- 18 Procedures, but Wanda, I can tell is ready.
- 19 MEMBER MUNN: Oh, good.
- 20 (Laughter.)
- 21 MEMBER MUNN: Procedures has only
- 22 met twice this year. We have quite a gap

1	between	our	last	meeting	and	our	next	one

- 2 upcoming in July, because of other activities
- 3 and the absence of a couple of our Members
- 4 being out of the country for a while.
- 5 We have quite a bit on our plate,
- 6 and we'll have a full agenda in July, when we
- 7 do meet on the 14th. We have taken a look at
- 8 our last meeting at some 14 of our two pagers
- 9 that we are just about ready to put up on the
- 10 website.
- 11 They are not quite ready yet
- 12 because one of our Members wanted to make one
- or two minor adjustments, at least do a little
- 14 editing before that happens. We also have
- 15 another group of two pagers, just slightly
- larger than that, that are ready for us to
- 17 address at this next meeting.
- 18 The really good news is that in
- 19 the interim, our IT folks have finally gotten
- 20 together the new format and new Working
- 21 Regulations for our internal electronic matrix
- 22 that we use to track things with.

1	And	we	haven't	taken	it	out	for	а

- 2 dry run yet. We'll be doing that in July.
- 3 But, we're very pleased that it's reached the
- 4 point it has and thank all of the people who
- 5 have been involved in them.
- 6 CHAIRMAN MELIUS: Thank you. Any
- 7 questions for Wanda?
- 8 (No response.)
- 9 CHAIRMAN MELIUS: Okay.
- 10 MR. KATZ: If I could just add
- 11 something. Wanda, the other thing that's
- 12 important that we'll be taking up at this
- 13 meeting is the portion of the Norton SEC
- 14 petition that is yet to be considered by the
- 15 Board.
- 16 MEMBER MUNN: Thank you, Ted.
- 17 Yes, there are a couple of items which we
- haven't had before, which will be new. Norton
- 19 will be one of them.
- 20 CHAIRMAN MELIUS: Okay, thanks.
- 21 TBD-6000, Paul?
- 22 MEMBER ZIEMER: Yes, Paul Ziemer

I and I m note on IBB coco. Inc worm cros	1	and	Ι'm	here	on	TBD-6000.	The	Work	Grou
---	---	-----	-----	------	----	-----------	-----	------	------

- 2 hasn't met since late last year because we've
- 3 been awaiting some deliverables from NIOSH.
- 4 But I can now report on the status
- of those. First of all, on the main document,
- 6 TBD-6000, all of the matrix issues have been
- 7 resolved by the end of our last meeting.
- 8 And I can now report to you, this
- 9 is in the deliverable list that the Board
- 10 Members got in the last few days, that we have
- 11 a June 20th, date listed for delivery and for
- the revision of TBD-6000.
- 13 So I believe that means we'll be
- 14 in a position also for the old Dose
- 15 Reconstruction Sheet reviewed for updating.
- 16 And of course the Work Group
- doesn't do that, but the fact that there will
- 18 be a revised TBD available, I think will be
- 19 good news for the petitioners as well as for
- 20 the claimants, at least General Steel
- 21 Industries.
- The other thing to report is that

1	for	General	Steel	Industries,	we	now	have	the

- 2 commitment from NIOSH for, on the so-called
- 3 path forward, for four deliverables on July
- 4 29th, dealing with radiography with radium
- 5 sources and by St. Louis testing, and by
- 6 portable x-ray sources and cobalt-60.
- 7 So all the radiography documents
- 8 are going to be addressed in terms of source
- 9 terms. And so the Work Group will plan to
- 10 meet, we have to give SC&A time to review
- 11 those documents.
- 12 And we'll need to, at this
- 13 meeting, I think, this week we will meet to
- 14 authorize SC&A to go ahead and review those
- documents when they become available.
- 16 And then the Work Group would meet
- 17 probably late August or early September. I
- 18 thought late August, although I've already
- 19 heard from SC&A that their staff people might
- 20 not be available until early September.
- But, in any event, we will meet as
- 22 soon as we can after the documents are

1 reviewed. There is another set of docu	uments	S
--	--------	---

- 2 that are shown as having a deliverable date in
- 3 December.
- 4 And these deal with betatron
- 5 source terms, both the old and new betatron.
- 6 Some activation issues for air activation and
- 7 activation from uranium that was tested or
- 8 handled in the betatron and steel activation
- 9 from the betatron.
- 10 And then some related issues with
- 11 the dose modeling and the film badge records
- in terms of determining the extent to which
- 13 those complement or supplement each other.
- 14 So we have two sets of
- 15 deliverables. I know, as far as the
- 16 petitioners are concerned, they will be
- 17 concerned about the fact that some of these
- 18 deliverables will not show up now until
- 19 December, which means we would get into, you
- 20 know, February or so, before we could resolve
- 21 everything.
- 22 And you heard the concerns

1	expressed	by	the	Illinois	Representative

- 2 yesterday about this particular facility and
- 3 the concerns the petitioners have about the
- 4 time that has elapsed.
- 5 Anyway, that is what we have, what
- 6 we see coming down the pike. I would
- 7 certainly be my wish that we resolve all of
- 8 these as quickly as we can upon receipt of the
- 9 documents.
- 10 CHAIRMAN MELIUS: Okay, thank you,
- 11 Paul. And I'll make a note, we will task
- 12 SC&A, see if there are any other items that we
- 13 need to task them with that come out of this
- 14 session. TBD-6001, Henry.
- 15 MEMBER ANDERSON: We held our
- 16 second meeting on May 16th, and we spent
- 17 considerable time, because it was our second
- 18 meeting, we felt we needed to have a name
- 19 change, since we were disbanded as 6001.
- So we're now going to be known as
- 21 the Uranium Refining AWEs Work Group. So,
- 22 that's the first thing.

1	CHAIRMAN MELIUS: URAW.
2	MEMBER ANDERSON: URAW, right,
3	URAW.
4	(Laughter.)
5	MEMBER ANDERSON: But at our May
6	16th meeting we made great progress and we're
7	just about closing out Hooker Electrochemical.
8	What remains there is we're doing a very
9	careful review of the use of the Surrogate
10	Data there, but all the other issues have been
11	resolved there.
12	So we're hoping in August to be
13	able to have a final recommendation for the
14	Board. ElectroMet, we also reviewed and we're
15	narrowing down the number of issues there, as
16	well. And then United Nuclear is our third
17	site that we're just getting started on.
18	CHAIRMAN MELIUS: Thank you.

from I think later on today.

Surrogate Data is gone, I think we got rid of

that last meeting. Weldon Spring we'll hear

And then Worker Outreach, I don't

19

20

21

22

1	believe	Mike	is	on.	Josie,	do	you	want	to
---	---------	------	----	-----	--------	----	-----	------	----

- 2 update?
- 3 MEMBER BEACH: Yes, with Kathy's
- 4 help I threw together a quick update this
- 5 morning. And Wanda, I know you're on the Work
- 6 Group, so if I miss anything, help me out,
- 7 thank you.
- 8 We had our last Work Group meeting
- 9 on December 16, and the focus of that meeting
- 10 was to review the matrix items for OCAS PROC-
- 11 12. That procedure we had five findings and
- 12 five observations, so we reviewed all those.
- We also did a follow up review of
- 14 the Outreach Tracking System. During the
- 15 October Work Group meeting, the Work Group
- 16 agreed to focus on Objective 3, of our
- 17 Implementation Plan, and Rocky Flats was
- 18 chosen as the pilot site for the review of the
- 19 workers' comments and how their comments are
- integrated into the technical work documents.
- 21 The plan was approved with some
- 22 minor changes. Those changes were forwarded

1	to	our	Federal	Official,	Ted	Katz,	and	the
---	----	-----	---------	-----------	-----	-------	-----	-----

- 2 Office of General Counsel for approval.
- 3 That approval came back and the
- 4 work began on January 5th. Let's see, the
- 5 Objective 3, right now is about 50 percent
- 6 complete. The Progress Report for that should
- 7 be coming out.
- The Work Group Members should be
- 9 seeing that shortly. But at this time we've
- 10 kind of put a hold on Objective 3 review,
- 11 because the Work Group needs to get back
- 12 together.
- 13 Kathy, the task lead, for SC&A
- 14 needs some more guidance from the Work Group
- 15 at this time. So we're hoping to get together
- 16 with Mike and come up with a Work Group
- 17 meeting shortly.
- 18 I do know there were several
- 19 action items that came out of that list. Some
- 20 that I do know of for SC&A, was they were
- 21 required to provide documents that were
- 22 necessary for the worker comments review.

1	And I know NIOSH has supplied most
2	of those documents by March. Wanda do you
3	remember any other actions? I reviewed the
4	transcript briefly, but didn't really pinpoint
5	anything in the time I had this morning.
6	MEMBER MUNN: No, Josie, I haven't
7	reviewed the transcript myself and I've slept
8	since then, so. No, I don't remember anything
9	else.
10	MEMBER BEACH: I know there
11	several, most of them were pertaining to the
12	procedure. But I think we're fairly close to
13	coming to closure on PROC-12.
14	Unless anybody else has anything
15	else, that's all I have.
16	CHAIRMAN MELIUS: Thank you, is
17	this Rip Van Munn?
18	(Laughter)
19	MEMBER MUNN: Works for me.
20	CHAIRMAN MELIUS: You looked well
21	rested here. That concludes our, at least the
22	reports, the Work Group Reports and

1 Subcommittee Reports that we have	people
-------------------------------------	--------

- 2 available for. We'll surprise Mark.
- John and Ted, do we have any
- 4 tasking to do, relative to SC&A? Other, we
- 5 have this GSI issue, I'm just asking if
- 6 there's some more general stuff that we need
- 7 to try to do at this meeting?
- MR. KATZ: No, not that I'm aware
- 9 of. John, do you have anything you're aware
- 10 of?
- 11 MEMBER BEACH: While he's coming
- 12 to the mic, I noticed that in the tasking that
- 13 was sent out for SC&A, the Norton -- we had
- 14 asked them to provide a review of OTIB-70, I
- 15 believe, and I didn't notice that in that list
- 16 that came out. So I wanted to ask about that.
- 17 CHAIRMAN MELIUS: Go ahead, John.
- DR. MAURO: I'll start with that.
- 19 Norton is, the Draft Report is in my hands,
- 20 regarding, it was part of this Procedures. I
- 21 sent it over to Procedures.
- Issues had to do with OTIB-70. If

1	you	recall,	the	Norton	turned	out	to	be	an
---	-----	---------	-----	--------	--------	-----	----	----	----

- 2 OTIB-70 issue for the residual period.
- 3 So, in effect, our review of
- 4 Norton is complete and it has to do with the
- 5 degree to which, that we feel comfortable with
- 6 the way in which the residual period is being
- 7 handled.
- 8 And that really relies on our
- 9 review of OTIB-70, it's all interrelated. And
- 10 we will see a report very soon, I've already,
- and Bill Thurber is working, it's done.
- 12 As far as other places, regarding
- 13 the matters that were just discussed, where we
- 14 can see some work, the only thing I would say
- is that we're probably at a point where we
- 16 should be thinking about cases.
- 17 The next set, the 15th set, and
- 18 also the set of cases that need to be, I
- 19 noticed it before, the DR Subcommittee and the
- 20 cases that need to be identified for our
- 21 review of the PERs.
- 22 As sort of something that's been

1	languishing,	as	you	know,	we	have	completed	а

- 2 review of a number of PERs, but the work on
- 3 them has never really been completed.
- 4 Because the last piece is to
- 5 select cases, that would then evaluate the
- 6 degree to which the PER was implemented. So
- 7 we need, we do, I would request that the Board
- 8 order the DR Subcommittee, start to consider
- 9 the 15th set of DRs to review, the next set,
- 10 and also DRs for, that support the PER Review
- 11 Process.
- MR. KATZ: So just to add to what
- 13 John just said. The DR Subcommittee has sort
- 14 of taken first steps on both of these.
- 15 Because we've asked, I believe, DCAS to
- develop a new roster for the 15th, whatever it
- is, whatever set number we're on now, we did
- 18 that at the last Dose Reconstruction meeting,
- 19 a Subcommittee meeting.
- 20 So that should be going forward
- 21 and they should be compiling that initial
- 22 roster of possible cases and they're supposed

1	to	be	taking	up,	we	tried	to	get	that	done	in

- 2 the last DR Subcommittee, but we should get
- 3 that done in this one.
- 4 The assignment of cases for the
- 5 PER that we were going to start with, which is
- 6 the lymphoma one, I believe.
- 7 CHAIRMAN MELIUS: Thank you, good.
- 8 Since there doesn't appear to be any other
- 9 tasking, at least general tasking we need to
- 10 do for SC&A, why don't we take care of this
- 11 GSI issue.
- 12 And, Paul, do you want to tell us
- 13 what --
- 14 MEMBER ZIEMER: You need a motion?
- 15 CHAIRMAN MELIUS: I think we need
- 16 a motion, yes, from the Work Group Chair.
- 17 MEMBER ZIEMER: Sure. I move that
- 18 we task SC&A to review the four documents that
- 19 DCAS is scheduled to release on July 29th,
- 20 dealing with radiography at General Steel
- 21 Industries.
- 22 And to report their results to the

- 2 to.
- 3 MEMBER BEACH: I second that.
- 4 CHAIRMAN MELIUS: Second from
- 5 Josie. Any discussion?
- 6 (No response.)
- 7 CHAIRMAN MELIUS: If not, all in
- 8 favor, say aye.
- 9 (Chorus of ayes.)
- 10 CHAIRMAN MELIUS: Opposed?
- 11 Abstained?
- 12 (No response.)
- 13 CHAIRMAN MELIUS: Okay, thank you.
- I don't believe we have any other Board Work
- 15 Session issues at this point in time. So, I
- 16 think we would, might take the time now to
- 17 hear from LaVon.
- 18 And we should all listen carefully
- 19 to LaVon, since we have, we can't really start
- 20 Sandia until 9:30, until the petitioners are
- 21 around. So we have a half hour to ask
- 22 questions.

1	MR. RUTHERFORD: Great.
2	(Pause.)
3	CHAIRMAN MELIUS: We just added
4	this time to the question period.
5	MR. RUTHERFORD: That was my
6	method of cutting on time. All right, thank
7	you, Dr. Melius. I'm going to talk about our
8	status of upcoming SEC petitions.
9	We routinely do this presentation
10	at the Board Meetings to give the Board some
11	information on the petitions that are in the
12	evaluation phase and upcoming 83.14s that we
13	have.
14	The Board uses this information to
15	prepare for upcoming Work Group Meetings and
16	as well as Advisory Board Meetings.
17	As of May 9th, and this has
18	changed a little bit. We had 186 petitions.
19	We have one petition in the qualification
20	process, 113 petitions have qualified for
21	evaluation. And of those 113, five
22	evaluations are in progress.

1	And that number is a little less
2	and you'll see why. NIOSH Evaluation, we've
3	completed 108, and we have 13 evaluations with
4	the Advisory Board.
5	And 72 petitions that didn't
6	qualify. Again, as a, now this is as of May
7	2nd, we have Hanford, this, it says these are
8	petitions that are currently in the evaluation
9	process.
10	However, Hanford is complete now.
11	At the time of preparing for the
12	presentation, Hanford was not complete. Dr.
13	Glover will be presenting that later today and
14	will give much more information than I'm
15	prepared to.
16	Sandia National Lab, again this
17	evaluation was not complete when I prepared
18	the presentation, it is now complete. And Dr.
19	Glover will be presenting that one shortly
20	after my presentation.
21	Clinton Engineering Works, this

one has, was delayed a little while. During

22

1	our	evaluation,	we	uncovered	some	inform	ation

- 2 that went to the facility designation
- 3 question.
- 4 We sent that information to the
- 5 Department of Labor, and we are waiting for
- 6 them to come back with a finding on that
- 7 review.
- 8 We anticipate having that very
- 9 shortly and we will, we do plan on presenting
- 10 Clinton Engineering Works at the August Board
- 11 Meeting.
- 12 W.R. Grace, and this one is in
- 13 Curtis Bay, Maryland. This was received on
- 14 December 21st of last year and we are almost
- 15 complete with the evaluation on W.R. Grace.
- 16 And we anticipate concluding it in
- 17 early June or mid-June, actually. And we will
- 18 present that Evaluation Report at the August
- 19 Board Meeting.
- 20 The Ames Laboratory and Y-12 were
- 21 both 83.14s. These came about as a result of
- 22 our review of SEC Class Definitions.

1	We had identified some claims that
2 v	we felt probably should have fit into the
3 €	existing Class Definitions and recognized that
4 t	the Class Definitions were difficult to
5 a	administer.
6	These were Class Definitions that
7 v	were defined fairly early in the, after
8 g	promulgating the rule in 2004. And so these
9 v	were pretty early Class Definitions.
10	Prior to the involvement that
11 v	we've had with the Department of Labor. We
12 á	anticipate completing those 83.14s in July and
13 e	early August, and presenting those at the
14 7	August Board Meeting.
15	In addition, we were also going to
16 p	present the second part of our Vitro
17 N	Manufacturing evaluation. We had held up the
18 p	post-1960 period on that one, because we were
19 v	waiting determination from General Counsel, on
20 v	whether Port Hope material would be covered
21 6	exposure or not. We have a finding from
22 (	General Counsel on that, and we're moving

1	forward	to	completing	that	second	part	of	the
---	---------	----	------------	------	--------	------	----	-----

- 2 evaluation.
- And we will present that one at
- 4 the August meeting. Additionally, Grand
- 5 Junction Operations Office, we, if you
- 6 remember, we pulled back on the post-1975
- 7 period evaluation, because we uncovered
- 8 information prior to our presentation, I
- 9 believe, at the Santa Fe Meeting.
- 10 And we are working towards
- 11 completing that post-1975 Revision to the
- 12 Evaluation. And we anticipate presenting
- that, as well, at the meeting.
- 14 Also, Hangar 481, which is another
- one that's with the Advisory Board, we're
- waiting for, we had sent a number of questions
- 17 to the Office of Secure Transport, and we
- have, they have responded to those questions.
- 19 However, their responses are under
- 20 review at this time. And we do anticipate
- 21 having those back very shortly. And that
- information provided to the Board, sometime, I

	1	would	suspect,	in	late	June.
--	---	-------	----------	----	------	-------

- 2 Which should allow the Advisory
- 3 Board to move forward with Hangar 481, as
- 4 well.
- 5 And then I know Dr. Melius will
- 6 speak later on General Electric. We are
- 7 working a couple of the issues that the SEC
- 8 Work Group identified.
- 9 And we anticipate having answers
- 10 for that Work Group within the next couple of
- 11 weeks. And that's pretty much it. So, I will
- 12 say, just in summary, the ones that we will
- 13 present, we anticipate presenting at the
- 14 August meeting, are Vitro Manufacturing, Grand
- 15 Junction Operations Office.
- We should, hopefully we'll be
- 17 ready for Hangar 481 to move forward. And
- then we'll present W.R. Grace, Ames and Y-12
- 19 83.14s. Okay, questions.
- 20 CHAIRMAN MELIUS: Questions for La
- 21 Von? You know, I would just comment that if,
- depending on how some of the other older sites

1	work	out,	you	know,	we	are,	where	we	stand

- with Savannah River, Fernald.
- We are either going to have a
- 4 very, have to have an extended meeting in
- 5 August or we're going to have to defer some of
- 6 these, or move some of them forward.
- 7 In our discussions on GE and we'll
- 8 talk a little bit more about this later. But,
- 9 in detail, we did say that we may try to, if
- it's possible, resolve that and do that on the
- 11 July conference call.
- 12 And I'm afraid, what I'm concerned
- about is that with some of these 83.14s, which
- 14 are easier to do on, by conference call. We
- 15 have Ames and Y-12 here, for example, coming
- 16 up that I don't think will be ready for the
- 17 conference call.
- MR. RUTHERFORD: We may have Ames
- 19 ready in time.
- 20 CHAIRMAN MELIUS: Okay, I think it
- 21 may, since these are Class Definition changes,
- they should be fairly straightforward.

1	So, if possible, we'd like to get
2	them on the July conference call. And I just
3	want to alert people and we'll just sort of
4	see. It's hard to sort of figure out what's
5	going to be ready, when, on some of these
6	other older sites.
7	But I think they should have some
8	precedent. And since people waited so long
9	and do that, and we just may not have time to
LO	get through everything.
L1	But, to the extent we could move
12	it up, or move some of these, if they're more
13	straightforward to the follow up conference
L 4	call after the August meeting.
15	So that was sort of my thinking,
16	and Ted and I have talked a little bit about
L7	this and I just wanted to mention it to the
18	other Board Members.
19	MR. RUTHERFORD: I will add, I car
20	check on Y-12 as well. I mean I generally
21	know we're pretty close on that one. And

there's no, I will throw up, you know, the

22

1	Curtis	Bay,	Maryland	one	is	

- 2 CHAIRMAN MELIUS: Please don't
- 3 throw up.
- 4 (Laughter.)
- 5 MR. RUTHERFORD: The Curtis Bay,
- 6 Maryland, I honestly feel it's fairly
- 7 straightforward. And it's a couple year
- 8 period and I think that evaluation is very
- 9 close to being complete.
- I can give the, Dr. Melius and Ted
- an update, by email, shortly after I get back,
- 12 exactly when those, you know, maybe we can
- move those forward.
- 14 CHAIRMAN MELIUS: Because we don't
- want to delay and some of these may not take
- long, but some of them are going to involve,
- 17 at least some discussion, in the limited time.
- 18 And so then I'm afraid if we do
- 19 some of the older, larger sites, that's going
- 20 to involve, fairly, we're going to have to
- 21 leave a significant amount of time for
- 22 discussion on those.

1	They're	not	going	to	be
---	---------	-----	-------	----	----

- 2 straightforward Board deliberations on that.
- 3 Stu?
- 4 MR. HINNEFELD: In the interest of
- 5 waiting for Savannah River or Sandia, I want
- 6 to make sure either I have the correct
- 7 understanding or we didn't leave a missed
- 8 impression about Hangar 481, response from
- 9 Office of Secure Transport.
- 10 You said they had responded. Now,
- in fact, they have drafted a response.
- MR. RUTHERFORD: That's what I
- 13 said. I said they responded, we did not
- 14 receive it until --
- MR. HINNEFELD: Well, you didn't
- 16 say we didn't receive it.
- 17 MR. RUTHERFORD: I said --
- 18 MR. HINNEFELD: You said they had
- 19 responded and it was under review. That would
- 20 imply that we got it, we sent it to DOE for
- 21 review.
- We don't have it yet. They are

- 2 Reviewers. We have not recieved it yet. I
- just want to clear up the misunderstanding on
- 4 my part.
- 5 CHAIRMAN MELIUS: Thanks for the
- 6 clarification. Any, yes, Josie.
- 7 MEMBER BEACH: You mentioned on
- 8 Grand Junction, it wasn't on your report.
- 9 MR. RUTHERFORD: Right.
- 10 MEMBER BEACH: You're just going
- 11 to report on those later years?
- MR. RUTHERFORD: Yes, we're going
- to report on the post-1975 years.
- 14 MEMBER BEACH: Thank you.
- 15 CHAIRMAN MELIUS: Is that residual
- 16 period?
- MR. RUTHERFORD: No, actually it's
- 18 a DOE facility and so it's not --
- 19 CHAIRMAN MELIUS: Okay, so it's
- 20 not --
- 21 MR. RUTHERFORD: It's an
- operational period. It has a, there was a

1	number	of	questions	that	were	brought	up	late.

- We had actually found a document, just after
- 3 we issued the Evaluation Report, that kind of
- 4 gave us an indication that there may have been
- 5 thorium used in the post-1975 period that
- 6 wasn't previously identified.
- 7 So that's why we pulled the
- 8 Evaluation for the post-`75 period and back.
- 9 CHAIRMAN MELIUS: Okay, okay,
- 10 good. Wanda?
- 11 MEMBER MUNN: Just in response to
- 12 your comment, I wanted to make sure that all
- of the Board understood the Tri-Cities is very
- 14 hospitable.
- We would have no objection to your
- 16 extending your time there, as our needs would
- 17 require us to do.
- 18 CHAIRMAN MELIUS: Thank you. I
- 19 would report at this time, you know, a
- 20 Conflict of Interest form for the Tri-Cities
- 21 Chamber of Commerce?
- 22 (Laughter.)

1	MEMBER	MUNN:	⊥'⊥⊥	speak	with

- 2 Counsel about that.
- 3 MEMBER ROESSLER: I think I'm
- 4 really expanding on what Wanda was trying to
- 5 say. But I think we, with the full agenda, we
- 6 should plan on going for a full day on the
- 7 third day.
- 8 CHAIRMAN MELIUS: That may, that
- 9 was, I think maybe and I think we've done that
- 10 before. Given the airline schedule also for
- 11 those of us from the east coast, a full three
- days may be more practical there, too.
- 13 It's a little tricky to get out
- and get back to the east coast, yes, do that.
- 15 MEMBER BEACH: Plan early.
- 16 CHAIRMAN MELIUS: We will try to,
- 17 do it this way. We will work with, Ted and I
- 18 will work with Stu and LaVon and DCAS, trying
- 19 to figure out the schedule and what's going to
- 20 be practical to do.
- 21 And we will let you know by email,
- 22 as we pin that down and so forth, so that you

1	can	plan	accordingly,	because	I	think	it	will
---	-----	------	--------------	---------	---	-------	----	------

- 2 be, airline scheduling is going to be an
- 3 issue.
- It's a general issue anyway. I
- 5 mean, even for this meeting. Any other Board
- 6 Members with questions, yes, Josie?
- 7 MEMBER BEACH: This isn't for you,
- 8 Brad texted me and he wanted you to know that
- 9 he was online and had a Pantex report for you,
- 10 just letting you know.
- 11 CHAIRMAN MELIUS: Welcome, Brad,
- we apologize for not noting you earlier.
- 13 MEMBER CLAWSON: I thought you
- 14 were just ignoring me when Dr. Ziemer chimed
- 15 in and said he was here and you never
- 16 acknowledged me, but I understand.
- 17 (Laughter.)
- MR. KATZ: Brad, we never heard
- 19 you, but sorry.
- 20 MEMBER CLAWSON: Oh, I know that.
- 21 That's why I sent Josie, because when you went
- 22 into the Pantex, I was trying to talk, so I

1	figured	vou	couldn't	hear	me.

- 2 CHAIRMAN MELIUS: Anything to add.
- 3 If you heard that, anything to add beyond
- 4 what Joe and we have Greg Lewis. We had DOE
- 5 reporting on your behalf.
- 6 MEMBER CLAWSON: I've been here
- 7 from the very beginning. There was nothing to
- 8 add, they covered all the meetings we've got
- 9 coming up and everything else. I just wanted
- 10 to try to figure out how come you couldn't
- 11 hear me.
- 12 (Laughter.)
- 13 CHAIRMAN MELIUS: Thank you. Any
- other missing Board Members to report? Okay,
- 15 since it's almost 9:15, and I think we've
- exhausted our questions for LaVon, but we may
- 17 call him back, if you have others.
- 18 Why don't we take a 15 minute
- 19 break and be back in here 9:30 sharp. We will
- 20 do Sandia then.
- 21 (Whereupon, the above-entitled
- 22 proceeding went off the record at 9:15 a.m.

- and came back on at 9:32 a.m.)
- 2 CHAIRMAN MELIUS: If we could get
- 3 ready to reconvene now. We've got a
- 4 petitioner that's going to be on the line.
- 5 Okay, Ted, do you want to?
- 6 MR. KATZ: Just for the record,
- 7 Mr. Schofield has recused himself from this
- 8 session.
- 9 CHAIRMAN MELIUS: And, for the
- 10 record, we have an unconfirmed report that
- 11 Mark Griffon is on the way in from the
- 12 airport. We track everybody now.
- No, he emailed me, so, he should
- 14 be here, we'll be able to do Savannah River
- on, as scheduled. First time now we're back
- 16 is for the Sandia National Laboratories and
- 17 Sam Glover is going to present and I believe
- 18 the petitioner is alerted and may very well
- 19 be on the line.
- 20 And after Sam's presentation,
- 21 after the Board Members have had a chance to
- 22 ask questions, we'll ask for any comments from

1	the	petitioners.	So,	Sam,	go	ahead.
---	-----	--------------	-----	------	----	--------

- DR. GLOVER: Ted, do you need to
- 3 verify that they're on the line?
- 4 MR. KATZ: I mean it's time, I
- 5 don't think we do, thanks.
- DR. GLOVER: Thank you, Dr.
- 7 Melius, Members of the Board. I'd like to
- 8 present Sandia National Laboratories Exposure
- 9 Cohort Petition Report.
- I would first like to start off by
- 11 thanking members of my team. Tim Adler and
- 12 his folks did a really good job, they really
- worked hard with me on this.
- 14 I'd like to also thank Scott
- 15 Stafford and the DOE folks at Sandia. They
- 16 really have worked hard to get us access to
- 17 the data and people.
- 18 And, of course, Greg Lewis and the
- 19 DOE, you'll see that they're also helping us
- 20 do a lot of work, ongoing, even after this
- 21 petition report.
- So petition overview, the petition

1	was	received	on	Januarv	19th,	2010.	The

- 2 petitioner proposed the following Class
- 3 Definition.
- 4 All employees who've worked within
- 5 the Sandia National Laboratory Reactor
- 6 Division from January 1, 1957, through
- 7 December 31st, 1962. The petition qualified
- 8 for evaluation on April 13th, 2010. The
- 9 petition basis was radiation monitoring
- 10 records from members of the proposed Class
- 11 have been lost, falsified or destroyed.
- 12 Monitoring data retrieval problems
- incurred by NIOSH while processing individual
- 14 claims and performance site data capture, were
- in support of this petition basis.
- 16 NIOSH evaluated the following
- 17 Class. All employees who worked at Sandia
- 18 National Laboratories in Albuquerque, New
- 19 Mexico, from January 1st, 1949, through
- 20 December 31st, 1962.
- You can see we backed it up beyond
- 22 the 1957, which the petitioner had asked for.

1	And	Ι	would	also	sav	that	NIOSH	will	address

- 2 the period covering 1963 through the early
- 3 1990s in a separate report.
- 4 Sources of available information
- 5 are those that are typically used by us. The
- 6 Technical Information Bulletins, the TIBs. We
- 7 interviewed many employees of Sandia. We
- 8 certainly looked at existing Claimant files,
- 9 documentation provided by the petitioner.
- We have over 2,400 documents that
- 11 have been obtained from Sandia. We had 12
- 12 data capture visits to Sandia. We had data
- 13 capture related to Sandia, across the DOE
- 14 complex.
- We certainly looked at the OSTI
- 16 databases as well as Internet resources. Just
- 17 to give you a feel for the dose
- 18 reconstructions that have been done. There
- 19 have been 346 cases submitted to NIOSH.
- 20 Claims with employment during the
- 21 period evaluated, there's 193. Dose
- 22 reconstruction completed for claims, 154.

4	~ '			1 ' '		
Τ	Claims	containing	internal	dosimetry	lS	$\perp \perp$ .

- 2 Claims containing external dosimetry is 88.
- A little bit of background on
- 4 Sandia. In 1945, the Z-Division from Los
- 5 Alamos, moved from, moved down to what was to
- 6 become the Sandia National Laboratory in
- 7 Albuquerque. So, in, the covered period for
- 8 Sandia National Lab, was established by the
- 9 Department of Labor in 1949.
- 10 So we've got a little four year
- 11 gap. We have a letter to them to address this
- 12 early four year period, but in 1949, is the
- 13 beginning of our, the covered exposure period
- 14 for Sandia National Laboratories.
- 15 Its early occupations were weapons
- 16 assembly, weapons ordnance engineering and
- 17 production coordination amongst various atomic
- 18 energy commissioned facilities, such as
- 19 Clarksville, Medina and Pantex.
- In the early 1950s, they expanded
- 21 their activities to support fuel testing and
- 22 atmospheric tests. They further expanded its

1	capabilities	in	the	late	1950s	when	testing

- 2 moratoriums were set in place, providing
- 3 accelerators and reactors to test weapons
- 4 components.
- 5 Sandia is now divided into five
- 6 technical areas. Technical Area 1 nominally
- 7 has electron and ion beam accelerators. They
- 8 also have a Toxic Metals Machine Shop.
- 9 TA-II was weapons components
- 10 assembly and waste handling and barrel. TA-
- 11 III, Radioactive Mixed Waste Landfills. TA-
- 12 IV, Neutron Generator Test Equipment. And TA-
- 13 V includes Reactors and Hot Cell Facilities.
- 14 This is a map. You can see that
- 15 the colored areas are only a small part of
- 16 this large facility that they actually are a
- 17 part of.
- 18 So when you go to Sandia, you're
- 19 actually at a large Air Force Base, so you're
- 20 mixed into an unusual atmosphere for a DOE
- 21 facility.
- 22 Potential external radiological

1 exposure during the Class, are the full gamu
--

- 2 We have photon exposures related to weapons
- 3 assembly.
- 4 Generators, accelerators, materials
- 5 returned from weapons testings. So they would
- 6 bring the materials back to the site. You had
- 7 beta exposures from activated components.
- 8 Materials returned from weapons
- 9 testing and air filters from cloud sampling.
- 10 Neutron, the neutrons, we have weapons
- 11 assembly, accelerators, reactors and neutron
- 12 sources.
- 13 And I will also say that Sandia
- 14 National Lab's dosimetry system did not
- 15 measure neutrons until 1958. Internal
- 16 radiological exposures also cover a broad
- 17 gamut.
- They include plutonium, tritium,
- 19 uranium, americium, fission and activation
- 20 products and other radionuclides which we've
- 21 seen in the air sampling data, including
- 22 manganese-54, zinc-65, sodium-22, cobalt-57,

1	thorium,	polonium-210,	radium-226,	and	carbon-
---	----------	---------------	-------------	-----	---------

- 2 14.
- 3 So this has a bit of a
- 4 Brookhavenish feel. The Health Physics were
- 5 the responsibility of the Industrial Hygiene
- 6 Division, prior to 1957. At which point
- 7 Health Physics Section was formed. NIOSH
- 8 located minimal documentation regarding the
- 9 practices and requirements during the
- 10 evaluation period.
- 11 Monitoring requirements were
- 12 developed based on the judgement of
- departments, divisions and supervisors.
- 14 Interviews indicated that coverage
- 15 was temporal and ad hoc in nature. If they
- 16 felt they needed coverage, they provided
- 17 coverage.
- 18 Availability of monitoring data is
- 19 a significant concern. November 2009, NIOSH
- 20 notified DOE the case responses were
- 21 incomplete, particularly as related to
- 22 internal dosimetry.

1	That basically we had found data,
2	during our data captures, which showed that we
3	had more data than what was being provided.
4	DOE and Sandia Laboratories have
5	implemented a massive records indexing effort,
6	which they feel will fix the issues.
7	Approximately 1.1 million records. Scanning
8	is complete, but I don't believe the QC has
9	been completely validated.
10	Indexing is approximately 40
11	percent complete, based on my last report on
12	this. And they expect still it will take six
13	to nine months to complete this.
14	In January of 2010, we re-
15	requested the records for all the Sandia cases
16	that had basically not been paid, had not been
17	compensated, which we did, actually.
18	So we have a request to DOE to get
19	all the data for those cases. Unlike many DOE
20	facilities, Sandia National Laboratory did not
21	report or at least if they did report it, we
22	haven't found the reports of how many bioassay

1	samples	thev	did.

- 2 So we don't know what the target
- 3 is. Hanford monthly reports how many urine
- 4 samples, how many fecal samples, ad nauseam.
- 5 You know exactly what the number
- 6 is, should be. We have no idea what the
- 7 target number is. Based on interviews it's
- 8 thought to be small.
- 9 I've also obtained copies of some
- 10 bioassay records, part of it is site data
- 11 capture and claimant data requests. The
- 12 number of samples by year are provided in the
- 13 following table.
- 14 You see that in the early years we
- 15 have nothing. Beginning in '55, we start
- seeing some tritium data, some early plutonium
- 17 data.
- But it is pretty spotty. Not
- 19 enough to create coworker data sets. External
- 20 dosimetry results are centralized from the
- 21 beginning. So, personnel data requests seem
- 22 fairly complete.

1	We also have the Atomic Energy
2	Commission Monitoring Reports available during
3	this time frame. So we have a ballpark idea
4	of what fraction of the employees were
5	monitored.
6	Documentation of pre-1950s
7	external dosimetry program has not been
8	obtained by NIOSH. The post-1950
9	documentation, in the case of all workers in
10	radiation areas were to be badged.
11	This just gives you a feel for the
12	total employees, certainly after 1958, what
13	the total number of employees would be and the
14	total of number of employees not monitored
15	would be.
16	And also the doses incurred. In
17	the '49 to '57 time frame, they didn't track
18	that as part of these records. They changed
19	that report in 1958.
20	You can see, even from '58 on, a
21	larger portion of the workers were not
22	monitored. Feasability of dose

1	reconstruction. NIOSH determined that
2	monitoring data, process information,
3	monitoring program information, are
4	insufficient to support bounding internal
5	doses for the evaluated Class.
6	There are indications additional
7	data exists, microfilm, microfiche, but these
8	data are not readily accessible, based on a
9	lack of internal monitoring, program
10	documentation and source term information for
11	the evaluated period, NIOSH feels it can not
12	establish a bounding approach, even if the
13	microfilm/microfiche data become available.
14	NIOSH concludes it cannot bound
15	internal doses for the period of January 1,
16	1949, through December 31, 1962, but will
17	continue to assess post-1962 dose
18	reconstruction feasibility in a subsequent
19	Evaluation Report.
20	Regarding non-SEC claims, although
21	NIOSH found it is not possible to completely
22	reconstruct internal radiation doses for the

1	proposed Class, NIOSH intends to use any
2	internal and external monitoring data that may
3	become available for an individual claim that
4	can be interpreted using existing NIOSH dose
5	reconstructing processes or procedures.
6	NIOSH recommended Class, all
7	employees of the Department of Energy, its
8	predecessor agencies, its Contractors and
9	Subcontrators who worked in any area of Sandia
10	National Laboratories in Albuquerque, New
11	Mexico, from January 1, 1949, through December
12	31st, 1962, for a number of work days
13	aggregating at least 250 work days.
14	Occurring either solely under this
15	employment or a combination with work days
16	within the parameters established for one or
17	more other classes of employees in the Special
18	Exposure Cohort.
19	And our summary of recommendations
20	is that internal dosimetry is not feasible.
21	That we believe that the external dosimetry

reconstructed,

records

can

be

22

including

1	medical	X-rav	7. Thank	vou	verv	much.

- 2 CHAIRMAN MELIUS: Thank you, Sam.
- 3 Questions for Sam? Yes, Bill.
- 4 MEMBER FIELD: Sam, I was just
- 5 wondering, how did the periods, were these the
- 6 periods that were requested by the petitioner?
- Because I'm looking at '62. Why '62, and not
- 8 '63, or '64?
- 9 CHAIRMAN MELIUS: That was going to
- 10 be my question, too.
- DR. GLOVER: In order to --
- through '62, is what he had asked for. I'd be
- remiss in saying Sandia was a 83.14, possible,
- we were evaluating them in an 83.14, when this
- 15 came in.
- They asked through '62, in order
- 17 to get this done in a timely fashion. We
- 18 wanted to get this to the petitioner, and not
- 19 have them wait any longer.
- 20 Because of the ongoing data
- 21 capture efforts by DOE, trying to fix this,
- 22 we've seen the 180 days. And so we really

1	felt	this	time	was	necessary	to	get	this
---	------	------	------	-----	-----------	----	-----	------

- 2 report done.
- 3 CHAIRMAN MELIUS: So, essentially,
- 4 1962, is sort of an arbitrary designation.
- 5 DR. GLOVER: Only that's where he
- 6 stopped, yes.
- 7 CHAIRMAN MELIUS: Okay, fine,
- 8 that's helpful. Bob?
- 9 MEMBER PRESLEY: Sam, do we know
- when they transferred the teardown operations
- 11 to either Medina or Pantex? Do we have that
- date when they transferred that stuff? When
- they transferred those operations?
- DR. GLOVER: The assembly, the
- 15 actual weapons assembly type work?
- 16 MEMBER PRESLEY: Yes,
- 17 assembly/disassembly.
- DR. GLOVER: It was around
- 19 '57/'58, is when they stopped doing that,
- 20 according to our documentation.
- 21 MEMBER PRESLEY: Okay, okay.
- 22 MEMBER ZIEMER: Dr. Melius?

1	CHAIRMAN MELIUS: Yes, Paul, go
2	ahead.
3	MEMBER ZIEMER: LaVon, can you
4	clarify the neutron exposure that you show
5	reconstruction feasible, but I thought you
6	indicated that you have no neutron data prior
7	to '58 maybe.
8	Are you just saying that where you
9	have neutrons you will use it if there's a
10	person not eligible for the SEC?
11	DR. GLOVER: Basically, we do not
12	have neutron data before 1958, as far as badge
13	information. In the TBD right now, there is a
14	back extrapolation of the N/P ratio. We have
15	data that is contemporaneous to other
16	facilities who would have done weapons
17	handling.
18	And we would propose to use N/P
19	ratio-type data to do that.
20	MEMBER ZIEMER: Okay, thank you.
21	CHAIRMAN MELIUS: Josie, then

Wanda.

22

1	MEMBER BEACH: I have a question,
2	Sam, on the external monitoring for the period
3	of '49, to '57. It doesn't look like you have
4	a whole lot of data, and I was wondering if
5	you could go in to a little more detail of
6	that time period?
7	DR. GLOVER: Again, it was, it's
8	not well documented. They chose to monitor
9	who they monitored. And so we don't have a
10	great breadth of information.
11	We are going to use the data that
12	is available to us, to do dose reconstruction
13	on the non-SEC cancers as best we can.
14	MEMBER BEACH: You're going to the
15	data from that time period or for a later time

DR. GLOVER: We would use their

period back to that time period?

- 18 data. The activity has significantly changed
- 19 the function of time. You've got weapons
- 20 handling early and then it goes to, it's an
- 21 evolving complex.

16

It would be very hard to back

1	extrapolate.

- 2 MEMBER BEACH: Okay, the other
- 3 question I had was on incidents. I noticed
- 4 that in the ER Report, there was only one in
- 5 the Site Profile actually had a couple of
- 6 others listed.
- 7 Where are those documented or
- 8 where, I guess I was wondering why there was a
- 9 discrepancy between the two?
- DR. GLOVER: I'd have to go back
- 11 and double check. I recall the one,
- 12 particular one with an accelerator, but I'd
- 13 have to look. So, I apologize, I just don't
- 14 recall.
- MEMBER BEACH: No, that's fine,
- 16 thanks.
- 17 CHAIRMAN MELIUS: Wanda, then
- 18 Henry.
- 19 MEMBER MUNN: Just curious about
- 20 the microfiche data that you mentioned. Do we
- 21 know what's on that data? Are you likely to
- 22 be able to find some internal exposures that

<pre>1 you don't have now'</pre>	now?	have	don't	you	1
----------------------------------	------	------	-------	-----	---

- 2 As you began to go through that
- 3 material, do you think it's even there?
- DR. GLOVER: We have seen
- 5 indications that there is some internal
- 6 dosimetry data in there. We believe, based on
- 7 all the discussions we've had with the staff,
- 8 and we've had some great cooperation.
- 9 Again, we had the guy who started
- in the early years, and we talked to them.
- 11 There's just not a lot of bioassay. Even if
- we had everything.
- We hope that those microfiche,
- 14 there were several times where they started
- doing all this microfilm, and then they went
- 16 back, is our understanding, and made it
- 17 complete. And so we're hoping that this will
- 18 allow the DOE to provide complete responses.
- 19 At this time we're not, you know,
- 20 we don't know the full extent, if everything
- 21 is there.
- 22 MEMBER MUNN: And you don't have a

1	real	feel	for	how	long	it's	going	to	take	for

- them to get through that and get it to you?
- 3 DR. GLOVER: I could defer to
- 4 Greg, if you'd like. I understand it's going
- 5 to be six to nine months. Budgeting always,
- 6 you know, this is not a cheap process to get
- 7 all that in.
- 8 MEMBER MUNN: I understand, yes,
- 9 thanks.
- DR. GLOVER: They are committed to
- 11 helping us, though.
- 12 CHAIRMAN MELIUS: Henry.
- 13 MEMBER ANDERSON: I was just
- 14 wondering, in your one slide, you indicated
- 15 that 154 have been, dose reconstructions
- 16 completed for people who were employed during
- 17 the period.
- 18 How were those reconstructions
- 19 done for the time period?
- DR. GLOVER: As best as we could.
- MEMBER ANDERSON: Yes, okay.
- 22 CHAIRMAN MELIUS: Can I just, a

1	quick	follow	up	on	that.	How	many	of	those
---	-------	--------	----	----	-------	-----	------	----	-------

- were with PoCs over 50?
- 3 DR. GLOVER: I did not check that
- 4 statistic, I apologize.
- 5 CHAIRMAN MELIUS: For future
- 6 reference, that's sometimes helpful when we're
- 7 dealing with these, that information. Just to
- 8 give us a sense of what has gone on at the
- 9 site and so forth.
- 10 So, Stu, if you could make a note
- of that, and where it's feasible to get the
- 12 information and so forth.
- 13 MR. HINNEFELD: I would just offer
- on that question about, you know, how did you
- do 150, I think a number of those were done
- 16 before we actually recognized that Sandia had
- 17 additional data that we weren't getting, on
- 18 their individual exposures.
- I mean that's a fairly recent, not
- in the last few weeks, but in the ten years,
- 21 that's a fairly recent discovery on our part.
- 22 CHAIRMAN MELIUS: Thanks, Stu.

1	MEMBER PRESLEY: A little
2	information on microfiche and microfilm. We
3	didn't start microfiche until late '60s. And
4	one of the problems that we're having and I
5	think you all are probably having, and I don't
6	know whether the Board knows it or not.
7	We're finding microfiche, but we
8	don't have anything to read them on. A lot of
9	the microfiche are classified and the design
10	labs and places like that, have got rid of all
11	of their readers.
12	And right now we're having a
13	problem finding somebody with a classified
14	reader to read the silly things. So, that may
15	be one of the problems that they're running
16	into, that I'm aware of.
17	And, the other thing is, are we,
18	when are we going to be ready for, to vote on
19	this petition?
20	CHAIRMAN MELIUS: Well, when we're
21	done discussing and hearing from the
22	petitioner.

1	MEMBER	PRESLEY:	Holler	at	me.

- 2 CHAIRMAN MELIUS: Greg, can
- 3 someone explain to me what a classified
- 4 reader? I know what a microfiche reader is.
- 5 I got back. But I don't know what a
- 6 classified one is.
- 7 DR. GLOVER: They are actually in
- 8 classified space and they have, so they
- 9 actually have to be able to be cleaned and
- 10 wiped, and sometimes then can't print.
- 11 CHAIRMAN MELIUS: Okay, okay --
- DR. GLOVER: Sandia actually has
- 13 one.
- 14 CHAIRMAN MELIUS: I thought like a
- 15 special lens or something. I just was trying
- 16 to, maybe I'm not supposed to know that.
- 17 MR. LEWIS: And this is Greq.
- 18 Just to declare, I mean Sam kind of clarified
- 19 already. But they do have a classified
- 20 reader, that's not the issue there.
- 21 The issue there is the time it's
- taken to scan and get this into an electronic

1 format. We've had to actually hand-key	1	format.	We've	had	to	actually	hand-key
--	---	---------	-------	-----	----	----------	----------

- 2 everything. It's taken much longer than
- 3 expected, because it's hard to read, it's
- 4 handwritten data.
- 5 Some of it we're hand-keying the
- 6 best interpretation we have but we're not sure
- 7 that it's correct. You know, our people are
- 8 just trying to interpret the handwriting and
- 9 the faded information as best they can.
- 10 And the QC process, as you can
- imagine, is a little bit difficult there. So
- that's what's taken much longer than expected.
- 13 CHAIRMAN MELIUS: We understand, I
- think we all appreciate the effort that DOE is
- 15 making here.
- 16 MEMBER BEACH: The other question
- 17 I have, Sam, is the number of employees and
- 18 the number that are monitored, are you able to
- 19 put these employees in the locations readily?
- DR. GLOVER: We do not feel we can
- 21 put people in places, based on their, really
- they have some phone books or some logs, it

1	lists	where	people	had	an	office.

- But we don't believe that we can
- 3 put people in places.
- 4 MEMBER BEACH: Okay, thanks.
- 5 CHAIRMAN MELIUS: Any other
- 6 questions for Sam from Board Members?
- 7 Yes, Bill?
- 8 MEMBER FIELD: I just had a
- 9 question about the size, Sam, real quick, size
- of the workforce? From the monitoring data it
- looks like it was in '58, low were 7,000, and
- then it dropped to 6,000, 5,000, 4,000.
- So it decreased over time, it
- 14 looks like from this. Is that realistic to
- the size of the workforce, once we're set on
- 16 the external dosimetry?
- DR. GLOVER: I would say in '49,
- 18 your workforce is probably a couple of
- 19 hundred. Then they began to ramp up. Based
- on just my recollection on how the Z Division,
- 21 you know, they started as just a small
- 22 division that translocated down to Los Alamos,

then ramped up to fill this new mission. Ar	ssion. An	miss	new	this	IIIII	to	up	ramped	then	Τ
---	-----------	------	-----	------	-------	----	----	--------	------	---

- then in the early '60s, things would have been
- 3 maybe pushed to Pantex, Clarksville, Medina.
- 4 There were lots of things going on
- 5 with, so I would have to double check, but
- 6 that's the best information I have regarding
- 7 that.
- 8 MEMBER FIELD: And the people you
- 9 do have bio-monitoring data for, does it look
- 10 like they were getting a lot of exposure? Or
- do you have any ballpark figure on that?
- DR. GLOVER: We put these, you
- 13 know, what bioassay we do have we've graphed
- 14 and what is the range, you know, fairly large.
- We don't see the magnitude of dosimetry that
- 16 you would, per se, say the Hanford Z, or the
- 17 Hanford Plutonium Finishing Plants.
- But, again, it's also very unclear
- 19 with the source terms that we have, will we
- 20 have captured the breadth that we need to.
- 21 CHAIRMAN MELIUS: Okay, thanks.
- 22 Sam, I just wanted, I thought it was a very

1	good	report	and	I	think	it	clearly	explained
---	------	--------	-----	---	-------	----	---------	-----------

- things, and I forgot, Dick, okay, Mr. Lemen.
- 3 But I do want to compliment NIOSH and whoever
- 4 was involved in putting this together.
- 5 MEMBER LEMEN: Sam, maybe you
- 6 covered this and I missed it. But on your
- 7 table where you had total number of employees
- 8 and number of employees not monitored, that's
- 9 the exposure data submitted.
- 10 How come you don't have the number
- of employees from '49 to '57?
- DR. GLOVER: Those, the DOE Report
- 13 changed. So they didn't report that in the
- 14 beginning.
- 15 MEMBER LEMEN: There's no way to
- 16 get that number? I mean you said a few
- 17 moments ago, the reason I asked it. Because
- you said a few moments ago there was about 100
- in '49? How do you know that?
- 20 DR. GLOVER: I just, based on the
- 21 Z-Division, what they, you know, reading some
- of the quarterly reports. This was extracted

1	from	the	annual	reports	of	the	AEC.	And	SO
---	------	-----	--------	---------	----	-----	------	-----	----

- that's where this table comes from.
- 4 other reports if we had to.
- 5 CHAIRMAN MELIUS: Josie, you have
- 6 another question? No, okay. I think you can
- 7 sit down now, Sam, thanks. Are the
- 8 petitioners on the line? No. Paul, did you
- 9 have more or anybody?
- 10 MEMBER ZIEMER: I have no more
- 11 questions.
- 12 CHAIRMAN MELIUS: Okay, now can we
- 13 hear from the petitioner, if you'd like to
- make comments, you don't need to?
- DR. FUORTES: I don't know if you
- 16 can hear me, I'm on speaker phone.
- 17 CHAIRMAN MELIUS: Yes, we can.
- DR. FUORTES: Thank you very much.
- 19 This is Lars Fuortes from Iowa City and I
- 20 want to thank Dr. Glover and the folks at
- 21 NIOSH incredibly for this, this result in the
- 22 process.

1	The dates, the reason for the
2	limitation of the dates was that this was
3	based on the oral history and work records
4	obtained regarding one employee who I'd
5	interviewed at the Ames Lab, who used to work
6	at Sandia.
7	So it was an entirely arbitrary
8	time frame. And I'm very impressed by the
9	speed with which NIOSH processed this.
10	I would like the Board and NIOSH
11	to please consider this same process for other
12	facilities, such as Pantex, for whom you might
13	have very similar tables indicating a dearth
14	of exposure data for workers prior to a
15	particular time frame.
16	NIOSH is in a position, and the
17	Board, I would think, to set those time frames
18	which they can agree there's not sufficient
19	exposure data.
20	But thank you very much for having
21	done this at Sandia and beg that you look into
22	this process for the folks at Pantex and other

1	sites	2 0	TAT 🗀 📗	Thanks,	arain
_	$S \perp C \subseteq S$	as	$w \subset \bot \bot \bullet$	Illalins,	ayaıı.

- 2 CHAIRMAN MELIUS: Okay, thank you.
- 3 Okay, Board Members, comments, further
- 4 questions, discussion?
- 5 (No response.)
- 6 CHAIRMAN MELIUS: Do we hear
- 7 suggestion, suggested Board action?
- 8 MEMBER CLAWSON: Can you hear me?
- 9 CHAIRMAN MELIUS: Yes, so sorry.
- 10 Yes, hi Brad, go ahead.
- 11 MEMBER CLAWSON: Listen, I just
- 12 had one question especially pertaining with
- 13 Pantex and Clarksville. Do we have a clear,
- is there, can you see a change at Sandia when
- these, when everything kind of got centralized
- 16 at Pantex?
- 17 I'm just wondering if Sam could,
- 18 has seen any documentation. Because it seems
- 19 like that's when Sandia's kind of mission
- 20 would have changed a little bit.
- DR. GLOVER: Sandia continued to
- go out to Medina and Clarksville, after they

	1	stopped	doing	it	there,	eventually.	But	we
--	---	---------	-------	----	--------	-------------	-----	----

- 2 have indicated that we have found microfilm
- 3 and microfiche associated with these other
- 4 facilities.
- 5 And have let SC&A and others in
- 6 NIOSH who are part of that review. It is very
- 7 difficult to work in that area, because we had
- 8 to find the right thread buried in these
- 9 classified microfilms that are not indexed
- 10 well.
- 11 And so it is a great deal of
- 12 effort to find those source terms and activity
- 13 reports.
- 14 MEMBER CLAWSON: Okay, well I just
- wanted to see if there was something to clear
- 16 it up. I'm concerned about Pantex and Medina
- 17 and those.
- 18 I'm just looking for a common
- 19 thread there that maybe we can see a change.
- 20 Thank you very much. Your presentation was
- 21 very good.
- 22 CHAIRMAN MELIUS: Back on Sandia,

1	Wanda.
2	MEMBER MUNN: I'm ready to make a
3	motion if you are ready to receive it?
4	CHAIRMAN MELIUS: Yes, I am.
5	MEMBER MUNN: I move that we
6	accept the NIOSH recommendation that all
7	employees of DOE and its predecessor agencies
8	or Contractors and Subcontractors who worked
9	at Sandia National Laboratories in
10	Albuquerque, New Mexico, from January 1, 1949,
11	through December 31, 1962, for the number of
12	aggregated 250 workdays, be accepted as
13	presented by NIOSH.
14	MEMBER FIELD: Second.
15	CHAIRMAN MELIUS: Bill, no, Bill
16	was there first. We go by, I've got my
17	stopwatch.
18	(Laughter.)
19	CHAIRMAN MELIUS: Any further
20	discussion?
21	(No response.)
22	CHAIRMAN MELIUS: I would like to

1	offer,	I	believe	we	can	do	this	as	а	friendly	7
---	--------	---	---------	----	-----	----	------	----	---	----------	---

- 2 amendment. Ted, do you want to pass these
- 3 around? I think there are enough going this
- 4 way.
- 5 And I will point out, ahead of
- 6 time, that we've changed the letter slightly.
- 7 The standardized letter, and it's going to be
- 8 probably changed again. And I'll also point
- 9 out that we checked and the actual designation
- 10 and I believe the DOE facilities databases,
- 11 Sandia National Laboratories.
- 12 So, it certainly is referred,
- 13 commonly, as Sandia National Laboratory, but
- 14 whatever. So, for official communication
- 15 purposes, we do that.
- So, a few minor changes in this
- 17 letter, as I, I'll read, go through, but
- 18 nothing that I think is substantial from
- 19 what's in front of you.
- 20 The Advisory Board on Radiation
- 21 Worker Health, the Board, has evaluated
- 22 Special Exposure Cohort petition 00162,

1	concerning workers at Sandia National
2	Laboratories in Albuquerque, New Mexico, under
3	the statutory requirements established by the
4	Energy Employees Occupational Illness
5	Compensation Program Act of 2000, EEOICPA, and
6	incorporated to 42 CFR 83.13.
7	The Board respectfully recommends
8	that SEC staffs be accorded to all employees
9	of the Department of Energy, predecessor
10	agencies and its Contractors and
11	Subcontractors who worked in any area of
12	Sandia National Laboratories in Albuquerque,
13	New Mexico from January 1, 1949, through
14	December 31, 1962.
15	For a number of work days,
16	aggregating at least 250 work days occurring
17	either solely under this employment or in
18	combination with work days within the
19	parameters established for one or more other
20	Classes of employees included in the SEC.
21	This recommendation is based on

the following factors. Individuals working at

1	the Sandia National Laboratories, during the
2	time period in question, worked on nuclear
3	weapon production and related operations.
4	The National Institute for
5	Occupational Safety and Health, NIOSH, review
6	of available monitoring data, as well as
7	available process and source term information.
8	Various production activities at the Sandia
9	National Laboratories, found that NIOSH lacked
10	adequate information necessary to complete
11	individual dose reconstructions with
12	sufficient accuracy for internal radiological
13	exposures to plutonium, tritium and other
14	radionuclides during the time period in
15	question.
16	The Board concurs with this
17	determination. Three, NIOSH determined that
18	health may have been in danger for these
19	Sandia National Laboratories workers during
20	the time period in question.

determination. Based on these considerations,

The Board also concurs with this

21

1	discus	sions	held	at	the	May	24	th	to	26th,
2	2011,	Board	Mee	ting	, he	eld	in	St		Louis,

- 3 Missouri, the Board recommends that the Class
- 4 covering all employees of the Department of
- 5 Energy, its predecessor agencies, Contractors
- 6 and Subcontractors who worked in any area at
- 7 Sandia National Laboratories, in Albuquerque,
- 8 New Mexico, from January 1st, 1949, through
- 9 December 31st, 1962, for a number of work days
- 10 aggregating at least 250 work days occurring
- 11 either solely under this employment or in
- 12 combination with work days within the
- 13 parameters established for one or more other
- 14 Classes of employees included in the SEC, be
- 15 added to the SEC.
- 16 Enclosed is supporting
- 17 documentation from the Board Meeting where
- 18 this SEC Class was discussed. This
- 19 documentation includes transcripts of the
- 20 deliberations, copies of the petition, NIOSH
- 21 review thereof, and related materials.
- The meeting's items aren't

- 2 shortly. So will you accept that as a
- 3 friendly amendment? Thank you.
- 4 MEMBER MUNN: Yes.
- 5 CHAIRMAN MELIUS: Yes. Any
- 6 further discussion?
- 7 (No response.)
- 8 CHAIRMAN MELIUS: Ted, do the roll
- 9 call.
- 10 MR. KATZ: Dr. Anderson?
- 11 MEMBER ANDERSON: Yes.
- MR. KATZ: Ms. Beach?
- MEMBER BEACH: Yes.
- MR. KATZ: Mr. Clawson?
- 15 MEMBER CLAWSON: Yes.
- MR. KATZ: Dr. Field?
- 17 MEMBER FIELD: Yes.
- 18 MR. KATZ: Mr. Gibson is absent.
- 19 Mr. Griffon?
- MEMBER GRIFFON: Yes.
- MR. KATZ: Dr. Lemen?
- MEMBER LEMEN: Yes.

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

1	MR. KATZ: Dr. Lockey?
2	MEMBER LOCKEY: Yes.
3	MR. KATZ: Dr. Melius?
4	CHAIRMAN MELIUS: Yes.
5	MR. KATZ: Ms. Munn?
6	MEMBER MUNN: Yes.
7	MR. KATZ: Dr. Poston is absent,
8	but would also recuse from this, in any event.
9	Mr. Presley?
10	MEMBER PRESLEY: Yes.
11	MR. KATZ: Dr. Richardson is
12	absent, I don't have to collect his vote. Dr.
13	Roessler?
14	MEMBER ROESSLER: Yes.
15	MR. KATZ: Mr. Schofield has
16	recused, and Dr. Ziemer?
17	MEMBER ZIEMER: Yes.
18	MR. KATZ: So, all in favor, the
19	motion passes. I'll collect the extra votes.
20	CHAIRMAN MELIUS: Thank you, and
21	if anybody has, finds any other typos or
22	changes in the letter, let me know. Pass it

_		
1	hack	
_	back	

- We'll take care of those. Sam,
- 3 good, since you were heading towards the --
- 4 yes, well, don't go away.
- 5 Do we have, I'm trying to figure
- 6 out, we need to form a Work Group on Sandia.
- 7 We have Site Profile review I believe that
- 8 SC&A has done, that we have not set up a Work
- 9 Group to review, if my memory is correct.
- 10 And Josie reminded me. And we
- 11 also have this, I think, a second report
- 12 coming from NIOSH, if I understood you
- 13 correctly?
- 14 DR. GLOVER: There will be a
- 15 second report, yes.
- 16 CHAIRMAN MELIUS: Do we have an
- 17 estimate on the timing on that?
- DR. GLOVER: It's based on DOE's
- 19 response time. We're looking at about a year.
- 20 CHAIRMAN MELIUS: Okay. So --
- DR. GLOVER: Although my boss
- could change my mind one way or the other, but

<pre>1 I believe that's pro</pre>	bably right.
-----------------------------------	--------------

- 2 CHAIRMAN MELIUS: Yes, Josie.
- 3 MEMBER BEACH: Sam, can you tell
- 4 us what years those, that next report is
- 5 covering?
- 6 DR. GLOVER: That would go from
- 7 the beginning of, the end of this one, '63,
- 8 and about through the early '90s, when CEP
- 9 data was the data falsification at CEP.
- 10 There was an issue where they
- 11 falsified data. So we'd be looking about that
- 12 time frame.
- 13 CHAIRMAN MELIUS: What I would
- 14 propose as a way going forward, is that we
- 15 probably should, it probably is timely at
- 16 least to form a Work Group on Sandia.
- 17 And since we have the Site Profile
- 18 review, aren't there going to have to be some,
- 19 at least initial review of that Site Profile
- and some thought given to how, what issues may
- 21 come up in terms of the additional years and
- 22 so forth.

1	Because I don't think we want to
2	spend a lot of time on Site Profile issues
3	that may, sort of get changed by an SEC
4	evaluation.
5	I suspect some of them may already
6	have, but at least if we got some initial
7	review going. Because, again, while we're, I
8	don't think we should postpone too long
9	dealing with the Sandia Site Profile.
10	And I think we also, while it's
11	sort of fresh in our minds, and reviewing it
12	is probably more appropriate to start work on
13	that. So, other Board Members have, yes.
14	MEMBER BEACH: I'm wondering if we
15	could task SC&A to review the Evaluation
16	Report. I don't think that's been done.
17	CHAIRMAN MELIUS: Well, but, what
18	parts of the Evaluation Report? Because the,
19	we've accepted that and I believe that the
20	doses for which NIOSH can, says that they can,
21	the external doses, essentially.

They say they can construct, and

1	those	should	be	covered	in	the	Site	Profile.

- 2 I think the question is going to be to what
- 3 extent the Site Profile and the SC&A review of
- 4 that Site Profile, may not reflect some of the
- 5 newer information that came up in the SEC
- 6 Evaluation.
- But, I think perhaps a meeting of
- 8 the group to, before they do any further
- 9 tasking, can sort of review the issues and see
- 10 where that is.
- I think a meeting with NIOSH,
- 12 maybe even done by conference call, I don't
- 13 know. But could, rather than have a separate
- 14 review of the Evaluation Report.
- Now, it may turn out that the Site
- 16 Profile needs to be changed, I don't, Sam, do
- 17 you have any thoughts on that? Or you've been
- 18 probably busy --
- 19 DR. GLOVER: I believe there are
- 20 revisions that are required to the Site
- 21 Profile. And the post-'62, time frame. But I
- 22 did want to remind that you guys had tasked

1	SC&A to accompany us on some of these visits.
2	And so some of this, because it is
3	classified, it's hard to get to these things.
4	So they've been participating with us, so
5	they are able to stay abreast of what the
6	current, what we are seeing down there.
7	I do not believe we've created an
8	issues matrix, and so perhaps that's a good
9	place to start.
10	CHAIRMAN MELIUS: Exactly. And I
11	also think that since, remember we had tasked
12	SC&A to go out to Sandia because the nature of
13	some of these interviews and difficulties of
14	trying to do them again, so, repeating them.
15	So there is information there. And
16	I think it's worth getting at least started.
17	It may not be on sort of a fast track review,
18	but it certainly will be helpful to get going.
19	Anybody else have comments? If
20	not, I think we need a motion to form a Work
21	Group?

MEMBER PRESLEY: So moved.

1	CHAIRMAN MELIUS: Okay, Bob moved,
2	seconded by Wanda?
3	MEMBER MUNN: Yes.
4	CHAIRMAN MELIUS: And to that, all
5	in favor say aye.
6	(Chorus of ayes.)
7	CHAIRMAN MELIUS: Opposed?
8	(No response.)
9	CHAIRMAN MELIUS: Okay, and you
10	can let me know, since there are a number of
11	Board Members who are not here, and give them
12	a fair opportunity to volunteer.
13	I will circulate an email asking
14	for volunteers for this Work Group and then
15	make the appointment, hopefully between now
16	and our July meeting, if I can track everybody
17	down for that.
18	Okay, we have some time. We have
19	scheduled the review of Savannah River until
20	11:00, but, not to put you on the spot, Mark,
21	but now that we've got you here, we're going
22	to wes we're going to keep it at 11.00

1	However, are you ready? And we
2	can put this off to this afternoon but I think
3	we have some other Board work time later. But
4	there are some Work Group Reports and
5	Subcommittee Report on the Dose Reconstruction
6	Committee that we'd like to hear from.
7	And LANL, I believe, is the other
8	outstanding Work Group that we haven't heard
9	from and is not scheduled elsewhere on the
10	agenda.
11	I don't know if you want, rather
12	do those later or, since you're just off the
13	plane? Yes, okay, we'll do that this
14	afternoon.
15	Then, I believe we then will, we
16	will then take a break until 11:00 and if we
17	can be in here about five of 11:00 to get
18	started with Savannah River. Yes?
19	Yes, well, that's, I think we've
20	pretty much dealt our Board work time issues
21	and we're tied down on some of these petitions
22	in terms of timing.

1	So, this, yes, we'll make up for
2	this in lovely, beautiful Tri-Cities.
3	MEMBER MUNN: As requested.
4	(Whereupon, the above-entitled matter
5	went off the record at
6	10:12 a.m. and resumed at
7	11:02 a.m.)
8	CHAIRMAN MELIUS: I think we're
9	ready to reconvene the Board Meeting. We will
10	now discuss the Savannah River SEC petition,
11	and I believe Tim Taulbee is going to lead
12	off, and then we'll hear from Mark Griffon,
13	from the Work Group. So, Tim, go ahead.
14	DR. TAULBEE: Thank you, Dr.
15	Melius, Members of the Board. The goal of my
16	presentation here is to give you an update on
17	where we are with some of the priority issues
18	that SC&A and the Work Group have identified.
19	And first let me go through what
20	those priority issues are. I've got the seven
21	of them listed here. Issues 1 and 2 are
22	thorium-related.

1	We've got these divided by
2	different time periods as to whether thorium
3	metal was worked with or thorium oxide. And
4	then the exotic radionuclides, the trivalents,
5	the neptunium mixed fission products, cobalt-
6	60 and then other exotics.
7	The bulk of this presentation will
8	be on the first two issues there: the thorium.
9	And my goal here is to try and give you an
10	overview of the SRS isotope production.
11	As you know, Savannah River was
12	one of the sites that made materials,
13	specifically plutonium-239, was their primary
14	mission.
15	But they also made other isotopes,
16	as well. Plutonium-238, using neptunium as a
17	target, but for thorium, what their main goal
18	was, was uranium-233, that was what they were
19	trying to produce.
20	And in order to do that, they
21	would use thorium, in this process. So I'm
22	going to walk through the different steps of

1	the	isotope	prod	uction	so	that	you	can	see
2	where	e thoriur	n was	worked	wit	th, at	the	Sava	nnah

- 3 River Site, using thorium as the example and
- 4 going through this, so that I can identify it
- 5 and illustrate it for the Board.
- 6 The three basic steps are a target
- 7 manufacture. You start with a material and
- 8 then you put it into a reactor, that would be
- 9 target irradiation of 100 areas.
- 10 It would absorb neutrons and
- 11 undergo some nuclear reactions to produce the
- 12 material you are interested in. In this case,
- uranium-233. But to get the uranium-233 out
- 14 of this target material, you have to go
- 15 through some chemical separations.
- And so these are the three main
- 17 processes that Savannah River went through
- 18 whenever they made any material, plutonium-
- 19 239, uranium-233, plutonium-238, et cetera.
- 20 So you start with the target
- 21 manufacturing and the location of where this
- 22 was conducted was up here in this corner, that

1	you	can	see	up	here	in	the	300	area.
---	-----	-----	-----	----	------	----	-----	-----	-------

- 2 It's also called the M area. And
- from prior to 1965, to make uranium-233, they
- 4 primarily used thorium metal. Post-1965, the
- 5 used thorium oxide.
- And so that's why we've divided
- 7 Issue 1 and Issue 2, there separately. The
- 8 main operations in target manufacturing is
- 9 material canning.
- 10 And that is to put this material,
- 11 this thorium metal into a can, if you will, an
- 12 aluminum can and -- before they put it into a
- 13 reactor. Now, on-site, they did on-site
- 14 canning prior to 1955.
- They were using a dipping method,
- and I'll get into that a little more later.
- 17 But the bulk of it, from 1955 to 1964, was
- 18 actually using a different method, a hot press
- 19 bonded method.
- 20 And these were actually canned
- off-site, at Sylvania. Now, starting in 1964,
- 22 again, with thorium oxide, they moved it back

4				1		- 1	
	$\cap$ n	q + p	ın	order	$\pm \cap$	$\alpha \alpha$	that
_	$\circ$	$\mathcal{O} \perp \mathcal{C} \mathcal{C}$		$O \perp G \subset \bot$		$\alpha$	CIIC .

- 2 The main operations within this
- 3 area, after the canning, is you would weld the
- 4 endcap on, you'd do pressure tests. You'd do
- 5 radiography on these end smears before they
- 6 would be sent to the reactors for target
- 7 irradiation.
- And here you can see the five
- 9 production reactors. Again, M area was way up
- 10 here, and now the production reactors are all
- 11 kind of in a semi-circle here, about the
- 12 center of the site. These canned thorium
- 13 slugs would be coming in. The outside jacket
- is all aluminum and in the assembly area at
- the reactors, these encapsulated thorium slugs
- 16 would be loaded into long assemblies to be
- 17 lowered into the reactor.
- 18 So these, about ten inches to 12
- inch slugs would be hand put into an assembly.
- Now, once they're into an assembly, then they
- 21 would be sent into the reactor and irradiated
- 22 for some specified time period in order to

	,			$\sim \sim \sim$
1	mako	tha	uranium-	<b>-</b> ソイイ
	max = 1	ric		$ \sim$ $\sim$ $\sim$ $\sim$ $\sim$

2	Following the irradiation, they
3	would be moved, pulled out of the reactor,
4	transferred through a channel, into the
5	disassembly area or the disassembly pool, and
6	these thorium slugs would be unloaded from the
7	assembly, and allowed to cool for 30 to 90
8	days, depending on what the specifications
9	were.
10	After the irradiation, after the
11	cooling took place the main purpose of
12	that, by the way, was to allow short-lived
13	fission products to decay out the slugs
14	would then be sent to chemical separations.
15	Now prior to 1964, I've got this slide here
16	because at that point, pre-1964, these slugs
17	were shipped off-site to Oak Ridge National
18	Laboratory for the actual chemical separation.

19 It wasn't done at Savannah River.

Now some of these slugs would be, a sample

21 would be taken from them and those samples

22 would be sent up to the 700 area, into the

1	high-level	cave areas	, for	analysis.

- 2 There is also some non-destructive
- 3 testing that would be done there at the
- 4 reactors as well, where they do visual
- 5 inspections and that type of thing.
- But prior to 1964, there wasn't
- 7 any thorium separations that were going on in
- 8 the 200 areas. Post-1964, that changed. This
- 9 is when they introduced the thorex process
- 10 there in the 200 H Canyon.
- 11 And the first campaign took place
- in 1964, when they did this. And, initially,
- 13 thorium was actually treated as a waste
- 14 product.
- So, when they separated it or
- 16 dissolved the thorium down, they kept the
- 17 mixed fission products with the thorium and
- 18 sent it right out to the waste tanks.
- 19 So there really wasn't any
- 20 handling. It went from the canyon directly
- into the waste tanks. Now in later campaigns,
- 22 they introduced an additional stream to

_			
1	recover	the	thorium.
_	$\perp$	$c_{11}c$	

- 2 And so they recovered the thorium
- 3 as thorium nitrate and they sent it to
- 4 Fernald. So at that point, they started
- 5 pumping it into rail cars and then they would
- 6 send it up to Fernald.
- 7 So within the chemical
- 8 separations, again, the product was uranium-
- 9 233, that was what they were going after. And
- 10 so in this latter time period, after that
- 11 first campaign, you had three waste, you had
- 12 three product, or three streams of material:
- the uranium-233 that went to the B-Line, the
- 14 mixed fission products which went out to the
- 15 waste tanks, and then the recovered thorium
- 16 nitrate which was pumped into rail cars and
- 17 sent to Fernald.
- 18 So for our evaluation, of these
- 19 three steps for the U-233 production, we
- 20 originally felt that the main exposures were
- 21 in the 300 area. This is where un-
- 22 encapsulated material was handled. This is

- 2 thorium in a form that could result in
- 3 airborne radioactivity and inhalation hazards.
- In the 100 areas, this is
- 5 encapsulated material. And then, in the 200
- 6 area, again the material wasn't present until
- 7 1964, and after '64, this was a wet process.
- 8 So of these three different steps,
- 9 we felt the 300 area was the largest or of the
- 10 greatest concern. So, let me go into a little
- more detail about the 300 area at this time.
- 12 And this was, again, a thorium canning method.
- Now prior to 1955, they used a dipping
- 14 method, and so what you'd take is a thorium
- 15 slug and you put it inside a can, but you
- 16 needed to seal the edges of it.
- 17 And so, in order to do this, they
- 18 would dip it in a molten aluminum silica bath
- 19 and you can see here in the picture that
- 20 that's what workers are doing. They have
- 21 tongs that they're dipping them down into the
- 22 bath.

1	Sometimes the slugs coming from
2	the rolling mill wouldn't fit inside the cans.
3	So they had to do lathing and other cutting,
4	that type of thing, in order to get them in
5	the cans initially.
6	So there was some potential for
7	exposure in this area, during this process.
8	Now, in later years, after 1956, they had two
9	simultaneous canning operations going on. The
10	dipping method and then the hot press bonded
11	method which was done by Sylvania. Now, what
12	turned out was the hot press bonded method was
13	a better method compared to the dipping. They
14	had less slug failures. In failures, I mean
15	when they do the pressure tests in an
16	autoclave. And so they had a higher
17	acceptance rating.
18	So, they went solely with the hot
19	press bonded method, starting in about 1956.
20	So the slugs would then come from Sylvania,
21	mostly canned, not completely canned, and
22	Savannah River would finish them. They would

1	weld	the	ends	on,	and	then	they	would	do	all
---	------	-----	------	-----	-----	------	------	-------	----	-----

- 2 the pressure testing for them.
- 3 So this process was very similar
- 4 to uranium canning. Using the dipping method
- 5 and the hot press bonded method. And so, what
- 6 we had for dose reconstruction was we had a
- 7 lot of uranium bioassay data available, and
- 8 since the processes were similar, we felt we
- 9 could use the uranium bioassay to determine
- 10 what a mass intake would be.
- 11 Recognizing it's a different
- 12 material, but if you go back to mass, how much
- 13 would be breathed into an individual? We
- 14 could determine the mass, and assuming an
- 15 equal mass of thorium, calculate the dose out.
- 16 And so we felt that this was
- bounding primarily because of the thorium slug
- 18 production. And when you look at the number
- 19 of slugs produced of uranium targets versus
- the number of thorium targets, you'll see that
- 21 the actual thorium fraction in the greatest,
- 22 the largest year, was still less than five

1	percent.	

- 2 So the bulk of their operation was
- 3 producing plutonium-239, and the amount of
- 4 thorium was actually rather small, when you
- 5 think about it on a large scale. Because, you
- 6 know, in this case 16,000 slugs sounds like a
- 7 lot, but compared to 400,000, we feel that
- 8 this pretty similar or a bounding type of
- 9 approach.
- 10 So we cut that off, though, at
- 11 1965, because the whole operation changed.
- 12 They were no longer working with metal; they
- 13 started working with thorium oxide, which is a
- 14 powder. And in order to can that material,
- they actually used vibration and compaction.
- 16 Totally different than what they were doing
- 17 with uranium metal.
- 18 So we couldn't use the uranium
- 19 bioassay anymore. So we wanted to look at,
- 20 was there any other data, any other method to
- 21 estimate dose.
- 22 And because this was a powder type

1	of	operation,	Savannah	River	actually	used	а
---	----	------------	----------	-------	----------	------	---

- 2 glove box to do this work. And here's a
- 3 picture of the thorium glove box that was in
- 4 the 300 area. And a worker is standing there.
- 5 And what you'll see here in the lower right-
- 6 hand corner, in this area right here, is some
- 7 completed thorium slugs.
- 8 You'll see them laying there in a
- 9 tray, after they've gone through the
- 10 compaction and all of the other work
- 11 associated with it.
- 12 Well, on the backside of this
- 13 glove box, if you look here at the top. Up
- 14 here, this is the ventilation coming out of
- 15 the top of the glove box.
- 16 And this line comes right down
- 17 here into this HEPA filtration system. So
- 18 right there next to the glove box was the air
- 19 recovery unit for the glove box, where they
- 20 were pulling the samples, or pulling air
- 21 through the glove box.
- 22 And you also notice there, behind

1	the	chain	rope,	materials	coming	out	of	the

- 2 glove box were bagged for radiation control.
- 3 Now, one of the things that we wanted to look
- 4 at was, is there any air sampling data? And
- 5 there is for this particular area.
- And this particular plot that I'm
- 7 showing here is that, one of the concerns was
- 8 we don't have air sampling data for the
- 9 entire time period, from 1964 through 1971.
- 10 And the reason for this was that
- 11 these campaigns were periodic. And here, you
- 12 can see on the graph, the bars are when the
- 13 campaigns transpired and the individual black
- 14 dots are when we have air sample data with --
- 15 the magnitude of those samples are.
- So, one wouldn't expect that there
- would be a lot of air sample data when they
- 18 weren't doing any work in that particular
- 19 area.
- 20 But, in this case, we have the air
- 21 sample data when they were doing this work.
- We obtained these air samples, as you saw, and

1	we	confirmed	through	interviews	with	the

- 2 Radiological Control Technician, who actually
- 3 took them; he's still alive, and we
- 4 interviewed him. And this samples were taken
- 5 outside the glove box and he considered them
- 6 breathing-zone equivalent.
- 7 Because he put it on a tripod type
- 8 of stand and he would position that air
- 9 sampler where the workers were working, at
- 10 nose height.
- So, in his opinion, these were
- 12 breathing-zone equivalent. So, based upon
- this air samples, we felt we could calculate
- 14 the doses to the workers, during this thorium-
- 15 oxide time period.
- So, again, our main impression was
- 17 that the 300 area was the predominant exposure
- 18 potential and we have methods to estimate
- 19 those doses.
- In early interviews with workers
- 21 about the thorium operations, we did have
- 22 indications that they did some research and

1	development	work,	but	all	the	inter	views
---	-------------	-------	-----	-----	-----	-------	-------

- 2 indicated this was minor benchtop-type of
- 3 levels, nothing significant.
- 4 SC&A in January of this year, in
- one of their findings, was that NIOSH did not
- 6 address thorium exposures in other areas.
- 7 And so, at that time, we committed
- 8 that we would go back to the site and look for
- 9 thorium exposures in some of these other
- 10 areas.
- Now, what we wanted to go back and
- 12 look at, was the material accountability
- 13 ledgers or inventories. And this was
- 14 conducted after the last Board Meeting. We
- 15 did this in March.
- 16 And what was interesting about
- this was from our interviews, the people who
- 18 worked with the material said that there was
- only small quantities, nothing significant.
- That's not what the ledger showed
- 21 us, when we looked at this in March. It was
- 22 rather surprising, to be quite honest, in this

1 case. And two areas popped out and	that was
--------------------------------------	----------

- the 700 area and the TNX area.
- Now, the 700 area was the research
- 4 or Savannah River Laboratory. And, as best we
- 5 can kind of figure, Savannah River methodology
- 6 for starting a new process or improving a
- 7 process, was they would start with lab work
- 8 and deal with small quantities.
- 9 And then they would scale it up to
- 10 a semi-works plant or pilot plant down at the
- 11 TNX facility, before they turned it into full-
- 12 scale production in the canyons or up in the
- 13 300 area for material canning.
- So that was their general process,
- and what you'll see here on this map is the
- 16 700 area is right next to M area, up there at
- 17 the top, and the TNX area is down along the
- 18 river.
- 19 So in the Savannah River, or in
- 20 the 700 area, we've found lots of memos
- 21 discussing benchtop thorium work in the B
- 22 wing, Room 131, appears very often.

1	And we also have indications of
2	thorium work in the high level caves. This is
3	a radiated thorium that actually came,
4	initially, from Hanford. And then some of
5	them from the reactor area, they would send
6	back to 700 area for analysis.
7	But none of these really coincided
8	with these large quantities we saw in the
9	ledgers. What we found, in addition, on the
10	back end of the 773 area, that laboratory, was
11	a metallurgical research and development
12	laboratory.
13	And is known to have a capability
14	of manufacturing full-scale fuel and target
15	assemblies. So, they had a lab that's best
16	described as a very large garage in which they
17	had a 300-ton press and other materials in
18	there, so that they could do this research and
19	development.
20	And our current belief is that
21	most of the thorium work, that's accounting
22	for these tons of material that we see in the

1 ledgers, was conducted here in th	conducted here i	ledgers, was	
-------------------------------------	------------------	--------------	--

- 2 metallurgical laboratory.
- 3 So, that's one area that has us
- 4 concerned, at this point. The other area is
- 5 the TNX or the separation semi-works area.
- 6 And the ledgers indicate
- 7 intermittent work, 1954 to 1956, and then '64
- 8 to '68. The '54 to '56, was more canning type
- 9 of work that they were doing down there.
- 10 And '64 to '68, was actually
- 11 dissolving. And this slide might be different
- 12 than what you got in your handouts, and I
- 13 apologize for that. In reviewing this
- 14 presentation yesterday, I ran into -- this
- 15 said irradiated thorium and that's incorrect.
- 16 This slide is correct.
- 17 The work involved dissolving
- 18 unirradiated thorium. And so these were not,
- 19 these are not high-level gamma slugs that they
- 20 were handling and which you'd have lots of
- 21 shielding to protect you.
- These were normal uranium slugs

1	that	they	were	dissolving	down	in	preparation
---	------	------	------	------------	------	----	-------------

- 2 for the separations canyons.
- 3 CHAIRMAN MELIUS: The time frame
- 4 changed also, yes.
- 5 DR. TAULBEE: Yes, that is
- 6 correct, as well. I apologize for that. So
- 7 that was, and this is the case where they
- 8 would be working from beaker-type of levels
- 9 and now moving into tanks and drums on the
- order of 50 gallons to 100 gallons type of
- 11 operations, in preparation to move to the
- 12 canyons.
- Now, a lot of the early memos
- 14 actually mention a thorium separations
- building. And especially in the early years,
- 16 1953, '54, and '55.
- What's interesting about that is
- 18 they are a little misleading in that they did
- 19 build a building to do thorium separations,
- 20 but the AEC cancelled it in 1956.
- 21 So the building was actually
- 22 built; it was never put into production. So,

1	а	great	deal	of	the	information	we	have	is
---	---	-------	------	----	-----	-------------	----	------	----

- 2 about building this building and it never
- 3 handled thorium.
- 4 But other areas there at the TNX
- 5 certainly did during this time frame. So,
- 6 kind of an overview, this slide is intended to
- 7 try and show you where we feel that dose
- 8 reconstruction is feasible and areas where we
- 9 have concerns and likely could be a problem.
- So, to kind of go from the top, or
- 11 actually let me walk through, based upon the
- 12 process. Again, the 300 area, I showed you
- the pre-metal or the metal workings as well as
- 14 the thorium oxide time frame.
- 15 And we feel the entire time period
- 16 we have a pretty good method of estimating
- 17 dose. Now, in the reactors, that would be
- 18 encapsulated material, so there really isn't
- 19 a significant or any airborne hazard in that
- 20 area.
- 21 The canyon areas didn't start up
- 22 until 1964. Actually, that could have been

1	1965; the first irradiation started in '64,
2	and there is a delay between irradiation and
3	separations.
4	And so that area, even though it's
5	in the canyons, it would be taking some
6	samples coming out of the processes at
7	different time periods.
8	And then at the end, the tail end,
9	they'd be pumping that into the rail cars to
10	send to Fernald.
11	The 700 area is where they did a
12	lot of research early on, up until 1956, and
13	then it appears that, at that time period,
14	most of the thorium research stopped for a set
15	time period.
16	It didn't completely shut down
17	immediately and when it started back up was
18	really in the '60 to '61 time frame, when they

## CHAIRMAN MELIUS: Can I interrupt,

oxide, in preparation.

# NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

started working with some of the thorium

The CMX facility listed there --

19

20

21

22

-		
1	TUST.	
_	lust	
_	J	

- DR. TAULBEE: Sure.
- 3 CHAIRMAN MELIUS: -- I'm a little
- 4 confused on the color coding here.
- 5 DR. TAULBEE: Yes.
- 6 CHAIRMAN MELIUS: For
- 7 unencapsulated thorium, you have three
- 8 different colors. Is that degree of exposure
- 9 or is that, I mean it's a nice slide but --
- 10 (Laughter.)
- DR. TAULBEE: That is what I'm
- 12 trying to convey at this point.
- 13 CHAIRMAN MELIUS: Okay, so it's
- low, medium, high?
- DR. TAULBEE: Effectively, yes.
- 16 CHAIRMAN MELIUS: Okay, okay, no
- 17 that's very good.
- DR. TAULBEE: That's what I'm
- 19 trying to convey, anyway, I'm sorry. But,
- yes, so, during that '57 to 1960 time period
- in the 700 lab, because there wasn't much
- thorium work going on or research, we consider

1	that	to	be	а	low	time	period.

- 2 But there would be residual
- 3 material around. In the CMX facility, this
- 4 was the reactor pilot plant or semi-works, if
- 5 you will. And what they would be doing there,
- is they would be testing these fuel elements.
- 7 They'd be heating up the water to see how
- 8 they behaved in that encapsulated form within
- 9 the reactor. It's not actually running a
- 10 critical experiment or critical reaction, but
- 11 they would be doing the thermodynamics
- 12 associated with the reactor there in the CMX.
- Right next to it is TNX, which is
- 14 the semi-works, and there they would be
- working with it in an unencapsulated form.
- 16 The next one down is the 777M
- 17 laboratory or this physics laboratory. And
- 18 this one is, was very difficult for me to try
- 19 and put into a bin.
- 20 Because some of the material was,
- 21 that they worked with there were bare thorium
- 22 slugs, not canned. Now, they didn't

1	physically	do	anything	with	them,	cutting	or
---	------------	----	----------	------	-------	---------	----

- 2 anything like that on them.
- 3 They were doing reactivity tests.
- 4 And so they'd be loading them into a critical
- 5 pile and determining what the effect on the
- 6 other fuel elements surrounding nearby would
- 7 be.
- 8 And so, but they had both bare
- 9 thorium slugs and encapsulated. So that was
- 10 where they were doing that work.
- 11 So it's really a low,
- 12 unencapsulated hazard, but there was some that
- 13 was unencapsulated. And then the kind of
- 14 grayed areas there, is when thorium was not
- 15 present.
- So, what you can see is that
- 17 you've got a really big mix here at the site.
- In some areas the exposure is minimal, and
- 19 then in other areas, it could be rather large.
- 20 So our time line, in evaluating
- 21 this, is we anticipate submitting to the Board
- 22 a revised Evaluation Report addendum or an

1	83.14	for	your	consideration	at	the	August
---	-------	-----	------	---------------	----	-----	--------

- 2 meeting.
- 3 So we're wrapping this up. We
- 4 have since the last Board meeting in February,
- 5 we've conducted additional interviews within,
- 6 more individuals who worked with thorium in
- 7 the 1950s.
- 8 We've identified them from some of
- 9 the memos that we found in March. As these
- 10 were the people doing the work. And, again,
- 11 all of them are, have indicated during the
- interviews, that they only worked with small
- 13 quantities, in fact, in every single case.
- 14 The interesting part is that we've
- 15 specifically started asking about the metal
- laboratory, and we haven't found anybody that
- 17 actually worked there. And all the
- interviewees have indicated that they really
- 19 didn't know much of what was going on in that
- 20 particular part of the laboratory.
- So, from their knowledge, the lab
- 22 part, the small individual labs where they'd

1	have	benchtop	work,	it	was	verv	small.	But	the

- 2 metallurgical laboratory, very likely had or
- 3 all of those large quantities, these tons of
- 4 thorium that we cite.
- 5 Early next month, we're going to
- 6 follow one last thread down at Savannah River,
- 7 and this is a box that was identified back in
- 8 the March time frame, I guess it was April,
- 9 I'm sorry.
- 10 And the line there in italics, A
- 11 Pu results Pu controlled thorium log '54 to
- 12 '58, is the only indication we have on this
- 13 box. It's in the Atlanta Federal Records
- 14 Center.
- The site is pulling it back so we
- 16 can look at it. And based upon other boxes of
- 17 this type of information, my interpretation is
- 18 that the A stands for A area, which would be
- 19 the 700 area. Pu results are the plutonium
- 20 bioassay for A area, controlled blanks and
- 21 spikes. And then the thorium log. This could
- be a thorium bioassay log book or air samples.

1	We just don't know, from this
2	standpoint. And then the time periods, '54 to
3	'58, which is that early area there for the
4	Savannah River laboratory.
5	But we do, like I said, the first
6	week of June, we will look at this and we will
7	wrap up all of the thorium work before your
8	August Board Meeting.
9	So, with that, let me switch now,
10	gears, and go to the exotic radionuclides. If
11	you recall, the Savannah River petition is for
12	construction trades-based.
13	Oh, I'm sorry, I do need to go
14	back, I apologize for this. On this slide, I
15	didn't get down to the central shops area.
16	One of the things that's important
17	to remember, because this is a construction
18	trades SEC, is that although thorium wasn't
19	present at the central shops, all of those
20	construction trades workers down at the
21	central shops could go to any of these areas.
22	So, a very likely could have gone

1 to the 700 area, if they went to the central
--

- 2 shops, picked up their badge that morning,
- 3 they could go to the 700 area.
- 4 They could go to the TNX. Where
- 5 they got farmed out to is really not
- 6 trackable. So, I've included it there as a,
- 7 kind of a gray type of area, because if we
- 8 were to recommend a Class, the people with the
- 9 construction trades in the central shops,
- 10 would be included because we just can't track
- 11 where they went, as well as we can all of the
- 12 other workers.
- So, again, this is construction
- 14 trades. Generally, with exotic radionuclides
- there's less bioassay for construction trades
- workers compared to operations workers.
- 17 And a concern has been raised as
- 18 to whether the coworker models, that we've
- 19 proposed in our SEC Evaluation Report, are
- 20 applicable to construction trades workers.
- 21 And the main reason is because of
- 22 the difference in the nature of the work.

	1	They	have	a	potential	for	higher	intensity
--	---	------	------	---	-----------	-----	--------	-----------

- 2 exposure, but less frequent. So how that
- 3 plays out is uncertain.
- 4 Now with exotic radionuclides,
- 5 what we proposed is to use the coworker
- 6 models. Now at Savannah River, we actually
- 7 have a large quantity of data, and so we're
- 8 proposing to compare construction trades
- 9 workers to all monitored workers.
- 10 And so we developed first the all
- 11 monitored worker/coworker model, and then
- develop a construction trades worker model,
- and then do a hypothesis test to compare the
- 14 two models, to see if there's a difference.
- When we compared them for tritium,
- 16 because that was the easiest to do, back in
- 17 December of this past year, we didn't see any
- 18 difference between construction trades and the
- 19 all monitored workers. But for exotic
- 20 radionuclides, it could be different; we just
- 21 don't know. In this particular case, for
- 22 bioassay samples for coworker models, the

	1	first	bullet	there,	the	trivalents
--	---	-------	--------	--------	-----	------------

- 2 americium, curium, californium, we have about
- 3 13,000 urinalysis samples between '64 and 1980
- 4 for that trivalent series.
- Neptunium we have about 3,000,
- 6 plus the NOCTS whole body counts. These would
- 7 be whole body count data that's within the
- 8 NOCTS data set.
- 9 And then for mixed fission
- 10 products, there's 49,000 urinalysis samples,
- 11 as well as the NOCTS whole body counts.
- Now, for the trivalents,
- 13 americium, curium and californium, I believe
- 14 during our Work Group meeting in February, I
- 15 had incorrectly spoken and said that we would
- 16 be able to provide this data set to the Work
- 17 Group and such that you all could do analysis
- on them simultaneously with us, by May, I
- 19 believe.
- 20 Well, what turned out was we were
- 21 trying to just use the NOCTS data and we
- 22 didn't have the full data set. And what

1 turned out was we didn't have sufficient da	1	turned	out	was	we	didn't	have	sufficient	da
---	---	--------	-----	-----	----	--------	------	------------	----

- 2 to do the comparison.
- 3 So, back in March, we started
- 4 coding those 13,000 americium, curium and
- 5 californium samples. That coding effort
- 6 should be completed by the middle of June, and
- 7 then we can begin on that analysis part.
- For neptunium, all of that data
- 9 has been coded. The mixed fission products
- 10 were currently under evaluation. Now, during
- 11 my presentation to the Board in February, when
- 12 I was discussing the tritium and I believe Dr.
- 13 Richardson asked about, or maybe it was Dr.
- 14 Field, about how we selected who was a
- 15 construction trade and who wasn't.
- 16 And I indicated at that time we
- 17 were using self-reported data. And there
- 18 appeared to be some concern from that. Well,
- 19 at Savannah River we have all of the work
- 20 history cards for people who worked there.
- So, one of the steps that we can
- 22 do is go through each bioassay sample within

1	that	time	period	and	actually	code	their
---	------	------	--------	-----	----------	------	-------

- 2 actual job. This is very time-consuming.
- I would like to be able to use the
- 4 self-reported data that we can readily get.
- 5 It's already electronic from with NOCTS, but
- 6 our current path is to use the work history
- 7 cards.
- 8 The bottom line with this is that
- 9 to complete all three of these analyses,
- 10 taking this path, has pushed the actual time
- 11 line out about a year, out to May.
- 12 And so that has some concerns in
- 13 and of itself, that we wouldn't get this
- 14 answer for a very long time in going down this
- 15 path.
- 16 The final issue is the time line
- 17 for the other exotics. And back in March,
- 18 when we were there at the site, we went
- 19 through the Savannah River Laboratory Monthly
- 20 Reports.
- 21 And we selected excerpts from
- 22 those reports that talked about other

1	radionuclides,	such	as	polonium,	thulium	and

- 2 technetium, actually, and several other ones
- 3 that they worked with.
- And so we've begun to build a
- 5 matrix of when they worked with some of these
- 6 small projects. Those excerpts are currently
- 7 undergoing classification review, so we
- 8 haven't gotten them yet.
- 9 But this was all done within the
- 10 classified vault with SC&A's assistance, as
- 11 well. And, so with that, I'd be happy to
- 12 answer any questions.
- 13 CHAIRMAN MELIUS: Thank you, Tim,
- 14 and can I remind people on the phone that,
- 15 please mute your phones. If you don't have a
- 16 mute on the phone, \*6, works, we're hearing
- 17 some background, an occasional sneeze, but it
- 18 would be helpful, thank you.
- 19 Board Members with questions? Why
- 20 don't I start off because maybe Bill or Tim,
- 21 someone can sort of refresh my memory on the
- 22 concern about using the self-reported, you

- 2 to what degree it would be a problem or do we
- 3 know, so I just don't quite understand it.
- 4 DR. TAULBEE: I believe the
- 5 concern dealt with, that if you have people
- 6 who are actually not a construction trades
- 7 worker, it would be in that pile that your
- 8 hypothesis testing could be flawed, that if
- 9 you didn't see a difference it would be more
- 10 biased towards the null of never seeing
- anything, is what they were concerned about.
- 12 And I can't remember, I think it
- 13 was Dr. Richardson, is that correct, who
- 14 brought that up.
- 15 CHAIRMAN MELIUS: It actually
- 16 sounds like a David Richardson question.
- 17 Because it certainly does change the task.
- 18 And I think it somewhat depends on -- the
- 19 amount of bias is going to depend on how much
- 20 misclassification there is, and so forth.
- 21 And I don't know if there's a way
- 22 of sort of evaluating that before embarking

1	on,	you	know,	if	you	did	а	comparison	on	а
---	-----	-----	-------	----	-----	-----	---	------------	----	---

- 2 sub-sample or sample of those that you could
- 3 determine to what extent there is, how
- 4 significant the Misclassification is.
- I think it's hard to judge from a
- 6 distance because it somewhat depends on how
- 7 you're classifying and so forth.
- B DR. TAULBEE: One interesting part
- 9 about that component right there is that once
- 10 we, if we go down the path and code all the
- 11 work histories for the trivalents, we do have
- 12 that electronic data set so those two could
- 13 actually be compared.
- 14 MEMBER FIELD: Just so the next
- 15 time you speak, you can say it was me that
- 16 asked this question, okay?
- 17 (Laughter.)
- DR. TAULBEE: I'm sorry.
- 19 MEMBER FIELD: With the workers, I
- 20 quess the concern would be for self-reported
- 21 information for the next of kin that may not
- 22 know that information. So it would be a good

1	number	of	folks.	Ι	would	imagine,	that	would

- 2 construction workers that if they weren't able
- 3 to self-report, you would never know. Is that
- 4 correct?
- 5 DR. TAULBEE: That is correct to
- 6 some degree. If they were monitored for
- 7 external radiation, and 80 percent of the
- 8 claimant population was monitored, we would
- 9 have the indication based upon their badge
- 10 number, as to which they were.
- 11 So we could augment some of that
- 12 to reduce the misclassification, but you're
- absolutely right. If they were not monitored,
- 14 then they could be misclassified.
- 15 CHAIRMAN MELIUS: By the way, the
- 16 trick is to attribute the comment to a Board
- 17 Member who is not present. And that way --
- 18 so, Mark was the one that asked all the
- 19 questions and we blamed everything on
- 20 yesterday, before he got here.
- 21 Wanda, and then Josie.
- 22 MEMBER MUNN: It would seem just -

1 -	nothing	scientific		just	common	sense
-----	---------	------------	--	------	--------	-------

- 2 would tell one that a construction worker
- 3 would be more likely to self-identify, or the
- 4 family would be more likely to know that that
- 5 person was a construction worker than would be
- 6 true of almost any other designation, because
- 7 if a person works in construction, they work
- 8 in construction. Whether, regardless of who
- 9 their employer is, it's not likely that they
- 10 would be mistaken as a laboratory technician,
- 11 for example.
- 12 It just, on the other hand,
- families frequently don't know what the work
- is that a person does, if they do not have a
- 15 clear designated trade of that sort.
- 16 It just seems reasonable to me
- 17 that you'd more likely know that.
- 18 MEMBER FIELD: I quess it depends
- 19 on if construction workers have classification
- 20 or not. I don't know that, for the site. If
- 21 they do, then the family may not know.
- 22 MEMBER MUNN: No, I was thinking

1	in	terms	$\circ f$	self-	classi	fica	ation	here
_		CCLIIIO	$\circ$	$\circ$	$C \pm \alpha S S \pm$	- $       -$	$\mathcal{L} \cup \mathcal{L} \cup \mathcal{L}$	

- 2 CHAIRMAN MELIUS: Tim, do you want
- 3 to respond?
- DR. TAULBEE: I believe what Ms.
- 5 Munn is getting at is absolutely right. If
- 6 somebody was a carpenter the family would
- 7 generally know that they were a carpenter or a
- 8 plumber or a pipefitter or that type of a job.
- 9 So, I think that misclassification
- 10 would be minimal but I can't rule it out.
- 11 CHAIRMAN MELIUS: Okay, okay.
- Josie, you had a question or no, okay. Phil?
- 13 MEMBER SCHOFIELD: What about
- 14 those people who migrated from construction
- jobs into, like, lab workers or whatever?
- DR. TAULBEE: By the way that
- we're going through -- and that's one of the
- 18 problems that you identified there with the
- 19 self-report -- because it's generic over the
- 20 whole time period. By going through the work
- 21 history cards, which is taking us a
- 22 significant effort in order to do that, we're

1	pairing	the	individual	bioassay	with	what

- 2 their job was at that time. So it would
- 3 change and it would track a person going
- 4 through starting out in construction and then
- 5 maybe moving into a foreman or even to a
- 6 laboratory person. So, it would track that.
- 7 That's the, one of the major
- 8 benefits of the work history cards. But it is
- 9 a very time-consuming effort.
- 10 CHAIRMAN MELIUS: Okay, Board
- 11 Members on the phone, do you have any
- 12 questions?
- 13 MEMBER ZIEMER: Ziemer, here, I
- 14 don't have any questions, I just appreciate
- the presentation the Tim Taulbee has given.
- 16 MEMBER CLAWSON: This is Brad, I
- don't have any comments.
- 18 CHAIRMAN MELIUS: Okay, thanks.
- 19 And, by the way, that was one of our Board
- 20 Members sneezing, not someone on the phone.
- 21 So, just to clarify that.
- Okay, why don't we hear from Mark,

- 2 may have more questions.
- 3 MEMBER GRIFFON: My comments will
- 4 actually be pretty brief because I think Tim
- 5 went over a lot of the same ground. I wasn't
- 6 sure exactly how much of an update he was
- 7 going to give with regard to the thorium
- 8 issue.
- 9 So I think I can shorten this a
- 10 little bit. Now, I just have to find it.
- Okay, so just to give an overview of where the
- 12 Work Group has been on these issues.
- 13 And I think I used this, a similar
- 14 slide last time, that I gave an update. But
- there are 25 issues, and I think Tim touched
- on a lot of this.
- 17 Twenty-one remained at that point,
- 18 because we kind of merged a couple. And we
- 19 really closed out two items regarding external
- 20 exposure and the use of the electronic
- 21 database for external exposure, co-worker
- 22 model, closed out at least with regard to an

1	SEC	issue,	may	still	have	some	Site	Profile
---	-----	--------	-----	-------	------	------	------	---------

- 2 questions, but closed out for the SEC review.
- 3 Of the 19 remaining, there is 14
- 4 that are focused on internal dose. So the
- 5 highlight of the issues is mainly the internal
- 6 dose issues.
- 7 And the last bullet there says,
- 8 there are several items that we went through
- 9 the petition, we asked SC&A to go through the
- 10 petition.
- 11 And the petitioner has been, to
- 12 some extent, involved in the meetings and
- issues that have come up in that regard, we've
- 14 basically, I believe, all of them have fit
- into other matrix items at this point.
- So we're capturing all the other
- 17 petitioner items, but they all fit into these
- 18 19 remaining issues.
- 19 The focus here for me is going to
- 20 be the thorium question. And as Tim pointed
- out, it's broken up into this '53 to '65, and
- '65 to '71, and I'm going to say two different

1 words here. And beyond, is the question	that
---	------

- 2 I think has been raised.
- 3 So there's a question of this '71
- 4 cutoff or further regarding the thorium
- 5 question.
- 6 This summarizes a little bit of
- 7 where we're at. In April 28, 2010, NIOSH
- 8 published an addendum to its ER Report. Tim
- 9 went through a lot of this.
- 10 It focused on the 300 M area, and
- I guess the key bullet here, I'm skipping some
- things because it would be redundant from what
- we've heard already.
- 14 The key bullet here is that NIOSH
- 15 did not examine work on thorium in any other
- area during the '53 to '65 period.
- 17 The one last bullet there is that
- 18 also one of the rationale for the approach
- 19 presented to us was that they found the
- 20 bioassay work sheets that they concluded were
- 21 all, all the results were below the MDA.
- This was actually a success of the

1 Work Group process. We actually got off-	-line
--	-------

- 2 for a second and had everybody look at the
- 3 same computer, and we determined, no, in fact
- 4 there were some that were over the MDA.
- 5 Something, a little mini-win for
- 6 the Work Group, which I was quite proud of, we
- 7 actually got some work done.
- 8 Overall conclusions for this first
- 9 period, '53 to '65, this is SC&A's overall
- 10 conclusions. The key there, again, is in the
- 11 first bullet.
- 12 The concern of, that it omits
- 13 several source terms and this is still an
- ongoing project, obviously Tim has discussed.
- The second item is there's still
- 16 some questions remain, from SC&A's standpoint
- about the scientific validity of the approach.
- 18 There's a limited number of air
- 19 samples for this early time period. Only
- 20 about half of them were alpha-counted and
- 21 there's some question about the conversion
- 22 from the counts on the air sample to actual

4	' '	
1	21  MAMA	concontrations
1	allwulle	concentrations.

- 2 So you have CPM, is the way
- 3 they're recorded, I believe. And there's some
- 4 question about how that's converted, based on
- 5 calibration factors and other information.
- Time from sample to count time,
- 7 things like that. And, finally, the
- 8 representativeness of the air samples they, I
- 9 think Tim did touch on that a little this
- 10 morning, that they've interviewed some
- 11 technicians and that's more information than I
- 12 had heard before, regarding whether these are
- 13 representative of worker samples or the
- 14 exposures the worker would have received.
- The last item is something that
- 16 wasn't really hit on too much, but it related
- 17 to this thorium issue, there was a question on
- 18 the thoron dose reconstruction with radon-
- 19 220.
- The second time period, '65 and
- 21 after, as I say in this slide, again, the
- 22 report focused on the thorium oxide, as Tim

1	outlined	in	very	great	detail	in	his
---	----------	----	------	-------	--------	----	-----

- 2 presentation.
- 3 They went from the thorium metal
- 4 to the thorium oxide, in the 300 area. But
- 5 we're pointing out here that this -- only
- 6 recover the thorium oxide in that one area,
- 7 the 300 M area.
- 8 Use of the air samples from '64,
- 9 to '68, to draw conclusions for that entire
- 10 period, '65 to '71. And I would say possibly
- 11 further than '71, is some of the information
- 12 that SC&A has gathered that it may went, gone
- 13 beyond that.
- 14 And then the last item, is just
- 15 consistent with what was just said. That
- there's a data-capture effort and I believe
- 17 SC&A is working with NIOSH in that regard.
- 18 The preliminary review, again,
- 19 this is talking about that second time period,
- 20 '65 to '71. And I think, one of the key
- 21 points on this slide is that we had asked, and
- 22 this is key throughout the whole time period,

1	that	we	had	asked	SC&A	to	consider

- 2 construction workers and non-construction
- 3 worker data.
- 4 And partially because it's all
- 5 being rolled together, this is operations data
- 6 and even though the petition focuses on
- 7 construction workers, we ask that SC&A
- 8 consider the ability to reconstruct doses for
- 9 both those groups.
- 10 And I guess one point I would make
- 11 here is that I think NIOSH, in their
- 12 consideration of an approach or a possible
- 13 83.14, as Tim described in his one slide, I
- 14 think NIOSH should also consider, if they are
- 15 going to move in the direction of 83.14,
- whether it applies to construction workers and
- 17 possibly non-construction workers, NIOSH can
- 18 redefine that Class.
- 19 And SC&A did point out that there,
- these findings that they're finding, related
- 21 to the thorium reconstruction effort, apply to
- 22 both those populations. And here, now this

	1	might	be	а	little	confusing,	but	it,	because
--	---	-------	----	---	--------	------------	-----	-----	---------

- 2 the first bullet point points out that these
- 3 things apply to that whole time period.
- 4 Even though I was just talking
- 5 about the second, '65 to '71, time period.
- 6 But this points out, and it's not inconsistent
- 7 with Tim's slide. I guess part of the effort
- 8 going forward is going to be that SC&A NIOSH
- 9 have to compare their lists of possible areas
- 10 of concern because I'm not sure if all these
- 11 areas that I underlined, including the 200
- 12 area, 773 area, if I'm correct, that fits into
- the 700 series of buildings.
- 14 So that may have been touched on
- by what Tim presented. But I don't know that
- 16 he touched on some of these other areas. Like
- 17 the Building 643 G and the 100 reactor area.
- 18 So again, we, I think we need to
- 19 get SC&A and NIOSH to make sure that all these
- 20 areas of potential concern, potential thorium
- 21 exposure are considered. Then there are some
- 22 questions that SC&A raised about even the

1	reconstruction	effort	on	the	300M	area
---	----------------	--------	----	-----	------	------

- 2 notwithstanding the concerns about other
- 3 areas.
- And one is that, looking at the
- 5 underlying things here, NIOSH has not
- 6 discussed recycled thorium, so the thorium
- 7 that may contain uranium-233 and other
- 8 isotopes after it's been irradiated, whether
- 9 that came back in the 300M area.
- 10 The second bullet focuses on the
- 11 past 1971, kind of thing, the question of,
- 12 SC&A seems to have some documented evidence
- that it may have extended into, up to 1980, so
- 14 SC&A has raised that concern.
- The third bullet talks about the
- 16 other described work other than the thorium
- 17 oxide in the '65 and later period, may have
- been going on in this 300M building.
- 19 And then the combined exposure of
- thorium and enriched uranium in the 300M
- 21 area, how that will be dealt with. So several
- 22 other issues, even in the 300M area were

1	raised	by	SC&A.

- 2 Conclusions on the '65 to '71 and
- 3 beyond time frame. You know, it goes back to
- 4 these main themes, is that the question on the
- 5 source terms. Were all source terms
- 6 considered in the 300M area? Questioning of
- 7 the adequacy of the air sampling data. The
- 8 time coverage, but also the questions related
- 9 to the actual using the count data and how
- 10 converting that to airborne concentrations.
- 11 And then the processing beyond
- 12 '71. And this is the last slide. It just
- 13 lists the, it lists the reports that have gone
- 14 back and forth between SC&A and NIOSH, and I
- 15 guess a memo to me.
- 16 So that's all I had. I think Tim
- 17 did a very good job and Tim's presentation
- 18 actually went beyond where we were at the last
- 19 Work Group meeting, so there was some new
- 20 information put on the table by NIOSH. So
- 21 that's just sort of an update of where the
- 22 Work Group has been.

1	I think it looks clear that we'll
2	have to have another meeting before the August
3	meeting and hopefully we can come to some
4	decisions on thorium by the August meeting,
5	and that's all I have.
6	CHAIRMAN MELIUS: Thank you, Mark.
7	Any questions for Mark? Yes, Bill.
8	MEMBER FIELD: Mark, you have
9	mentioned the one slide, there was questions
10	with counting methods for the thoron. Was
11	there any thoron measurements performed at
12	all?
13	MEMBER GRIFFON: Thoron
14	measurements were very limited, but I'll,
15	maybe I'll bring Arjun up to say how limited,
16	or Tim could speak to it.
17	DR. MAKHIJANI: Yes, there were
18	some measurements where there were counts done
19	of the air samples repeatedly, so that thoron
20	could be inferred from those counts because of
21	the decay of the short-lived radionuclides.

samples

were

those

And

22

limited.

1	There	was	some	counting	problems	and	there
---	-------	-----	------	----------	----------	-----	-------

- were very few samples.
- 3 DR. TAULBEE: In that thorium
- 4 area, there were times where we had the
- 5 initial count, the 24-hour count and the 72-
- 6 hour count.
- 7 MEMBER GRIFFON: How many, you
- 8 said limited, Arjun, but do you recall how
- 9 many?
- DR. MAKHIJANI: I think I, in the
- 11 earlier, '53 to '65 period, there were only
- 12 eight samples, but three or four of them were
- 13 actually beta-counted.
- So I think only four usable
- 15 samples and almost all of them were in a
- 16 limited period. I think three of the four
- were on the same day, actually. And then
- there was one on another day, '54 and '55. So
- 19 the '53 to '65 period is essentially not
- 20 covered. So we didn't think, at least in that
- 21 earlier period, there was a basis to do thoron
- 22 dose estimation.

1	Τn	<b>'</b> 65	t.o	'71 <i>.</i>	Т	don't.	remember,
_		~ ~	~ ~	· <b>-</b> /	_	0.0	_ 000 0 _ /

- 2 if you give me a minute, I'll look at the
- 3 report.
- 4 CHAIRMAN MELIUS: Okay, anybody
- 5 else have questions? Can we figure out the
- 6 timetable for this? Does NIOSH have an idea
- 7 when, or whether either assuming an addendum
- 8 or an 83.14 is done, what the timing of that
- 9 will be?
- 10 Obviously, as Mark said, we'll
- 11 need a Work Group meeting before August.
- 12 MR. RUTHERFORD: Our full
- intention is to have something prepared for
- 14 the Board and be ready for the Board to take
- 15 action in August.
- 16 CHAIRMAN MELIUS: No, what I'm
- 17 asking --
- 18 MR. RUTHERFORD: For the Work
- 19 Group, okay. I think that it will depend on
- 20 what Tim finds out in early June. We can give
- 21 Mark an update as soon as Tim finds out what
- 22 he finds out in early June, we can give an

1	update,	as	quickly	after	that,	when	the	report
---	---------	----	---------	-------	-------	------	-----	--------

- 2 will be ready.
- 3 CHAIRMAN MELIUS: Okay, good.
- 4 MEMBER GRIFFON: We could probably
- 5 schedule our meeting near the next Board
- 6 Meeting. I think it's pretty evident that
- 7 you'll need as much time as possible.
- 8 CHAIRMAN MELIUS: Then two sort of
- 9 follow-ups on that. One is maybe this is
- 10 planned already or maybe this is
- inappropriate, so tell me, but for this data
- 12 capture that's coming up in early June, does
- it make any sense to have SC&A present for
- 14 that or involved in that?
- Just, again, in terms of
- 16 facilitating this process.
- DR. TAULBEE: It's obviously up to
- the Board, as to whether you want that or not.
- 19 If there's thorium information in that log
- 20 book, we will capture the whole thing.
- 21 CHAIRMAN MELIUS: Okay.
- DR. TAULBEE: So.

1	CHAIRMAN	MELIUS:	Can	someone	with

- 2 more knowledge on this weigh in? I just
- 3 don't, I want to get it, if we're going to do
- 4 it we've got to decide now, that's all.
- 5 If it's not worth doing, I'm not
- 6 pushing it unnecessarily, that's all.
- 7 DR. MAKHIJANI: Dr. Melius, I
- 8 don't know if this classified or non-
- 9 classified, the classified visit.
- 10 DR. TAULBEE: It's not in the
- 11 classified vault, but Savannah River does
- 12 require, in order to get access onto site, you
- 13 have to have a Q clearance.
- DR. MAKHIJANI: No, we would send
- a pre-cleared person, but the reason for my
- 16 question was, if there is some classified
- 17 documents or some review issues, it would be
- 18 better if somebody from SC&A were there, so we
- 19 could have some idea at least for, among the
- 20 people who have clearance, what is going on.
- 21 If the documents can be
- immediately posted, there would be no need.

1	Otherwise,	I	think,	since	the	time	frame	is
---	------------	---	--------	-------	-----	------	-------	----

- 2 very short, if it's unclassified and we can
- 3 make our notes, then we would have a basis for
- 4 discussion, rather than waiting.
- 5 So I don't know what the time
- frame would be for posting the documents. If
- 7 they were immediately posted --
- 8 MEMBER GRIFFON: If it's not an
- 9 issue with NIOSH, I just assumed we should
- 10 have SC&A represented. Then they are up to
- 11 speed and they can, you know, we can get a
- 12 full briefing for the Work Group.
- 13 But if it's not an issue with
- 14 NIOSH, I think we should just plan for that.
- MR. HINNEFELD: No, we're
- 16 certainly amenable to that and let's
- 17 facilitate this as much as we can.
- 18 CHAIRMAN MELIUS: And then my
- 19 follow-up issue, sort of related to timing and
- 20 so forth, is, I think we also want to
- 21 authorize SC&A to review the, whatever, if
- 22 NIOSH produces a report, when they produce the

1	report,	SO	it's	ready	for	the	Work	Group	and
---	---------	----	------	-------	-----	-----	------	-------	-----

- 2 for the Board Meeting.
- At least, you know, again it's
- 4 going to depend on timing, but at least some
- 5 review of that, and if there are issues that
- 6 need to be raised. Does that make sense,
- 7 Mark?
- 8 MEMBER GRIFFON: Yes, I think in
- 9 terms of actions, that makes a lot of sense
- 10 that we'll, instead of waiting for the Work
- 11 Group to test them, to review the product that
- 12 comes to us in early August.
- We should say that now, that we
- 14 would like you to review that product.
- DR. MAKHIJANI: One last thing,
- 16 Dr. Melius.
- 17 CHAIRMAN MELIUS: Sure.
- 18 DR. MAKHIJANI: We'd just
- 19 appreciate a coordination of the dates because
- 20 we've got limited Q-cleared people and just
- 21 make sure that we can send someone.
- 22 CHAIRMAN MELIUS: Okay, probably

1	you	can	work	out	with		yes.	So,	Mark,	do
---	-----	-----	------	-----	------	--	------	-----	-------	----

- 2 you want to, then, make a motion to authorize
- 3 SC&A to do the review?
- 4 MEMBER GRIFFON: Does that require
- 5 a motion?
- 6 CHAIRMAN MELIUS: Well, either the
- 7 Work Group or the Board has to do it, correct?
- 8 MR. KATZ: Well, this really
- 9 underway already and then Work Group --
- 10 CHAIRMAN MELIUS: Okay, okay, fine
- 11 then. I'm just trying to --
- 12 MEMBER GRIFFON: It's just ongoing
- work.
- 14 CHAIRMAN MELIUS: Yes, I just want
- to make sure we get it. Don't come back in in
- August and say, why didn't we do this and so
- 17 forth.
- 18 Any other comments or questions or
- 19 things we need. I'd like to thank both Tim
- 20 and Mark. I know that some of us are
- 21 reviewing and reacting on the fly to
- 22 information, but I think this is helpful in

_	1	terms	of	trying	to	expedite	this	goir	ıg
---	---	-------	----	--------	----	----------	------	------	----

- 2 forward.
- I know it's a big site and it's
- 4 very complicated and it's hard to get a handle
- 5 on it. And I think, hopefully this is a good
- 6 way forward on this and we'll be able to
- 7 certainly make significant progress by August.
- 8 MEMBER ZIEMER: Dr. Melius?
- 9 CHAIRMAN MELIUS: Yes, Paul, I'm
- 10 sorry.
- 11 MEMBER ZIEMER: Paul Ziemer here.
- 12 I wasn't able to locate a copy of Mark
- 13 Griffon's slides. Were those distributed or
- 14 can I get a copy?
- 15 CHAIRMAN MELIUS: We will all get
- 16 a copy. They were not distributed.
- 17 MEMBER GRIFFON: Those were
- 18 drafted in the Boston Express bus this
- 19 morning.
- 20 CHAIRMAN MELIUS: And then
- 21 slightly modified in the, when our break, in
- order to react to, at least initially react to

1 5	Tim's	presentation.
-----	-------	---------------

- When I say this is like you're on
- 3 the fly, it was, and we appreciate everybody's
- 4 effort. It was not, kind of like a well
- 5 planned effort on this one.
- 6 But I think it was very helpful
- 7 and we will get those distributed to
- 8 everybody. And certainly things like, I don't
- 9 know if it's a technical call or how we work
- 10 this, but trying to resolve this, the issues
- on different areas where thorium was used and
- 12 the building nomenclature sort of issues,
- 13 whatever you call it. Or, you know, getting
- 14 those, I think we can get that done soon, I
- think that would be helpful also, if only not
- 16 to confuse us Board Members who are not as
- 17 involved in this effort.
- 18 MEMBER GRIFFON: Right, I quess
- 19 that is a part that I would urge NIOSH and,
- 20 Arjun, I guess you're the point of contact on
- 21 that.
- 22 CHAIRMAN MELIUS: Yes, he does.

1	MEMBER GRIFFON: Because there, at
2	least to me, it seemed to be like some areas
3	that I mentioned in my slides that SC&A had
4	pointed out as potential thorium-exposure
5	issues were not captured in NIOSH's, so, yes,
6	go ahead, Arjun.
7	DR. MAKHIJANI: Yes, thank you,
8	Mark. We, I also noted the same thing. And I
9	just wanted to put a caveat that what we did
10	was just to illustrate that there were many
11	areas where thorium work happened.
12	We, I stated in our report, we

- We, I stated in our report, we
  made no attempt to make a comprehensive
  catalog or time frame or buildings, but there
  were many examples that came up on a simple
  thorium word search. And we gave some
  examples, many examples, actually.
- So we haven't done a comprehensive thing. But I did note that like the 643 G area and the burial grounds and so on, were not covered in the NIOSH presentation.
- 22 MEMBER GRIFFON: I quess I would

1 hope	e that,	in	whatever	form	NIOSH	presents,
--------	---------	----	----------	------	-------	-----------

- whether it's 83.14 or a revised approach, that
- 3 they do a comprehensive -- if those other
- 4 areas are insignificant quantities or things
- 5 like that, as long as you can account for it.
- And, as Arjun said, there may be
- 7 others that are not included in SC&A. They
- 8 pointed those out as examples.
- 9 CHAIRMAN MELIUS: Well, I think to
- 10 the extent it's feasible for NIOSH to do that
- 11 between now, and I'm not sure. It seems like
- 12 a fairly complicated site.
- 13 MEMBER GRIFFON: But at least to
- 14 address the ones that are on the table.
- 15 CHAIRMAN MELIUS: On the table,
- 16 yes, yes. And, no, and that's something that
- 17 certainly needs to be dealt with in the
- 18 future, going forward on this. Good.
- Okay, again, thank everybody. We
- 20 will take our break now and we will be back
- 21 here at 1:30. Ted, do you have any
- 22 announcements to make?

1	MR. KATZ: No, no announcements.
2	But at 1:30, we'll have Hanford.
3	CHAIRMAN MELIUS: And we Hanford
4	and so we need to start, since we'll have
5	petitioners online, we would like to start
6	directly at 1:30, so be on time if we can,
7	plenty of time.
8	I should make the announcement,
9	the hotel told us yesterday they had a soup
10	and sandwich special. I'm assuming it's there
11	today.
12	(Whereupon, the above-entitled matter went off
13	the record at 12:03 p.m.
14	and resumed at 1:35 p.m.)
15	
16	
17	
18	
19	A-F-T-E-R-N-O-O-N S-E-S-S-I-O-N
20	1:35 p.m.
21	CHAIRMAN MELIUS: Okay, if
22	everyone gets seated. We've got our music

- off, our people on. We've got Dr. Lemen in
- 2 the middle here.
- Finally, did someone take his
- 4 chair? If the Members of the Board could take
- 5 their chair -- the esteemed Members of the
- 6 Board.
- 7 MR. KATZ: I think I heard Dr.
- 8 Ziemer on the phone, is that correct?
- 9 MEMBER ZIEMER: I am here. I'm
- 10 not able to be esteemed and take a chair
- 11 there, but I will be on the line.
- 12 CHAIRMAN MELIUS: Dr. Ziemer, you
- 13 are esteemed, even from a distance.
- 14 MEMBER CLAWSON: Well, what does
- 15 that say about me, then?
- 16 (Laughter.)
- 17 MR. KATZ: So we have Mr. Clawson,
- 18 too, the esteemed Mr. Clawson, that's nice.
- 19 MEMBER CLAWSON: Oh, there we go,
- 20 yes.
- 21 MR. KATZ: Do we have any other
- 22 Board Members on the line?

1	(No response.)
2	MR. KATZ: Okay, very good.
3	CHAIRMAN MELIUS: Okay, Ted will
4	now remind you
5	MR. KATZ: Let me remind, yes,
6	please, everyone on the phone line, mute your
7	phone. And if you don't have a mute button,
8	press * and then 6 and that will mute your
9	phone, thank you.
10	CHAIRMAN MELIUS: Okay. This
11	afternoon we will start with a presentation on
12	the new Hanford SEC petition on the plutonium
13	finishing plant and Sam Glover is going to
14	present.
15	And I believe we then may hear
16	from the petitioners a little bit later.
17	Usually our procedure, so the petitioners
18	know, is we hear from NIOSH, the Board Members
19	ask about the NIOSH presentation. Then we'll
20	give an opportunity for the petitioners to
21	speak, if they wish.

KATZ:

MR.

22

Just for the record,

1	Ms.	Beach	and	Ms.	Munn	have	both	recused
---	-----	-------	-----	-----	------	------	------	---------

- 2 themselves from this session.
- 3 DR. GLOVER: Dr. Melius, Members
- 4 of the Board, I'm going to change gears from
- 5 Sandia to Hanford. And so we're talking about
- 6 a special, a new Special Exposure Cohort
- 7 Petition Evaluation Report and this was
- 8 received November 10th, 2009.
- 9 The petitioner proposed a Class
- 10 very late in the time frame and very specific.
- 11 And that's something we'll talk about. But
- 12 their proposed Class was: all personnel who
- were internally monitored by urine or fecal
- 14 measurements, who worked at the plutonium
- finishing plant in the 200 area at the Hanford
- site, from January 1, 1987, through December
- 17 31, 1989.
- 18 So on May 3rd, 2010, the petition
- 19 qualified for evaluation. And it qualified
- 20 under the basis that radiation monitoring
- 21 records for members of a Class -- proposed
- 22 Class had been lost, falsified or destroyed.

1	That	was	the	proposal.

- So, we'll go into that a little
- 3 bit more, but let me -- the backdrop, you guys
- 4 are pretty well versed, and we've talked
- 5 about Hanford quite a bit.
- 6 There are three current SEC
- 7 Classes that have been enacted for Hanford.
- 8 There was a Class enacted from October 1,
- 9 1943, through August 31st, 1946, for selected
- 10 areas within Hanford.
- 11 And that was SEC-57-1. Then a
- second Class from September 1, 1946, through
- December 31, 1968. Again, for selected areas
- 14 within Hanford, was 57-2.
- 15 After we looked at those Classes
- 16 and how they were being -- the inability to
- 17 properly implement them, a third Class, a
- 18 subsuming Class was added more recently as
- 19 SEC-152, from October 1, 1943, through June
- 30, 1972, for all areas of Hanford.
- 21 SEC-57 actually was a compilation
- 22 of several SEC petitions. Actually,

1	originally	requested	from	'43,	to	I	believe
---	------------	-----------	------	------	----	---	---------

- the early 1990s or around 1990.
- 3 So, it actually is an ongoing
- 4 still with the Board, we're continuing to
- 5 review those later years.
- 6 So we again continued to review
- 7 post-1972. The time frame associated with
- 8 SEC-155 was encompassed by 57, however, this
- 9 SEC-155 was so specific and so focused on the
- 10 data falsification, which really wasn't
- 11 brought up in this separate SEC petition, that
- 12 it was deemed appropriate for a separate
- 13 review.
- 14 The petitioner's specific evidence
- of accusations by the US EPA of purposeful
- 16 wrongdoing by US Testing resulted in NIOSH
- 17 determining that issues regarding quality of
- 18 bioassay data required further investigation
- 19 as a separate issue from the continuing Board
- 20 Evaluation.
- The intent of NIOSH's separate
- 22 Evaluation in this report for SEC-155 is to

1	ensure	that	issues	identified	with	US

- 2 Testing's non-bioassay analytical programs,
- 3 did not also adversely affect the company's
- 4 bioassay analysis operations in Richland,
- 5 Washington.
- 6 So what did we look at? Kind of
- 7 the standard, to some degree, the Technical
- 8 Basis Documents, the information we've done,
- 9 the Technical Information Bulletins.
- 10 We interviewed several people who
- 11 we thought would have information regarding
- 12 this process or this time frame. Obviously
- 13 looking at do we have existing claimant files,
- 14 documentation provided by the petitioner.
- We collected over 7,500, and these
- 16 are really SRDB entries, but they may contain
- 17 numerous documents and, in some cases, are
- well over 300 to 400 pages.
- 19 We also had data captures at
- 20 Hanford and at the Office of the Inspector
- 21 General for DOE. We want to start out by
- 22 saying that the interviews with the eight

1	workers,	none	of	the	statements	collaborated

- 2 the falsification of data from the radio
- 3 bioassay program.
- 4 So I was going to start with that
- 5 aspect. A bit about the previous dose
- 6 reconstructions, we have 4,034 claims
- 7 submitted to NIOSH.
- 8 Claims within the time frame was
- 9 1,347. Claims containing internal dosimetry,
- 10 914. Claims with external dosimetry are
- 11 1,310.
- 12 We did not break out specifically
- the plutonium finishing plant as part of this.
- 14 That may or may not be readily done, but not
- 15 within the existing NOCTS.
- 16 NIOSH evaluated the time period
- 17 requested by the petitioner, January 1, 1987,
- 18 through December 31, 1989. The location was
- 19 specified as employees who worked at the
- 20 plutonium finishing plant.
- 21 Evaluation was primarily focused
- 22 on the program which applies to all of

1	Hanford.	This	would	be	a,	if	they	were
---	----------	------	-------	----	----	----	------	------

- 2 falsifying data, it really wouldn't be just
- 3 the plutonium finishing plant, it would be a
- 4 broad scope problem.
- 5 The Evaluation does not repeat the
- 6 discussions from the Evaluation Report for
- 7 SEC-57 or SEC-152. We describe briefly the
- 8 activities at the plutonium finishing plant
- 9 during the time period in question.
- 10 The focus of the Evaluation was on
- data falsification and not source-term-related
- 12 information. Very briefly then, on the
- 13 plutonium finishing plant, in this late time
- 14 frame, they had weapons grade metal
- production, occurring in the remote mechanical
- 16 C line.
- 17 The plutonium reclamation facility
- 18 was operational, miscellaneous treatment
- 19 system glove box operations, analytical
- 20 laboratory operations, they had development
- 21 laboratory operations.
- They also had polycube processing,

1	which	is	an	unusual	material	mixture	of
---	-------	----	----	---------	----------	---------	----

- 2 polystyrene and plutonium oxide, they were
- 3 using to do criticality experiments.
- 4 They were basically handling that
- 5 probably for disposal purposes, how to break
- 6 that down and get that into -- they had a
- 7 large variety of metal handling and operations
- 8 going on in this late time frame.
- 9 So potential radiation exposures
- 10 during the Class period. They certainly have
- 11 internal exposure to plutonium finishing
- 12 plant, to a broad spectrum of internal
- 13 emitters, particularly plutonium and
- 14 americium. External sources of exposure,
- 15 really not the driving source here, because
- 16 we're really looking at falsification of
- 17 bioassay data.
- 18 But they do certainly have
- 19 photon/beta exposure from various activities,
- 20 as well as neutron exposure. Internal
- 21 monitoring data, US Testing processed several
- thousand bioassay samples during the period in

_	
1	question.
_	daescron.

- 2 Urinalysis was the principle
- 3 plutonium method. Workers deemed to have a
- 4 higher risk or those involved in potential
- 5 incidents may also had fecal samples.
- 6 Americium was typically monitored
- 7 by in vivo measurements. And so, while there
- 8 are some americium measurements that were done
- 9 by US Testing, those are usually corroborated
- 10 by a separate method, which was in vivo
- 11 measurements.
- 12 External monitoring data that's
- 13 available is extensive. Monitoring results
- 14 are available for the beta photon, as well as
- 15 neutrons, in this time frame.
- 16 A little background on US Testing.
- 17 US Testing began providing analytical
- 18 services to Hanford in 1965, so this company
- 19 did the work for a long time for Hanford,
- 20 including the bioassay.
- 21 US Testing's radioanalytical
- 22 facilities were located in Richland,

1	Washington,	and	the	Richland	facility	also	did
---	-------------	-----	-----	----------	----------	------	-----

- 2 non-radiological analyses.
- 3 US Testing had another laboratory
- 4 in Hoboken, New Jersey, and they also perform
- 5 non-radiological analyses. Pacific Northwest
- 6 National Laboratories was responsible for
- 7 overseeing the quality of the data produced by
- 8 US Testing from 1979 to 1991. They had a
- 9 Quality Assurance Program, including blind
- 10 bioassay samples. Approximately 250 blanks
- and QC samples during the 1987 through '89
- 12 time frame.
- 13 Annual reports during the time
- 14 period of interest were reviewed by NIOSH as
- 15 part of this evaluation.
- 16 Additional information on US
- 17 Testing audits. PNNL conducted a lengthy
- 18 procurement process prior to the awarding of
- 19 the September 1988 contract.
- 20 They included technical and
- 21 quality assurance control evaluations. They
- 22 further evaluated data quality provided by US

1	Testing	in	the	fall	of	1989,	and	they
---	---------	----	-----	------	----	-------	-----	------

- 2 presented the results to Westinghouse Hanford
- 3 Company, US EPA, US DOE and the state of
- 4 Washington.
- 5 US Testing participated in an
- 6 ongoing external quality assessment program,
- 7 conducted by the DOE Environmental
- 8 Measurements Laboratory, formerly the Health
- 9 and Safety Lab, and the EPA Intercomparison
- 10 Quality Control Programs.
- However, in 1990, April 25th, US
- 12 EPA suspended US Testing from federal
- 13 contracts. The Notice of Suspension alleged
- 14 that the management of US Testing conspired,
- 15 directed and carried out, and otherwise
- 16 condoned a scheme to defraud the United States
- 17 Government in its performance at the
- 18 facilities in Richland, Washington and
- 19 Hoboken, New Jersey.
- The Notice also alleges that this
- 21 scheme resulted in the submission of false,
- 22 inaccurate and the unreliable test results and

1 data. Suspension was related to	EPA's
-----------------------------------	-------

- 2 investigation of US Testing is related to
- 3 falsification of environmental, non-
- 4 radiological sample data.
- 5 US Testing admitted wrongdoing and
- 6 pleaded guilty to the felony on April 17,
- 7 1991. US EPA's suspension of US Testing
- 8 caused US DOE to order PNNL to review US
- 9 Testing's data quality.
- In the beginning of May, 1990,
- 11 PNNL conducted two separate activities. It
- 12 conducted a formal audit of past US Testing
- 13 activities, including data traceability.
- 14 They also had a three-week on-site
- 15 performance-based technical oversight of
- 16 current US Testing practices.
- 17 On June 1, 1990, the US DOE
- 18 announced the contract with US Testing was
- 19 being terminated for default. Termination was
- 20 based on findings that US Testing had sent
- 21 certain samples to its Hoboken facility
- 22 without appropriate quality control, quality

1 a	ssurance	as	required	by	the	Battelle
-----	----------	----	----------	----	-----	----------

- 2 contract. They also say that US Testing
- 3 billed the government through Battelle for
- 4 these samples.
- 5 The samples were dioxin and total
- 6 petroleum hydrocarbons. They were non-
- 7 radiological. Westinghouse Hanford, US EPA,
- 8 US DOE and the state of Washington also
- 9 performed independent evaluations of US
- 10 Testing.
- 11 A significant report was produced
- 12 by the University of Washington called the
- Omenn Report. They evaluated data from 1983,
- 14 to 1990, from US Testing, focusing on in vitro
- 15 bioassay data.
- In 1992, PNNL summarized the
- 17 series of reviews as they relate to the
- 18 quality and usability of US Testing data. The
- 19 report concluded that the data produced under
- 20 the Battelle contract with US Testing are
- 21 technically supportable for the purpose of
- 22 which they are collected. And all activities

1	performed	t o	date	support	the	technical
_	perrormed	LU	uate	Support	CIIC	CECIIIIICai

- 2 credibility of the data provided by the US
- 3 Testing Richland Laboratory.
- 4 No indication from any evaluation,
- 5 audit or surveillance of the data from US
- 6 Testing facility was technically compromised.
- 7 The feasibility of dose
- 8 reconstruction, based on our review, NIOSH
- 9 found no support for an SEC based on
- 10 falsification of data.
- 11 NIOSH and the Advisory Board
- 12 continue to evaluate various SEC-related
- issues in the 1972 to 1990 period. The NIOSH
- 14 recommendation, NIOSH has obtained numerous
- 15 documents containing monitoring results,
- 16 bioassay program audit reports, independent
- 17 bioassay program data evaluations, as well as
- 18 Hanford process and source-term information.
- 19 In addition, several individuals
- 20 with first-hand knowledge of the contractor
- 21 bioassay laboratory issues during the period
- 22 under the evaluation were interviewed.

1	Employee-specific information
2	provided through the EEOICPA claims process
3	and Technical Basis Documents written by NIOSH
4	have also been available for the evaluation.
5	Based on its analysis of these
6	available resources, NIOSH found no part of
7	the Class, under this very specific
8	evaluation, from this very focused
9	falsification issue, for which estimated
LO	radiation doses with sufficient accuracy could
11	not be performed.
12	So, based on this evaluation we
13	say that we have a feasibility of yes and
L 4	health endangerment is not applicable.
15	CHAIRMAN MELIUS: Okay, thanks,
16	Sam. Questions for Sam? Bill.
L7	MEMBER FIELD: Sam, on your one
18	slide, it talks about the Quality Assurance
19	Program and it indicates there were about 250
20	blanks. Were there spikes as well?
21	DR. GLOVER: Yes, there were QC
22	samples, as well, and they did evaluate those.

1	MEMBER FIELD: Do you know how
2	many there were?
3	DR. GLOVER: I don't, I mean it's
4	not a tremendous amount. It's in the order
5	of, I would say in that two-year period they
6	had
7	MEMBER FIELD: I'm just wondering
8	
9	DR. GLOVER: My recollection is
10	there were 60 to 70ish numbers in a year.
11	It's not a tremendously large number. We do
12	have that in the Evaluation Report. And I
13	apologize, I simply don't remember.
14	MEMBER FIELD: And that looks
15	pretty good?
16	DR. GLOVER: They had the typical
17	problems that you know, you had some bias.
18	They performed within acceptance of say, ANSI
19	criteria.
20	They had some MDA issues, but
21	nothing that said that they were falsifying

data, things that you would find in a normal

22

1	laboratory.
---	-------------

- 2 MEMBER FIELD: Because my
- 3 understanding would be that the data
- 4 falsification was reducing concentration, so
- 5 is that correct? Or was it increasing -- I
- 6 can't imagine why they would want to increase
- 7 it.
- DR. GLOVER: In the, for these
- 9 non-radiological samples, there were several
- things apparently happened. They sent samples
- 11 and there was not an appropriate QC sample
- 12 process at this facility.
- They used a facility that was not
- 14 approved to do the work for what they were
- 15 paid for. And so, because they didn't have
- 16 that QC in place, it invalidated those. At
- 17 least, you know, it makes them suspect.
- 18 And so that was a large part of
- 19 it.
- 20 MR. HINNEFELD: If I might, Sam,
- 21 some environmental samples also have a
- 22 timeliness requirement; they have to be

1	analyzed	l within	а	certain	amount	of	time.

- 2 And they didn't, and they
- 3 essentially rigged the record to make it look
- 4 like they did.
- 5 MEMBER FIELD: But your evidence
- 6 to believe that the data was reliable was
- 7 based mostly on the QA program they had in
- 8 place? Or the spikes? I'm just trying to
- 9 figure out what's the primary evidence you're
- 10 using to, I guess, convince yourself and
- others that the program was reliable?
- DR. GLOVER: So the only thing
- that we found where they basically caused this
- 14 problem, that they were doing, they had
- 15 separate facilities for doing a separate
- 16 laboratory.
- 17 It was not intermixed. It was a
- 18 non-radiological facility where they did this
- 19 kind of bioassay -- not bioassay but
- 20 environmental measurements.
- You see evidence of the fraud that
- 22 was related to that. All of the reports, all

1	of	the	audits,	you	know,	because	you	would

- 2 check, you know, with the sample, you would go
- 3 back to the counter data and say, okay, what
- 4 does my counter have to say? What did this
- 5 sample look like when it was counted? Does
- 6 that, is that something I can relate back to
- 7 the sample?
- 8 Now the Omenn Report is very
- 9 clear, that they say it would take 50 man-
- 10 years to go through all of the stuff.
- 11 It is, you know, from, they looked
- 12 at '83, to '89, a tremendous amount of work.
- 13 They selected some samples. They had DOE, the
- 14 Radiological and Environmental Sciences Lab,
- 15 RESL, come up from Idaho.
- They also conducted, and they also
- 17 report that, you know, they don't see anywhere
- 18 where they've got this falsification. They
- 19 had a QC program in place, US Testing had its
- 20 own internal standards.
- 21 PNNL was providing them blind
- 22 samples. Which, as the petitioner reported

1 out, there was some americium deviations
--

- 2 They had some MDA issues.
- But not where you're seeing, it
- 4 just doesn't -- there's nothing there. It's
- 5 proving the negative. But we found nothing
- 6 that can corroborate it.
- 7 CHAIRMAN MELIUS: Jim.
- 8 MEMBER LOCKEY: Just to follow up
- 9 on Bill's question, in the non-radiology lab,
- 10 was there any evidence of actual falsification
- of data, or was it more quality control, lack
- 12 -- was it a procedure problem or were they
- 13 actually falsifying data?
- 14 DR. GLOVER: There was some
- 15 discussion of peak shaving, where they were
- 16 manipulating chromatography data.
- 17 And so, there was some appearance
- 18 that there was some actual falsification of
- 19 data.
- 20 CHAIRMAN MELIUS: And then, in
- 21 addition, there was apparently, at least as I
- read it, false reporting of their QAQC methods

1 so	that	it	sort	of,	essentially	covered	up
------	------	----	------	-----	-------------	---------	----

- 2 what they were doing.
- I mean, dioxin sampling is
- 4 complicated and requires a lot of QAQC samples
- 5 to keep it, maintaining it right. And so
- 6 that's one reason it is so expensive to do.
- 7 And this time there's obviously a
- 8 lot of it going on and a fair amount of
- 9 competition for doing this. Because I worked
- 10 at the State Health Department down in New
- 11 York and we were doing a lot of dioxin work at
- 12 the time.
- 13 And so it's --
- 14 MEMBER LOCKEY: And you're
- 15 counting on the lab to do it correctly.
- 16 CHAIRMAN MELIUS: Right. And
- there are a number that are trying to get into
- 18 the business and so forth. And I don't know
- 19 the details on this problem, but again, it's
- 20 that.
- 21 And certainly in the -- looking on
- 22 page 9 of your report, there certainly were

1 some concerns raised about whether the
--

- 2 problems also carried over to the Richland Lab
- 3 and other types of samples with that.
- I think, as Sam says, this is all
- 5 a very hard situation to evaluate, because
- 6 you're trying to, again, prove the negative,
- 7 and it's difficult.
- 8 Other people, Board Members on the
- 9 phone have any questions?
- 10 MEMBER ZIEMER: I have no
- 11 questions. This is Ziemer.
- 12 CHAIRMAN MELIUS: Okay. Brad?
- 13 MEMBER CLAWSON: This is Brad. I
- 14 was just involved, I was involved with some of
- 15 the interviews that were held up there at
- 16 Hanford, and you know, this is what came out
- of some of the key people who were involved
- 18 with this.
- 19 It just kind of overflows from
- 20 there, at a facility that they found no
- 21 evidence of anything at Hanford.
- 22 CHAIRMAN MELIUS: Okay, any other

1	Board	Members?	Ιf	not,	Ι'd	like	to	hear	from
---	-------	----------	----	------	-----	------	----	------	------

- 2 the -- if the petitioners wish to speak?
- 3 MR. FOULDES: This is Tom Fouldes,
- 4 F-o-u-l-d-e-s, and I'm the counsel for the
- 5 claimant, [identifying information redacted],
- 6 who is the petitioner on SEC-155.
- 7 And just in the way of a few
- 8 general comments, before I get into details,
- 9 there is, in some of the written interviews
- 10 that were obtained by the Environmental
- 11 Protection Agency, which led to the
- 12 disqualification of UST to do any further
- 13 testing in any federal facility, these
- 14 interviews concern activities in 1987, '88,
- and they, some of them, some of the comments
- 16 are information that relates directly to
- 17 activities at the Richland Testing facility,
- 18 as distinguished from the other facility run
- 19 by UST in Hoboken, New Jersey.
- 20 But there's no question that a
- 21 review of these interviews, which I hope the
- 22 Advisory Board has an opportunity to go over,

1	implicates	fraudulent	activities	in	the
---	------------	------------	------------	----	-----

- 2 testing of samples at Richland.
- Okay, now I'll put that aside.
- 4 And of course it is curious, it's somewhat of
- 5 a contradiction that Battelle, after first
- 6 suing UST for fraud, following the disclosures
- 7 by EPA, and eventually that suit was resolved
- 8 with a guilty finding on behalf of UST.
- 9 But then when it came to determine
- 10 whether or not the pedigree of this data that
- was developed over the years '87, '88, '89 was
- 12 adequate, US Battelle managed to come up with
- a finding in its studies and some of which are
- 14 listed in the report to the Board from NIOSH,
- that basically the data was reliable.
- And of course, obviously that's in
- 17 total contradiction to the lawsuit that was
- 18 brought by Battelle.
- But leaving that now, and going to
- 20 the presentation provided by NIOSH, they do
- 21 have various reports that were created by
- 22 Battelle, which understandably is in a sense

1	trying	to	make	sure	that	they	kind	of	 they

- 2 have the basic contractual responsibility for
- 3 this testing, and so it's no surprise that
- 4 their retrospective studies show that
- 5 basically it was reliable.
- But now, also, though, however,
- 7 the NIOSH, and correct me if I'm wrong,
- 8 because I could have missed this. We didn't
- 9 get the announcement of this hearing until
- 10 late last week, and it wasn't until I got back
- 11 out of town early this week, that I had an
- 12 opportunity to go through it.
- 13 But what I have seen so far is
- 14 that NIOSH has presented, as I said, the audit
- is really done by Battelle or for Battelle.
- 16 And then also, however, an audit that was done
- for them was by the University of Washington.
- 18 And the University of Washington examination
- 19 was by -- they appointed, they engaged, well,
- 20 first of all, it was the University of
- 21 Washington Department of Public Health and
- 22 Community Medicine and they engaged the

1	service	of	а	biostatistician,	а	Gerald	van
---	---------	----	---	------------------	---	--------	-----

- 2 Belle, and then an Associate Professor, Dr.
- 3 Paulman, who was Professor of Environmental
- 4 Chemistry.
- 5 And Dr. Michael O'Brien, a Health
- 6 Physicist. And I'm not suggesting that these
- 7 were not good people, except they didn't have
- 8 the same degree of specialization that was
- 9 done in another study, which I do not believe
- 10 has been presented to the Board.
- 11 And that was an oversight of the
- 12 US Testing Company, analytical procedures and
- 13 protocol. And that was done by, signed off by
- 14 a B.C. Woods of the Environmental Protection
- 15 Agency and Laboratory, Region 10.
- 16 And Mr. L.C. Spearin of Department
- of Ecology, Quality Assurance Section of the
- 18 State of Washington. A Mr. Alvin of the
- 19 Washington Department of Health, and Mr.
- 20 Kasch, K-a-s-c-h, who is with the Department
- 21 of Energy itself. They went forward and
- 22 engaged some specialist, L.M. Albin, who -- he

1	was	from	the	Health	and	Radiation	Protection

- 2 Division.
- MR. KATZ: Excuse me, Mr. Fouldes,
- 4 if you would please, the last couple of
- 5 sentences you said were almost inaudible. But
- 6 much of your talk, you're very hard to hear.
- 7 I wonder if you're on a speaker
- 8 phone or --
- 9 MR. FOULDES: Okay, well, I can
- 10 just briefly wrap this up. He was a
- 11 radiological health expert.
- 12 And then there was two more, from
- some other laboratories, that were specialists
- 14 in radiological bioassay and radiation
- 15 counting.
- 16 And they, in their report,
- 17 Appendix F of their report contains numerous
- 18 references, which I won't take the Board's
- 19 time to go through, but they all relate to the
- 20 lack of adequacy in procedures and in testing
- 21 protocols that were being utilized to spite
- 22 the testing company, US Testing, on bioassay

1	samples	and	it	would	seem	impossible	if		to
---	---------	-----	----	-------	------	------------	----	--	----

- 2 anyone thoroughly reviewing the very detailed
- 3 report in Appendix F, to conclude that the
- 4 testing results done by this laboratory on
- 5 bioassay, and in this case particularly, this
- 6 particular petitioner is relying on the
- 7 bioassay results from his fecal samples.
- And there does not appear to be
- 9 any basis of reliability suggested in this
- 10 detailed study that I referenced, made by
- 11 these various names I've mentioned. And that
- 12 concludes my remarks.
- 13 CHAIRMAN MELIUS: Thank you, Mr.
- 14 Fouldes. Sam, do you have any response? I
- 15 don't know, it wasn't clear to me which
- 16 reports were included in your review?
- DR. GLOVER: Obviously, there were
- 18 many, we looked at many things. We looked at
- 19 those EPA documents that the Office of
- 20 Inspector General had. We -- I can't remember
- 21 which ones, I looked at so many.
- 22 CHAIRMAN MELIUS: Okay.

Τ	DR. GLOVER. We do agree with what
2	he says on the environmental stuff. We agree
3	that US Testing, in Richland, they were for
4	part of this. So it wasn't just in Hoboken,
5	but it was the non-radiological samples.
6	CHAIRMAN MELIUS: Right. Jim.
7	MEMBER LOCKEY: Sam, Gil Omenn did
8	which review? Gil Omenn, is that the Omenn
9	that you were
10	DR. GLOVER: The Omenn Report?
11	MEMBER LOCKEY: Yes.
12	DR. GLOVER: And we actually spoke
13	with several members of his who were on
14	that, as part of this review.
15	MEMBER LOCKEY: Is Gil, I don't
16	know if Gil is he still alive? Did you
17	speak with him?
18	CHAIRMAN MELIUS: Yes, he's
19	DR. GLOVER: I'd have to
20	CHAIRMAN MELIUS: I think he's at
21	University of Michigan now?
22	MEMBER LOCKEY: I'm not sure, I'm

1	not	sure	where	he	is	right	now.	I	asked	is	

- 2 CHAIRMAN MELIUS: He's no longer
- 3 Dean at Seattle.
- 4 MEMBER LOCKEY: No.
- 5 CHAIRMAN MELIUS: I believe he's
- 6 in Michigan, isn't he?
- 7 MEMBER LOCKEY: I was wondering
- 8 whether, I was just curious whether you
- 9 actually spoke with him or not about it?
- 10 DR. GLOVER: I think with
- 11 availability, we spoke to two other members.
- 12 I don't think we got to speak with him. I was
- 13 actually, I think, at Sandia the week that we
- were able to talk to him. So I didn't get to
- 15 participate.
- MR. VALERO: Hello?
- 17 CHAIRMAN MELIUS: Yes.
- MR. VALERO: Hi, I'm sorry, my
- 19 name is Oscar Valero and I'm a petitioner at
- 20 the Hanford site.
- 21 CHAIRMAN MELIUS: Okay.
- 22 MR. VALERO: I temporarily got

4	1.1	7 7 .	<b>-</b> •	1 1	- ·
	disconnecte	tiid be	ı'm	nack	$\cap$ nline
_	arbcomine cc	- <del>-</del>		200012	O11 ± ± 11 C •

- 2 CHAIRMAN MELIUS: Okay, did you
- 3 wish to speak? I understood Mr. Fouldes to
- 4 say that he was speaking on your behalf, so I
- 5 didn't know if you, do you wish to speak in
- 6 addition to him?
- 7 MR. VALERO: Yes, I do, sir.
- 8 CHAIRMAN MELIUS: Okay, then go
- 9 ahead.
- 10 MR. VALERO: All right, and I'll
- 11 make this brief, gentlemen and ladies. I do
- 12 have a prepared statement, so I'm just going
- 13 to read from the statement.
- 14 CHAIRMAN MELIUS: Fine, thank you.
- MR. VALERO: Thank you. As I
- 16 said, my name is Oscar Valero, I'm from the
- 17 Hanford site. Let me first say, thank you for
- 18 providing me with this opportunity.
- I understand this is a scientific-
- 20 based information, but let me also appeal to
- 21 the sentiments of your heart and that you will
- 22 do the righteous thing and your actions will

1	right	а	wrong.	The	actions	of	deceit	and
---	-------	---	--------	-----	---------	----	--------	-----

- 2 ultimate betrayal of trust, due to the
- 3 unethical acts for personal gain, have never
- 4 been so blatant.
- 5 A true disregard for my wellbeing
- 6 and threatening my life and the livelihood of
- 7 my family and numerous other victims of this
- 8 tragedy.
- 9 We, as courageous Americans, have
- 10 paid a high price for our service. We've
- incurred disabling and/or fatal illnesses as a
- 12 result of exposure to radiation chemicals and
- other hazards that are unique to the weapons
- 14 production and testing.
- I ask that you adopt this as a key
- petition and justify the award of full medical
- 17 and monetary compensation for the victims of
- this tragedy, due to the neglectful actions,
- 19 again, for personal gain, by US Testing. Of
- 20 which, none of this should have occurred, if
- 21 the company had not been engulfed by greed.
- The evidence you seek has been

-					.1
$\perp$	previously	outlined	ın	various	documents.

- 2 These reference to EPA referral memoranda,
- 3 dated April 4, 1989, which is further
- 4 substantiated by supporting data, based on
- 5 interviews of numerous US Testing personnel,
- 6 conducted by the Office of Inspector General
- 7 Office of Investigations dated June 6, 1989.
- 8 The facts are many, guys, but for
- 9 the sake of time, here are two. Number one,
- the SEC report, page 32 of 58, states "NIOSH
- 11 did not find bioassay data produced by US
- 12 Testing to have been effective."
- 13 However, the action referral
- 14 memorandum, item 9, states the contract was
- 15 lab-specific. Neither lab, whether it's
- 16 Hanford or the one in Hoboken, New Jersey, was
- 17 listed as an alternate site to perform work on
- 18 a contract basis.
- 19 Based on the Office of Inspector
- 20 General, the interview they conducted also
- 21 cites numerous chain of custody and protocol
- 22 violations. Second fact, the SEC report, page

1	29	of	58,	states:	"sample	card	and	final
---	----	----	-----	---------	---------	------	-----	-------

- 2 results were not found." And: "incomplete
- 3 record for one sample result."
- 4 To me this lends credence to
- 5 incomplete, inaccurate record keeping, and
- 6 really does cast doubt on accuracy of samples.
- 7 The two above statements are from
- 8 NIOSH themselves. The Office of the Inspector
- 9 General from their interview states: "two
- 10 separate log books were kept, they were
- 11 maintained."
- 12 Other facts still remain, such as
- 13 cut and paste activities. As I mentioned
- 14 before, the two separate log books, backdating
- of sample results.
- Doctoring samples and the use of
- 17 illegal drugs by management of US Testing.
- 18 Ladies and gentlemen, these are the facts and
- 19 many more can be found in the Office of
- 20 Inspector General report dated June 6, 1989,
- 21 which I'm sure you have.
- 22 These interviews are first-hand

1	witness	accounts,	conducted	by	credible

- 2 people, the Inspector General's office, who
- 3 took an oath to uphold the law.
- 4 The outcome of their investigation
- 5 substantiates the facts that create and
- 6 establish reasonable doubt and question the
- 7 credibility of the US Testing, which is
- 8 further supported by the EPA referral
- 9 memorandum fact section.
- 10 Because of the unscrupulous
- 11 actions of US Testing, many people have
- 12 incurred unjust suffering. To rely on an
- 13 organization, complete strangers, that have
- 14 the responsibility to analyze samples and you
- entrust them to be honest, because they have
- 16 the educational knowledge and experience, is
- 17 where my trust was.
- 18 Ladies and gentlemen, pardon the
- 19 pause, but this is difficult for me. You say
- 20 you want facts? Here are some more
- 21 undisputable facts.
- I have Stage 3 stomach cancer.

1	Two-thirds	of	my	stomach	were	surgically

- 2 removed, 50 percent of my esophagus was
- 3 surgically removed.
- I have irreparable damage to the
- 5 left side of my heart, due to radiation
- 6 treatments. I have incurred financial
- 7 hardship.
- 8 I live with these physical
- 9 limitations. My family and I bear emotional
- 10 scars and psychological trauma. Our lives
- 11 have been affected and changed forever.
- 12 All these are facts that have been
- forcibly and permanently etched into my life.
- 14 One can choose to dispute the evidence before
- 15 you, but science can only presume facts based
- on data analysis and can be manipulated to
- 17 support the desired outcome.
- 18 No data analysis or computer
- 19 programs can dispute the above-mentioned
- 20 facts. But one main ingredient is missing,
- one that we tend to sometimes overlook, and
- 22 it's called ethics. In this case, it's

1 economics over ethics. These people whom
--

- 2 entrusted to analyze these samples and provide
- 3 honest results, failed in their ethics.
- 4 Because they knowingly and
- 5 willfully were aware of what they were doing.
- 6 They just didn't care, and, in turn, placed
- 7 my life and my family's livelihood in
- 8 jeopardy, for their own self gain, for their
- 9 greed.
- 10 NIOSH further states on page 46 of
- 11 the handout, NIOSH, on no part of the Class,
- 12 which it cannot estimate radiation doses with
- 13 sufficient accuracy.
- I must ask, how can an estimate be
- 15 accurate when I myself have had three
- 16 different dose reconstructions with three
- 17 different results?
- I question US Testing protocols,
- ethics and methodology, which is why they were
- terminated, such as higher management's use of
- 21 illegal drugs on company time and premises.
- You'll find this information on those reports

1	that	Т	mentioned	ahove
_	CIIC		IIICIICIOIICA	above.

- 2 These people were tasked with
- 3 making major decisions, but were under the
- 4 influence at the time certain critical
- 5 decisions were made.
- Again, I must ask, where is the
- 7 credibility in this? Where are the ethics?
- 8 Ladies and gentlemen, the decay of the human
- 9 spirit for personal company gain has never
- 10 been so evident, as it is with this company
- 11 that I once trusted.
- In essence, in my case, I have
- 13 been left raped, stripped from my being,
- 14 betrayed by those I once trusted.
- I ask that you, right or wrong,
- 16 this is your opportunity to make a positive
- 17 difference in people's lives. The power to do
- 18 the righteous thing is, in the name of
- 19 humanity and justice, in your hands.
- 20 Don't turn your back on these
- 21 courageous Americans, who defended our
- 22 national security for the freedoms we enjoy.

and

1	We didn't use bullets and
2	missiles, but we worked in glove boxes in
3	high-hazard environments such as chemical and
4	radiological processes.
5	In closing, just let me reiterate.
6	I appeal to your consciousness and sentiments
7	of your heart. Because no one should go
8	through what these families and I have gone
9	through.
10	And to approve this SEC petition,
11	to compensate some of us, those courageous
12	Americans who have unnecessarily suffered and
13	those who have died.
14	This would be the righteous thing
15	to do. And I thank you for your time.
16	CHAIRMAN MELIUS: Thank you. Any
17	further questions or comments from Board
18	Members?
19	(No response.)
20	CHAIRMAN MELIUS: Any suggestions
21	on steps forward? I think one of my questions
22	would be as to whether the reviews looked at

	1	this	from	the	perspective,	not	of	the	NIOSH
--	---	------	------	-----	--------------	-----	----	-----	-------

- 2 review, but the other reviews on the
- 3 laboratory, were they looked at from a
- 4 perspective of whether these were reliable in
- 5 terms of environmental monitoring or workplace
- 6 monitoring, as opposed to dose reconstruction,
- 7 which might have a different criteria to it, I
- 8 don't know.
- 9 Also, I think there's an awful lot
- of information here, and though I think NIOSH
- 11 did a good job of summarizing it, I think our
- 12 past practice has been, in the situation, to
- 13 at least do some initial review on this
- 14 information, before trying to reach a
- 15 conclusion.
- So one step would be to refer it
- 17 to the Hanford Work Group for further
- 18 evaluation. Is that --
- 19 MEMBER LOCKEY: I concur with
- 20 that, I think that's a good idea.
- 21 MR. VALERO: If I may, just one
- 22 quick 30-second statement?

Τ	CHAIRMAN MELIUS: II IU'S QUICK,
2	please.
3	MR. VALERO: Yes, it is. Again,
4	my name is Oscar Valero from the Hanford site.
5	I want to make sure that the Board has access
6	to and has received and/or reviewed the
7	following documents:
8	Action Referral Memorandum from
9	the US EPA, April 4, 1989. Both interviews,
10	two interviews from the Office of Inspector
11	General, the Office of Investigations.
12	One dated August 15, 1989, and one
13	dated June 5, 1989. Thank you.
14	CHAIRMAN MELIUS: Okay. Go ahead,
15	Mark.
16	MEMBER GRIFFON: I was just going
17	to make a motion that the Board refer this to
18	the Hanford Work Group for further review.
19	MEMBER LOCKEY: I'll second that.
20	CHAIRMAN MELIUS: Second from Jim
21	Lockey. Any further discussion?

(No response.)

22

1	CHAIRMAN	MELIUS:	ΙÍ	not,	all	ın
---	----------	---------	----	------	-----	----

- 2 favor, say aye.
- 3 (Chorus of ayes.)
- 4 CHAIRMAN MELIUS: Opposed?
- 5 (No response.)
- 6 CHAIRMAN MELIUS: Okay, good,
- 7 thank you. Next item of business, at 3:15 we
- 8 need to do the GE, and I believe we need to do
- 9 that on time, since the petitioner may be on
- 10 the line for that.
- 11 Mark, are you ready to do your two
- 12 reports? Okay, so Mark, I don't know which
- 13 you want to do first. We have LANL and the
- 14 Dose Reconstruction Review Group, so we'll let
- 15 you choose.
- 16 MR. KATZ: Ms. Beach and Ms. Munn
- 17 can come back to the table. I don't see -- is
- 18 Ms. Munn out of the room? Could someone maybe
- 19 -- thank you, Jenny.
- 20 MEMBER GRIFFON: I can do the Dose
- 21 Reconstruction Subcommittee update first.
- They'll both be quick updates.

1	The Dose Reconstruction
2	Subcommittee had a meeting recently in
3	Cincinnati and it was actually more of a field
4	trip.
5	We took a field trip to the ORAU,
6	O-R-A-U offices. And the intent of the field
7	trip was to get a little better understanding
8	of the QAQC program that ORAU and NIOSH
9	undergo in their dose reconstruction program.
10	And just sort of walk it through
11	from start to finish. And the notion of the
12	trip was to have a meeting at ORAU and then to
13	go across town and visit the NIOSH offices and
14	see what they do on their side of the shop.
15	Because it took a little longer
16	than we anticipated, we ended up spending the
17	whole time at ORAU. We did get an in-depth
18	presentation from the ORAU folks on their QAQC
19	program and the procedures they go through in
20	the dose reconstruction process.
21	And I think most importantly, we
22	also got to go out on the floor, talk to a

1	couple	of	the	staff,	including	а	data	entry

- 2 supervisor and actually oversee some of the
- 3 data entry work that was ongoing.
- I think, you know, part of the
- 5 question there was our concern about some of
- 6 the QAQC findings that we had in the first 100
- 7 cases that we reviewed, some of them involved
- 8 sort of keying errors or data entry.
- 9 At least it seems to be related to
- 10 sort of data entry questions, so we wanted to
- 11 observe the process and see the working
- 12 conditions, see the sort of quality of data
- that the data entry folks had to deal with, in
- 14 terms of looking at the original hard copy
- 15 data and transferring it into a spreadsheet
- 16 format and that was very useful.
- Just to get that firsthand
- 18 observation. We also, the other useful part
- of the trip was that we were able to sort of
- see the state of the quality assurance/quality
- 21 control program as it exists now.
- 22 And I think part of the challenge

	1	for	the	Subco	mmittee,	in	our	review,	has	been
--	---	-----	-----	-------	----------	----	-----	---------	-----	------

- 2 since we're lagging the program a little bit,
- 3 we're finding errors that, in many cases, we
- 4 believe some of the updates that NIOSH has
- 5 done have corrected or, you know, will
- 6 minimize many of those errors.
- 7 So we sort of -- we have some
- 8 further assessment to do with this, but it was
- 9 at least some reassurance that some of the
- 10 comments, even though we haven't ever wrapped
- up our first 100 cases report officially, you
- 12 know, it's clear that our work on this Board
- is affecting the program, in a good way, in
- 14 terms of NIOSH actually making several of
- 15 these changes.
- Some examples, I guess a couple of
- 17 the most obvious examples were ways in which
- 18 they've modified their approach from a
- 19 computer standpoint and from a software
- 20 standpoint to allow -- or avoid, I should say,
- 21 these, what we were referring to as cut and
- 22 paste errors.

1	And basically some of the ways
2	they've done that is to actually avoid, you
3	know, not making the dose reconstructor have
4	to take data from one spreadsheet, copy it and
5	put it into something else. It's more
6	automated software now, so the transfer is in
7	the program, so that avoids these sort of
8	keying errors or cut and paste errors.
9	So some of the automation stuff we
10	were able to observe. And, like I said,
11	because we're lagging on our case reviews, a
12	lot of times we're looking at dose
13	reconstructions that were done in the earlier
14	years still.
15	We're not able to see these
16	changes that have taken place. So that was
17	useful. We do plan on following up and seeing
18	the NIOSH side of the system to sort of round
19	out how, once the cases go from ORAU over to
20	the NIOSH side, what does NIOSH do in terms of
21	its Quality Assurance Program?
22	And I think we scheduled that, I'm

1	trying	to	remember	the	date,	in	July	sometime.

- MR. KATZ: We have a, I think we
- 3 scheduled a Dose Reconstruction meeting for
- 4 July 15th.
- 5 MEMBER GRIFFON: Okay, maybe we
- 6 were --
- 7 MR. KATZ: So, maybe we were
- 8 thinking about piggybacking on that?
- 9 MEMBER GRIFFON: Yes, there was
- 10 some discussion --
- 11 MR. KATZ: Because it's a NIOSH
- 12 facility.
- MEMBER GRIFFON: Okay, so we have
- 14 a meeting scheduled for July 15th. But I
- think we did, we did all commit, when we were
- there, to doing a follow up on-site meeting at
- 17 NIOSH, a walk-through at the NIOSH facility.
- 18 So that's sort of just a status
- 19 update. The rest of our ongoing case review
- 20 work, I think, is still standing since the
- last Board Meeting. I don't think we have any
- 22 update on that front.

1	CHAIRMAN MELIUS: Mark, and I may
2	have missed this. But the in-depth reviews,
3	what did we call them
4	MEMBER GRIFFON: Oh, the blind?
5	CHAIRMAN MELIUS: Blind reviews,
6	yes.
7	MEMBER GRIFFON: Yes.
8	CHAIRMAN MELIUS: What's the
9	status on that?
10	MEMBER GRIFFON: The bline
11	reviews, the status is sort of, I mean, SC&A
12	has completed, I think we only asked them to
13	do two blind reviews.
14	We have not brought those up ir
15	our Subcommittee meeting, but we can. We may
16	want to prioritize those and if, you know,
17	probably something we should do, because we
18	talked about possibly doing more, but we
19	wanted to look at two as an initial sample, to
20	see if it was a fruitful effort.
21	CHAIRMAN MELIUS: I'm just
22	thinking that, one, it's been a long time, and

	1	we	talked	about	these	for	а	long	time.	So,	I
--	---	----	--------	-------	-------	-----	---	------	-------	-----	---

- 2 think we need to assess how useful they are
- 3 and whether a sample, how much a sample of two
- 4 can tell us. I think it can tell us
- 5 something.
- 6 Secondly, in the context of the
- 7 ten-year review and so forth, is it time for
- 8 us to think about how we go about doing the
- 9 dose reconstruction reviews and to what extent
- 10 those, you know, we might do more blind
- 11 reviews or some other changes and so forth.
- So I think it would be useful if
- 13 the Subcommittee could --
- 14 MEMBER GRIFFON: Yes, and we, I
- 15 will commit to putting that on our next
- 16 agenda. I think that's a -- I think it's just
- 17 been overlooked because we were so behind on
- 18 old matrices that we kind of just kept
- 19 plugging away at the old matrices.
- 20 But I agree that it should be
- 21 added to our next matrix, so that will be
- done.

1	CHAIRMAN MELIUS: Okay, good.
2	Anybody else have questions for Mark?
3	(No response.)
4	CHAIRMAN MELIUS: Board Members on
5	the phone have questions?
6	MEMBER ZIEMER: No questions.
7	CHAIRMAN MELIUS: Okay, thanks.
8	Okay, do you want to go on to LANL?
9	MEMBER GRIFFON: Sure. LANL will
10	be a quick one. I see Joe Fitzgerald is here
11	if people want a real, more in depth update.
12	But really it's sort of, we're
13	plugging away on the last years of the SEC
14	petition there. This has been taken in
15	pieces, as people remember.
16	And we're in the farther-out
17	years, I'm forgetting the dates right now, but
18	we had a meeting recently, early May, I
19	believe.
20	And we continued along the same

from the Work Group at this point.

We don't have any real recommendation

matrix.

21

22

1	I think if we, we do plan to
2	schedule another Work Group Meeting. I
3	haven't set a date yet because there were some
4	significant action items from NIOSH and some
5	of it is pretty labor-intensive and they might
6	have competing priorities. So we didn't want
7	to set a date yet for a follow-up.
8	But the work continues on the Work
9	Group.
LO	CHAIRMAN MELIUS: I was just
11	looking at their report, and it says, "respond
12	to Work Group issues to be determined."
13	(Laughter.)
L 4	CHAIRMAN MELIUS: That's not
15	helpful for this context.
16	MR. HINNEFELD: This is Stu. I
L7	don't think I've determined it since I got
18	here, so we'll have to provide updated
19	information.
20	CHAIRMAN MELIUS: Yes, could you?
21	This is the only time we've asked you.
22	MEMBER GRIFFON: After the LANL

	1	Work	Group	meeting,	as	is	my	custom	at	these
--	---	------	-------	----------	----	----	----	--------	----	-------

- 2 meetings usually, anyway, I did update the
- 3 matrix in real time and we forwarded it
- 4 around.
- 5 So that should be able to inform
- 6 NIOSH on what the outstanding actions are.
- 7 CHAIRMAN MELIUS: Okay. So the
- 8 issues don't need to be determined, just the
- 9 actions? Timing of the actions.
- 10 MEMBER GRIFFON: Timing, yes.
- 11 CHAIRMAN MELIUS: Okay, do that.
- 12 Any Board Members have questions for Mark,
- including those on the phone?
- 14 (No response.)
- 15 CHAIRMAN MELIUS: Okay. One other
- 16 issue: first of all, let's talk a little bit
- 17 about schedule. We have a GE update we'll do
- 18 at 3:25 with the petitioner.
- 19 We have a Weldon Spring update at
- 20 4:45, and again we should do that at that
- 21 time, simply because the petitioners will be
- 22 listening in.

Τ.	And then the petitioners will be
2	probably talking in the public comment period
3	on that. We got a communication from them;
4	due to the weather, they are not planning to
5	come into the meeting, but will be commenting
6	by phone for that.
7	Tomorrow morning we have a report
8	on the Quality of Science Report, as part of
9	the ten-year review from Doug Daniels. That's
10	scheduled for 8:30.
11	We're hoping that he makes in
12	tonight from, I forget where he's doing a
13	involved in a data capture, I believe, for
14	Chicago, okay.
15	So he can just hop on a river
16	boat. The river is flowing pretty well, so it
17	should be quick. But hopefully he'll make it
18	down tonight. We'll do that. And then my
19	plan would be that we would then be able to
20	finish up at 9:30 tomorrow morning.
21	So, if that helps you with your
22	plans. I don't think we'll have any other

1 Board actions to take after that. So as
---

- 2 Doug's presentation and questions, then we
- 3 will plan on adjourning the meeting.
- 4 So if that helps you with, people
- 5 with their travel plans and so forth; I hope
- 6 it does.
- 7 Though with airline schedules, I
- 8 suspect we're all pretty much locked in to
- 9 what we're doing. One other item that we
- should talk about now or, if you prefer, there
- should be some time after the GE session, so
- that should not be a long session, is how we
- want to handle the ten-year review and our
- 14 communications on that. I think Lew laid out
- 15 sort of the schedule for that.
- 16 And that there will be other
- 17 opportunity to comment as this evolves, both
- on the individual reports, as well as, I think
- 19 NIOSH has plans for actions and follow-up.
- 20 And I think, in particular, I
- 21 think it's an issue of how we feel in terms of
- 22 what we think and do we want to make

1	recommendations in terms of prioritizing
2	recommendations. Or, I guess, saying that we
3	disagree with the recommendations, don't think
4	they should be considered and do that.
5	Now it's a long list of
6	recommendations, and so it's not easy to go
7	through and there's some repetition there.
8	And, at the same time, I think there's a
9	number of recommendations that some
10	prioritization makes sense, given just the
11	scope of these, and so forth.
12	I just didn't know if people had
13	thoughts on how we should approach that. Do
14	we approach it as just individual Board
15	Members commenting to Dr. Howard and to the
16	Docket? Or do you want to try to do anything
17	in a group fashion? And I don't have any
18	great ideas on how to do it as a group
19	fashion, because it's unwieldy.
20	MEMBER ZIEMER: Dr. Melius?
21	CHAIRMAN MELIUS: Yes, Dr. Ziemer?
22	MEMBER ZIEMER: Well, I'll just

1 start it off to get some ideas on the fl	loor,
--	-------

- 2 because I think it's important that we have
- 3 input.
- 4 But as a practical matter, these
- 5 are a number of pretty thoughtful documents
- 6 that contain a number of recommendations.
- 7 I think, in many cases, we might
- 8 be able to, you know, go through and say, yes,
- 9 we all agree with this, or whatever.
- But, in terms of the timing, it
- 11 seems to me it will be very difficult to
- 12 systematically have the Board develop a
- 13 consensus recommendation or agreements or
- 14 particular items.
- So, just as a practical matter, it
- 16 just occurred to me that it might just be as
- 17 valuable to have individual Board Members
- 18 provide their comments.
- 19 This would allow two things. One,
- 20 I think a more timely input to Dr. Wade, so
- 21 that they can bring things to closure.
- 22 And, number two, it would not

1	necessarily	require	consensus.	And,	in	fact,
---	-------------	---------	------------	------	----	-------

- there may be a number of items where we don't
- 3 necessarily agree with each other, either on
- 4 the finding or the conclusion or the
- 5 recommendation.
- 6 Why not just say, okay, provide
- 7 your comments. Again, this is off the top of
- 8 my head. I don't object to doing it as a
- 9 Board, I'd be glad to do that.
- But, it seems to me, that it's as
- important to get individual viewpoints on the
- 12 record as well.
- 13 CHAIRMAN MELIUS: Yes. No, I
- 14 would agree with you, Dr. Ziemer. I just sort
- of wanted to provide the opportunity. I think
- 16 if there were, if people feel or a Board
- 17 Member feels strongly about -- that they
- 18 disagree, particularly with one of the
- 19 priority recommendations. Or that they have,
- think that there's another recommendation that
- 21 should be getting more serious consideration
- than was presented by Dr. Wade, that we should

- 2 But even though there may not be agreement on
- 3 the Board on a viewpoint or something, it
- 4 sounds like there'd be some benefit to airing
- 5 that and having some discussion of it.
- I agree with you, on a practical
- 7 level, it's going to be hard for us to respond
- 8 as a group on these.
- 9 But if there were things that
- 10 struck people from the presentation yesterday
- or after they thought about it or talked about
- 12 it over lunch or breakfast or dinner or
- whatever, at least we'd have the opportunity.
- 14 Wanda is reaching for her -- it's
- 15 sign that she's on the verge. So I'm going to
- 16 stop talking here and see if Wanda does want
- 17 to speak. Yes, she does, okay. Go ahead,
- 18 Wanda.
- 19 MEMBER MUNN: It would seem
- 20 logical that individuals would more likely be
- 21 able to cast their perceptions as they wished
- by doing any comments individually directly to

1	Dr. Wade, rather than having the Board
2	wordsmith them and perhaps dilute some major
3	item that an individual might feel
4	appropriate.
5	It would seem logical that if any
6	of our Board Members had serious concerns with
7	respect to the prioritization that Dr. Wade
8	and his colleagues have already made on those
9	points, that it would behoove us to bring
10	those to your attention, as the Chair of the
11	Board, and request that the Board perhaps
12	visit that particular aspect, but not the
13	individual comments that each of the Board
14	Members might make.
15	CHAIRMAN MELIUS: What I was going
16	to I think that's a good idea. And it's
17	common you and I have similar viewpoints on
18	many things. And what I thought is that these
19	will be posted and maybe we'll charge our DFO
20	with making sure that, I think to the extent
21	that, as we submit these, that these get
22	circulated to all of the other Board Members,

1 so we keep up. And then I will work to	1	so	we	keep	up.	And	then	I	will	work	to
--	---	----	----	------	-----	-----	------	---	------	------	----

- 2 identify issues that -- either where there's
- 3 disagreement or where it might warrant further
- 4 discussion by the Board for our Board
- 5 conference call.
- And again, it would just be trying
- 7 to elaborate and maybe fine tune. Because I
- 8 think, as Lew Wade pointed our on behalf of
- 9 Dr. Howard, I think NIOSH really is looking
- 10 for input on this and involvement of the
- 11 Board.
- 12 And certainly we're going to be
- involved and affected by the implementation of
- 14 these recommendations as they go forward. And
- some adjustments in how we work and how NIOSH
- 16 works and our activities.
- 17 So, it's as much to encourage
- involvement in this process and I think we'll
- 19 do as you suggested, Wanda, I think would be
- 20 probably the best way of going forward.
- I just didn't know if anybody had
- 22 already noticed things that were concerning to

1	them	or,	you	know,	sort	of,	these	are	big
---	------	-----	-----	-------	------	-----	-------	-----	-----

- 2 reports and to do it out of context and to do
- 3 it quickly is difficult. Mark, you weren't
- 4 here yesterday to go through, either.
- 5 MEMBER GRIFFON: But I was on the
- 6 phone on this part of it. The only -- I agree
- 7 with you and Wanda on most of this.
- 8 The one possible exception I would
- 9 make is, it may be useful for the Dose
- 10 Reconstruction Subcommittee to weigh in on the
- 11 dose reconstruction recommendations. I'm
- 12 looking down them and I'm not sure they're --
- 13 I think there might be quite a bit of
- 14 agreement and it might be actually very
- 15 consistent with our first 100 cases report on
- 16 several fronts.
- 17 And, you know, it might be useful
- 18 for us to consider those and try to close out
- 19 our first 100 cases report and submit them
- 20 back to the Board, and that way we could weigh
- 21 in on that front.
- So the Secretary has a group. You

1	know,	other	items	that	are	reported	on,	I

- 2 think it would make more sense to weigh in
- 3 individually.
- But on that front, I thought it
- 5 might be, since we have a body of work that
- 6 we've done in that area, it might be useful to
- 7 weigh in as a whole.
- 8 CHAIRMAN MELIUS: You know, I
- 9 think that would be excellent. And if you're
- 10 doing a meeting before our next Board call,
- and certainly there's this recommendation on
- 12 should NIOSH do away with the over- and under-
- 13 estimates.
- 14 And I think that's the kind of
- 15 thing that your Subcommittee, you know,
- 16 probably is in the best position to comment
- on. So, that's an excellent idea. Henry.
- 18 MEMBER ANDERSON: I was going to
- 19 push it back to that Committee too. But I
- 20 think the other thing that would be worth
- 21 doing would be to have -- there's a lot of
- 22 recommendations here, and the likelihood that

1 they'll all be moved on is probably r	remote
---	--------

- 2 So, it might -- one approach would be, rather
- 3 than to comment you like something or not,
- 4 which of these do we as a, we may want to
- 5 discuss, as a Board do we feel are the most
- 6 important that ought to get the priority to
- 7 move forward?
- Now I don't know, maybe NIOSH is
- 9 going to act on all of those, but there's a
- 10 lot of lists there that, in the shorter term,
- 11 we may want to say, like the over- and under-,
- this is an area that's going to take a lot of
- work. It ought to be worked on. And others,
- 14 while they're important, could wait.
- 15 CHAIRMAN MELIUS: Yes, and I
- think, sort of the, what they you call it?
- 17 The target list or the straw person or
- 18 whatever, for review, was Lew's list of
- 19 priorities and I think one thing it will help
- 20 clarify that.
- I think I've got them all marked
- off, but I might have missed one, but I'll

1	work	with	Ted,	because	we	have	а	number	of
---	------	------	------	---------	----	------	---	--------	----

- 2 Board Members who are absent. And I think we
- 3 also need to communicate this issue and a
- 4 number of other issues that have come up with
- 5 them, before the next Board Meeting.
- 6 So I think, and we'll copy the
- 7 entire Board on that, so that they, you have
- 8 this list and so forth and move forward. But
- 9 that's exactly what I had in mind.
- I just want to make sure that if
- 11 we disagree with Lew's list, positive or
- 12 negatively, in terms of making a
- 13 recommendation, that we do that, and now Lew's
- 14 is going to meet, has a meeting with -- an
- internal meeting, I believe in a couple of
- weeks.
- 17 And, again, report back to us if
- 18 there are changes in the priorities based on
- 19 that meeting or questions about how to
- 20 implement or something.
- It's an ongoing, iterative process
- 22 and there's no finalization, it's just making

1	sure	that	I	think	we	stay	engaged	with	it.
---	------	------	---	-------	----	------	---------	------	-----

- DR. WADE: If I may, even more
- 3 important than the Wade list of priorities,
- 4 will be the Howard list of priorities. And
- 5 that will be available come the middle of
- 6 June, and you'll have that before your next
- 7 call. And you can react to that list as well.
- 8 CHAIRMAN MELIUS: Well, we're
- 9 confident that Dr. Howard's list will be close
- 10 to the esteemed Dr. Wade's list.
- DR. WADE: The man is no fool.
- 12 (Laughter.)
- 13 CHAIRMAN MELIUS: Some of us may
- 14 even suspect that Dr. Howard may have, just
- osmosis, sort of communicated some of these
- 16 ideas, in terms of discussion, casual
- 17 conversations over coffee.
- 18 Any other comments or suggestions
- on our ten-year effort?
- 20 (No response.)
- 21 CHAIRMAN MELIUS: Okay, why don't
- we take a break, half hour? 3:15 we'll do GE.

1	Again,	I	apologize,	we'll	probably	be,	I
---	--------	---	------------	-------	----------	-----	---

- don't think it will necessarily take too long,
- and then we'll probably have another break.
- 4 (Whereupon, the above-entitled
- 5 matter went off the record at 2:46 p.m. and
- 6 resumed at 3:17 p.m.)
- 7 CHAIRMAN MELIUS: Okay, we will
- 8 reconvene. The next item on our agenda is the
- 9 GE Evendale SEC petition. And even though I'm
- 10 listed here, I have drafted the distinguished
- 11 LaVon Rutherford to do a summary of the
- 12 changes to the SEC.
- 13 There's an amended Evaluation
- 14 Report, I guess you'd call it. That's been
- done. It's got several changes in it, though.
- 16 I think the bottom line is the same. I'll let
- 17 LaVon talk briefly about what those changes
- 18 were, and then I will speak to the Work Group
- 19 review and what the Work Group believes should
- 20 happen next.
- 21 MR. RUTHERFORD: We did issue a
- 22 revised Evaluation Report for GE. The focus

1 of the revised Evaluation	n Report was to pu	ιl]
-----------------------------	--------------------	-----

- 2 in all the information that we had uncovered
- 3 from the time we initially issued Rev 0 of the
- 4 report and pull that into this revision.
- 5 Some of the key things that were
- 6 added in that report were just after we had
- 7 issued Rev 0. We received some data, a
- 8 significant amount of data, from General
- 9 Electric, which included some external
- 10 monitoring data. A very little internal
- 11 monitoring data. But the monitoring data
- 12 focused from the aircraft nuclear propulsion
- operations starting in the '50s, up through
- 14 the 1970 period.
- The report actually laid out where
- we determined that, even though we had this
- 17 new data, that was identified, mainly external
- data, our feasibility finding was the same.
- 19 And the reasons behind that were
- 20 tied to the personal monitoring data did not
- 21 include identifiers. Identifiers such as
- location, job activities. We had a few that

1	indicated	locations,	however,	the	majority	of
---	-----------	------------	----------	-----	----------	----

- 2 that data really did not provide specific job
- 3 location, activities, to tie those individuals
- 4 to that.
- 5 We also got a little additional
- 6 information on the processes that were taking
- 7 place during that time period. We updated the
- 8 report to include that.
- 9 And some additional interviews
- 10 that had occurred during the time period. And
- 11 then we provided that all to the Work Group.
- 12 There may have been one or two additional
- items, I can't remember.
- 14 And then we had the Work Group
- 15 meeting that was a few weeks ago. You can
- 16 take it from there or I can tell them what the
- 17 results were.
- 18 CHAIRMAN MELIUS: No, I'll go on
- 19 from there. I'll do that. But thank you,
- 20 LaVon. The Work Group met by conference call
- 21 a couple of weeks ago, and we discussed the
- 22 revised report and had a fairly -- about an

2	ourselves, about the report.
3	And, while I don't think that the
4	based on looking at the report and
5	reviewing the new information, the new
6	sampling data, exposure data, that I don't
7	think the Board has any or the Work Group,
8	excuse me, has any I think they basically
9	agree with NIOSH's recommendation that doses
10	cannot be reconstructed for those that worked
11	in that part of the GE facility.
12	I think there's still some
13	questions about the Class definition. Let me
L 4	just add that Jim Lockey also joined us for
15	that call, since he had expressed an interest
16	earlier and been involved in the Board
17	discussions on that.
18	So we agreed with the
19	Whoever is on the line, could you
20	please mute your phone, because we are hearing
21	your background conversations. If you don't
22	have a mute button, then do *6. Ted has

hour's discussion with NIOSH staff and among

1	taught	me.

- 2 And, okay, back on the track here.
- 3 So the issue is the Class definition, which
- 4 NIOSH was basically feeling that they did not
- 5 have adequate information to be able to
- 6 restrict that, so was recommending that
- 7 everybody that worked in the facility during
- 8 that time period should be included in the
- 9 Class.
- 10 I think the Work Group still had
- 11 some concerns about that, and recommended we
- 12 reached an agreement with NIOSH to go forward
- on some additional fact-finding.
- One is related. There was a list
- of, what appeared to be people that had worked
- 16 in the radiological operations at the
- facility, that was referenced in the report.
- 18 It may have been even two of them,
- 19 I can't recall. And we were trying to
- 20 understand that list and so forth. It
- 21 appeared to be something that was used for,
- 22 actually for a reunion or some sort of social

Τ	event involving those people.
2	But it was useful, it did have
3	names and addresses and so we were trying to
4	understand that, and particularly trying to
5	understand how that compared with people that
6	had applied for compensation and some of the
7	other information that had been gathered from
8	the interviews with people that had worked at
9	the facility.
10	We also wanted some follow-up
11	information on exactly how the buildings were
12	set up and what were the restrictions on
13	people going in.
14	Some of that information had been
15	collected so early, before the more recent
16	data and so forth had been collected, so there
17	was, we thought it would be useful to go on
18	and gather further information on that, so we

# We're hesitating here, for those on the line, because there's a siren blowing in the background.

better understood that information.

# **NEAL R. GROSS**

1	CHAIRMAN MELIUS: While Ted is
2	out, why don't we continue a little bit? So
3	we recommended that NIOSH go back and do
4	further work, report back to the Work Group on
5	that, and then the Work Group will probably
6	meet again by conference call.
7	And we may even be able to take
8	this up at our July conference call. You
9	know, again, depending on the information. I
10	don't know, Paul, Josie or Jim Lockey, do you
11	have anything to add to that?
12	MEMBER LOCKEY: No, I think you
13	have summarized it.
14	MEMBER ZIEMER: Dr. Melius, one
15	comment.
16	CHAIRMAN MELIUS: Yes, Paul.
17	MEMBER ZIEMER: Ziemer here. I
18	had raised an issue of how we might consider
19	having claimants self-identify their access to
20	the work area. There was some discussion in
21	the Work Group that maybe we could discuss
22	these ideas with Rachel in DOL. I don't know

1	if	that'	S	been	done	or	it's	the	proper	time	to
---	----	-------	---	------	------	----	------	-----	--------	------	----

- do that, or will that be done sort of offline?
- 3 CHAIRMAN MELIUS: Well, this may
- 4 be a time to at least raise it initially,
- 5 since Rachel is in the audience and may want
- 6 to comment. I don't know if NIOSH has spoken
- 7 to her about it.
- 8 I'm going to let her -- she's
- 9 actually at the microphone, Paul.
- 10 MS. LEITON: Yes, we had spoken a
- 11 little bit about this with NIOSH and I'm not
- 12 sure if I completely understand the idea --
- 13 MEMBER ZIEMER: Well, the idea is
- 14 this. The starting point right now is that
- 15 everyone who is on the GE site is a potential
- 16 claimant.
- MS. LEITON: Right.
- 18 MEMBER ZIEMER: So my idea was
- 19 that there are certainly people who worked on
- 20 that site, who know that they never were in
- 21 the buildings of question.
- So all you really, and there may

1	even	be	some	honest	people	who	worked	for	GE,
---	------	----	------	--------	--------	-----	--------	-----	-----

- 2 I'm going to concede that. And, if so, why
- 3 not ask claimants simply to provide an
- 4 affidavit that they had access to or that they
- 5 spent some time in the building in question?
- I mean, we know where the work was
- 7 done. The problem seems to be that we can't
- 8 tell who might or might not have gone into
- 9 those buildings.
- 10 Obviously, if a person isn't sure,
- 11 you give them the benefit of the doubt. But
- there are many people who will know that they
- never went in or near those buildings, and why
- include them as claimants?
- 15 It's not fair to others who have
- legitimate claims. So my idea was, not to put
- 17 the burden on NIOSH or on Department of Labor
- to place the people, but simply to ask them to
- 19 affirm that they had spent time in the
- 20 buildings in question.
- 21 MS. LEITON: Okay, let me just
- 22 summarize and make sure I'm understanding.

1 This is assuming that you made the	Class
--------------------------------------	-------

- 2 limited to certain buildings.
- 3 Then when DOL went to verify
- 4 employment, you're suggesting that we rely
- 5 solely on what the employee says as placing
- 6 them in the Class or not, assuming that those
- 7 who weren't in the buildings are going to tell
- 8 us they're not. Is that, am I getting that
- 9 right?
- 10 MEMBER ZIEMER: Yes, and in the
- 11 worst case, everybody lies to you and you're
- 12 no worse off than you would be if you assumed
- 13 everybody is in the cohort.
- I'm saying, I would bet you
- there's a good fraction of honest people who
- worked for GE, who aren't going to make claims
- if they knew they weren't in that area.
- 18 MS. LEITON: In our experience,
- 19 that's really just not the case.
- 20 Unfortunately, I mean, I know that there's
- 21 some honest people out there, but when the
- \$150,000 is on the line -- you know, we've got

1 a certain adjudication process which include
--

- 2 affidavits.
- 3 But when we just have one
- 4 affidavit from a person whose self-interest is
- 5 to say that they're in a building and that's
- 6 it, without any verification that they were
- 7 there -- it's just, it's not administrable.
- 8 It would cross all of our sites.
- 9 People would just -- they would say, well, I
- 10 said I was in the building at Rocky Flats, and
- I said I was in this building, why don't you
- just take my statement as well?
- We really need more solid
- 14 verification from Department of Energy
- 15 somewhere that these people worked in a
- 16 building.
- 17 So if you were to go and say,
- 18 these buildings --
- 19 MEMBER ZIEMER: So you don't accept
- 20 affidavits per se?
- MS. LEITON: We do accept them,
- 22 but we accept them in conjunction with other -

1 -	either	affidavits,	like	supervisory
-----	--------	-------------	------	-------------

- 2 documentation or some kind of evidence that
- 3 they were actually there.
- But a self-serving affidavit in
- 5 and of itself alone is not going to be
- 6 sufficient to meet the burden of proof, I'm
- 7 afraid.
- 8 MEMBER ZIEMER: Okay, I didn't
- 9 realize that. I have been given the
- 10 impression that affidavits were accepted per
- 11 se. But you need an independent verification.
- MS. LEITON: Yes, unfortunately,
- 13 just because --
- 14 MEMBER ZIEMER: I got it, I got
- 15 it.
- 16 MS. LEITON: -- it would cross our
- 17 entire program.
- 18 MEMBER ZIEMER: It was an idea
- 19 that I thought, it couldn't be any worse than
- 20 you would have to start with. There might
- 21 actually be people who, I mean -- well, I just
- 22 don't know that everybody would lie for

1	\$150,	000
_	$\gamma \perp \cup \cup_{I}$	000.

- MS. LEITON: Right, I understand
- 3 the concept.
- 4 CHAIRMAN MELIUS: What about, do
- 5 you accept coworker affidavits?
- 6 MS. LEITON: In some situations,
- 7 we would accept coworker affidavits. Usually,
- 8 it's more prominent if we have something from
- 9 a supervisor that, you know, that worked there
- 10 with them.
- We can accept that, it's just, it
- gets a little bit iffy when, you know, there's
- 13 a cohort of people and they all work there and
- 14 they all are going to say, hey, look, if you
- say you were there and I'll say you were there
- 16 -- it gets a little bit sketchy there.
- 17 And we have this issue only, you
- 18 know, if it were just this one facility and it
- 19 weren't going to be, it's just that it will
- 20 run throughout the entire program.
- 21 They'll start doing this
- 22 everywhere. And they'll say, if you did it at

1	GE, why didn't you do it everywhere else?
2	And that would just kind of the
3	credibility of what we're doing would be
4	diminished.
5	CHAIRMAN MELIUS: Okay.
6	MEMBER ZIEMER: Okay, well, thank
7	you.
8	MS. LEITON: Sorry, that's
9	probably not the answer you wanted to hear.
10	MEMBER ZIEMER: No, I was trying
11	to find a way to sort of make it more fair, in
12	terms of this particular site where we know
13	the work is restricted to a pretty small area.
L 4	And it's not like some of the
15	other sites, where you're going from one
16	building to another and there's nuclear work
L7	going on all over the place. This is very
18	much more restricted.
19	MS. LEITON: I understand that.
20	MEMBER ZIEMER: And we had a

similar case in Oak Ridge, except the site was

much smaller, so we kind of grit our teeth a

21

1	little	bit	and	went	with	it	that	way	with

- 2 covering everybody at the Oak Ridge Hospital.
- MS. LEITON: I understand.
- 4 CHAIRMAN MELIUS: Okay, thank you,
- 5 Rachel. Any other questions or comments from
- 6 Board Members on this? Yes, Bill.
- 7 MEMBER FIELD: Yes, I just had a
- 8 question. At one point, maybe half a year ago
- 9 or so there was discussion of documents being
- 10 in the UK. I guess that's not, there's
- 11 nothing at -- I just want to get some
- 12 clarification on that.
- MR. RUTHERFORD: Yes, we got a
- 14 follow-on, I can't remember exactly when, but
- 15 another follow-on that came back and said that
- they've searched like 50,000-something, large
- 17 number of stuff, and then there was no
- documents there. Or they provided everything.
- 19 CHAIRMAN MELIUS: Yes. We found
- 20 significant, or NIOSH found significantly more
- 21 documents, information on this. I think, as
- 22 LaVon said, it wasn't necessarily helpful in

1	terms	of	identifying	work	areas	or	people	for
---	-------	----	-------------	------	-------	----	--------	-----

- 2 dose reconstruction purposes.
- 3 But I think there was some, there
- 4 was cooperation. So it's not a question of
- 5 lack of cooperation, but rather that there
- 6 doesn't appear to be records and I'm not sure
- 7 if we ever quite understand the reasons for
- 8 that and so forth.
- 9 Or maybe they are yet to be
- 10 discovered somewhere. Any other questions?
- 11 So, if not, we will be reporting back to you,
- 12 possibly as early as the July meeting, if not
- 13 at the August meeting, on that.
- 14 That concludes this session. We
- need to reconvene at 4:45, since that's when
- we've scheduled the Weldon Spring update. That
- 17 will be relatively brief.
- Dr. Lemen is going to do that, so
- 19 I would suggest we break again until then.
- 20 And I would suggest that since there is a --
- 21 my understanding is there's a tornado warning
- 22 until 4:00, so people should probably not stay

1	in	the	room	but	rather	in	the	hallways	or

- 2 something, and certainly stay away from the
- 3 windows, which are over there behind the
- 4 curtains. Yes, an hour and 15 minutes. Or go
- 5 up to your rooms, but be careful in the
- 6 elevators.
- 7 (Whereupon, the above-entitled matter
- 8 went off the record at 3:33 p.m. and resumed
- 9 at 4:48 p.m.)
- 10 CHAIRMAN MELIUS: Okay, we'll
- 11 reconvene and our speaker disappeared. Let me
- 12 explain, we're doing a little change in
- 13 schedule here. Hopefully, this will be
- 14 helpful.
- 15 First we have an update, Richard
- 16 Lemen will give it on the Weldon Spring Work
- 17 Group and the review of the Weldon Spring SEC.
- 18 And then what we'll do is we have
- 19 a public comment period scheduled for 5:30.
- 20 We know there's some people here already, and
- 21 rather than hold you up and especially given
- 22 the weather and so forth, we will go right

- 2 speaks.
- 3 But we will certainly hold the
- 4 public comment period open through 5:30 and a
- 5 little bit after, for other people that may
- 6 want to be calling in.
- 7 Some have already indicated to us,
- 8 including one of the petitioners, that they
- 9 might call in a little bit later. And there
- 10 may be some other people, too.
- But hopefully that will facilitate
- those of you that need to get home tonight and
- 13 have a longer drive in this weather.
- 14 So, we'll start with Dr. Lemen.
- 15 Ted, do you want to check the line?
- MR. KATZ: Two things, yes. Let
- 17 me check the line, just to see. Do we have
- 18 Board Members on the line?
- 19 MEMBER ZIEMER: Yes, Paul Ziemer
- 20 on the line.
- 21 MR. KATZ: Great, Paul. Any other
- 22 Board Members?

1	(No response.)
2	MR. KATZ: I also just wanted to
3	announce for everyone in here who some
4	folks might be a little nervous about the
5	situation here.
6	The people in the hotel are
7	monitoring the weather, and if things start to
8	look truly dicey, they'll come and let us know
9	and there's a route out to a safer place.
10	Which would be, just to tell you about it so
11	you have it in your head anyway, is we go back
12	through the glass doors to the lobby and then
13	down out from the lobby into the parking
14	garage.
15	And we keep going down to the
16	bottom of the parking garage. But that's the
17	safest place to be if there is a tornado in
18	the area, and that's what we would do, just to
19	let you know.
20	But the hotel people are watching
21	and they will come and speak to us if it's
22	starting to look iffy.

1	MEMBER	BEACH:	Someone	to⊥d	Zaida

- 2 that it was downgraded from a warning to a
- 3 watch.
- 4 MR. KATZ: Understood, I heard
- 5 that, but who knows what will happen over the
- 6 next 45 minutes or an hour.
- 7 CHAIRMAN MELIUS: Just so everyone
- 8 knows that -- I don't want Wanda to worry.
- 9 MEMBER MUNN: Really?
- 10 CHAIRMAN MELIUS: Mike Gibson, who
- is the Chair of the Work Group, couldn't be
- here this week for the meeting, so Dr. Richard
- 13 Lemen, who is another Member of the Work Group
- and Member of the Board, will be giving us the
- 15 update. Dick.
- 16 MEMBER LEMEN: Thanks, Dr. Melius.
- 17 As Jim said, Mike Gibson is not here. I'm on
- 18 this Work Group, as is Robert Presley, and I'm
- 19 going to briefly go through the slides that
- 20 Mike had had prepared for today.
- 21 A brief review of the Weldon
- 22 Spring site, and I think you all have a

1	handout,	SO	Ι'm	not	going	to c	go th	ırough	each

- of these. You can read those. Does everyone
- 3 have a handout, is that right?
- 4 CHAIRMAN MELIUS: I believe so.
- 5 MEMBER LEMEN: Okay. As you can
- 6 see, the dates that are applicable in the
- 7 brief history here. This is, the site is west
- 8 of St. Louis and this is a diagram of the
- 9 site.
- This is a photo of the engineering
- 11 disposal cell, as it appeared in 2008. To
- 12 recap the Weldon Spring Site Profile and the
- 13 SEC activities, in June of 2005, NIOSH issued
- 14 their Site Report.
- And in March of 2009, SC&A issued
- 16 the Weldon Spring Site Profile Review. And in
- 17 September of 2009, the SEC-00143 was
- 18 qualified.
- 19 And then in April of 2010, NIOSH
- 20 issued an Evaluation Report, and the first
- 21 Working Group meeting was held on October of
- last year. The second meeting was January of

1	+ h - ' ~		2 22 2	+ h ~	+ b - 1 20 0	maa+ i na		0021102
<b>T</b>	UHIS	year,	and	LHE	LIIIIA	meeting	was	eartter

- 2 this month of this year.
- I'll give you the summary first,
- 4 and then I'll address each of these nine
- 5 items. But the summary of the SEC issues from
- 6 '57 to '67 are, one, accuracy and completeness
- 7 of the internal and external dose data,
- 8 including air and coworker data.
- 9 Secondly, the lack of egress
- 10 monitoring. Third, the lack of dose records
- 11 from 1967. Fourth, the no radon or thoron
- 12 measurements.
- 13 Five, validity of method used to
- 14 assess recycling uranium intakes. Six, lack
- of neutron dose data. Seven, lack of air
- 16 measurements at quarry and raffinate pits
- during 1957 through '67.
- 18 And, eight, impact of accidents --
- 19 incidents on dose reconstruction. And
- 20 finally, geometry and extremity monitoring.
- 21 There were 28 Site Profile issues
- 22 identified. Most of these Site Profile issues

1	have	been	incorporated	into	the	SEC	issues,	or
---	------	------	--------------	------	-----	-----	---------	----

- 2 have been addressed and/or are being
- 3 addressed.
- 4 As far as number one, that we just
- 5 went through the nine, the accuracy and
- 6 completeness of data. The accuracy of data:
- 7 the dose reconstructors use only photocopies
- 8 of the original Weldon Spring data sheets.
- 9 And electronic or CER databases
- 10 are not used for the dose reconstruction.
- 11 Completeness of the data is an issue, and
- 12 that's not yet been verified.
- 13 And presently, NIOSH is addressing
- 14 that. Second, the lack of egress monitoring,
- 15 sufficient bioassay data to reconstruct dose,
- if ingestion did occur, is being looked at.
- 17 Second, external exposure
- 18 addressed by monitoring and skin dose
- 19 calculations. And third, issue is presently
- 20 being closed because of these issues being
- 21 addressed.
- 22 Third, the lack of dose records

1	for 1967 has been an issue. And indications
2	are that 1967 may have been a transition year.
3	Operational period, external and
4	internal data sufficient to bound dose
5	incurred during 1967.
6	And the issue has presently been
7	closed because of that decision. The fourth,
8	no radon or thoron measurements. NIOSH
9	performed analysis of potential environmental
10	and/or radon and thoron intakes, and issued
11	response on April the 21st, 2011.
12	SC&A is presently reviewing
13	NIOSH's response and its SEC implications, and
L 4	we'll hear more about this as this progresses.
15	Fifthly, the validity and method used to
16	assign recycled uranium intakes, the method is
L7	presently being addressed to determine if
18	consistent and appropriate intakes are being
19	applied during dose reconstruction.
20	The sixth issue, the lack of
21	neutron dose data, there is, as you see, a

lack of that at Weldon Spring. The Fernald

1	neutron	dose	met.hod	can	be	used	as	surrogate,
_	110001	4000	1110 0110 01	0411	200	4504	۵.	

- 2 because of similar materials, according to the
- 3 NIOSH Evaluation.
- 4 SC&A and NIOSH are presently
- 5 evaluating Weldon Spring's neutron dose
- 6 assignment methodology to see if this really
- 7 will be effective.
- 8 Seventh, the lack of air
- 9 measurements at the quarry and raffinate pits
- 10 during 1957 to 1967. Measurements were
- 11 performed in the latter period and appear to
- 12 be acceptable to operational period, because
- 13 the quarry and pits not released to DOD and
- 14 conditions remained fairly constant.
- 15 The issue has presently been
- 16 closed and is not considered an issue any
- 17 longer.
- Number eight, the impact of
- 19 accidents or incidents on dose reconstruction.
- 20 Bioassay data is available for workers with
- 21 accidents and claims reviewed. The
- 22 accidents/incidents are factored into the dose

1 response process on an in	ndividual case-by-case
-----------------------------	------------------------

- 2 basis. NIOSH is to provide a statement to the
- 3 Working Group concerning claimant-favorability
- for using group bioassay monitoring. So we're
- 5 awaiting that information.
- And lastly, the geometry and
- 7 extremity monitoring, NIOSH is currently
- 8 evaluating methods used at other DOE uranium
- 9 sites for dosimetry, geometric and extremity
- 10 monitoring and the impact on recorded doses at
- 11 the Weldon Spring site.
- 12 So, in summary, the Weldon Spring
- 13 Working Group, NIOSH and SC&A have been
- 14 actively working on the SEC and Site Profile
- issues during the last year.
- We've had three meetings, as you
- 17 can see, starting in October of last year.
- 18 And then another in January and another in May
- 19 of this year.
- The progress has been made on each
- of the nine SEC issues, as you had seen in the
- 22 nine issues I just presented. And several

1	important	areas	are	yet	to	be	evaluated,	which

- 2 I pointed out among the nine areas.
- 3 So that's my presentation from the
- 4 Board Working Group. I don't know if SC&A or
- 5 NIOSH wants to make any comments at this time
- 6 or not.
- 7 CHAIRMAN MELIUS: Stu or anybody,
- 8 I'm not sure who is involved from -- Mark's
- 9 the lead, okay, I didn't know that. Okay,
- 10 Mark.
- MR. ROLFES: Thank you, Dr. Lemen.
- 12 I did have one additional update, since I've
- 13 come back into the office, we do have an
- 14 additional response ready for the Work Group.
- I should be able to send that
- 16 within the next couple of weeks. It is an
- 17 updated response on recycled uranium, so that
- 18 was one of the nine issues that had been
- 19 discussed previously.
- 20 And we do have a new White Paper
- 21 to deliver on that.
- 22 MEMBER LEMEN: We will be looking

1	forward	to	aet	that.

- 2 CHAIRMAN MELIUS: One of my
- 3 questions, and maybe while you're both up
- 4 there, is sort of, I didn't quite understand
- 5 the schedule on all of this, in terms of the
- 6 various reports and so forth.
- 7 MEMBER LEMEN: Well, we're hoping
- 8 that in our next Working Group Meeting, that
- 9 we'll have answers to all of these issues.
- 10 CHAIRMAN MELIUS: Okay.
- 11 MEMBER LEMEN: And that's what we
- 12 had decided. We haven't set a next date yet,
- but it will be in the next couple of months.
- 14 CHAIRMAN MELIUS: Okay.
- 15 MEMBER LEMEN: So we hope to have
- it completed in the next couple of months.
- 17 CHAIRMAN MELIUS: Okay.
- 18 MR. ROLFES: So I think we should
- 19 have some tentative information, at least, in
- 20 the next couple of months, certainly.
- 21 CHAIRMAN MELIUS: Okay, so this
- 22 would be potential closure of this --

1	MEMBER LEMEN: We're hoping by the
2	August meeting.
3	CHAIRMAN MELIUS: August meeting.
4	MEMBER LEMEN: We would have
5	something a little bit more finite for you.
6	CHAIRMAN MELIUS: Okay, good,
7	thanks. Joe, who is behind you?
8	MR. FITZGERALD: Actually, Ron
9	Buchanan is our lead on this Work Group, he
10	couldn't be here. But the one thing I would
11	add is that, at the Work Group we decided
12	that, from a data accuracy standpoint, what we
13	need to do is submit a sampling plan to the
14	Work Group, on how we would actually sample
15	for the accuracy of the database and that
16	sampling plan was developed and submitted to
17	the Work Group last week.
18	And we didn't hear any objections
19	and we're hoping NIOSH had a copy of that as
20	well. Okay, we need to make sure you have a
21	copy. And we're going to proceed with that
22	over the next three or four weeks.

1 $ exttt{MEMBER}$ LEMEN: I'm not sure t
--

- 2 Mike sent that on to NIOSH.
- 3 MR. FITZGERALD: Oh, okay. That
- 4 might be the issue.
- 5 MEMBER LEMEN: I'll check and find
- 6 out what's wrong.
- 7 MR. FITZGERALD: We'll make sure
- 8 that gets around so everybody has a copy.
- 9 MEMBER LEMEN: Can you go ahead
- 10 and send it to NIOSH?
- 11 MR. FITZGERALD: I'll go ahead and
- 12 make sure that --
- MR. KATZ: I think we have that,
- 14 so I think I have it too and we can
- 15 distribute. But I think it just came in last
- 16 week. We just got it, really.
- 17 MEMBER LEMEN: It's very new.
- 18 MR. KATZ: Yes, so, I think we
- 19 probably need a little -- the Work Group
- 20 Members need a little bit of time to look at
- 21 it and make sure that they're --
- MR. FITZGERALD: Well, particularly

1	at	this	meeting,	I	just	want	to	make	sure
---	----	------	----------	---	------	------	----	------	------

- 2 everyone is aware that that is in, it's being
- 3 looked at.
- 4 MR. KATZ: Right, give them a
- 5 chance to give a thumbs up before you proceed.
- 6 MR. FITZGERALD: Again, the only
- 7 thing that we'll be doing from our standpoint,
- 8 is that sampling.
- 9 MEMBER LEMEN: Again, I think
- we'll have most everything we need to address
- 11 this in much more detail with some finality in
- 12 August.
- 13 CHAIRMAN MELIUS: Okay, very good.
- Board Members have questions for Dr. Lemen?
- 15 (No response.)
- 16 MEMBER LEMEN: Good, I don't have
- 17 any good answers.
- 18 (Laughter.)
- 19 CHAIRMAN MELIUS: Board Members on
- 20 the phone, any -- Paul, do you have any?
- 21 MEMBER ZIEMER: No questions.
- 22 CHAIRMAN MELIUS: Okay, thank you.

1	MEMBER LEMEN: Thank you, Paul.
2	CHAIRMAN MELIUS: For those of you
3	that live here locally, Dr. Lemen happens to
4	be from Missouri, you may have detected in his
5	accent from California, Missouri, I believe.
6	South California, is that right?
7	MEMBER LEMEN: Yes.
8	CHAIRMAN MELIUS: He's going to
9	his high school reunion. Tenth, right?
10	(Laughter.)
11	CHAIRMAN MELIUS: This weekend.
12	We all wish, right? Why don't we go into
13	at least start the public comment period.
14	Ted, do you want to
15	MR. KATZ: Yes, let me just
16	explain some ground rules for public comments.
17	As you may or may not have noted, because I
18	think some people here have just joined us
19	recently this afternoon.
20	All of the proceedings of the
21	Board are fully transcribed verbatim. So
22	whatever you might say in your public comments

1	will	be	captured	and	will	end	up	in	а

- 2 transcript of the Board that will be on the
- 3 public website available to everybody.
- 4 Everything you say, everything you
- 5 say personally about yourself will be
- 6 included. If you include personal details
- 7 about other individuals, however, we'll redact
- 8 that information to the extent that it
- 9 protects the privacy of whoever you might
- 10 speak about.
- 11 So, though it will all be heard
- 12 here, when the transcript is published, we
- 13 would leave out whatever details would
- 14 identify those other individuals you might
- 15 speak about.
- 16 And if you want to see the full
- 17 rules about this Redaction Policy, as it's
- 18 called, it's on the website. It's also out on
- 19 the table with the other papers.
- 20 But it's on our NIOSH website
- 21 under the Board section of the NIOSH OCAS --
- or I think it's still called OCAS -- web page.

1	$\bigcap k \supseteq m$	that!c	i +	thanks.
Τ.	Oray,	chat s	⊥ ∪ <b>,</b>	chanks.

- 2 CHAIRMAN MELIUS: Anybody, any of
- 3 the petitioners here that would like to make
- 4 comments? Okay. Would you mind stepping to
- 5 the mic and, again, don't be intimidated by
- 6 the big group, okay? We're actually very
- 7 friendly.
- 8 MS. TRIPLETT: My name is Tina
- 9 Triplett. I'm one of the co-petitioners for
- 10 the Weldon Spring plant and I basically just
- 11 have a statement that I'd like to read.
- 12 CHAIRMAN MELIUS: Okay, go ahead,
- 13 Tina.
- 14 MS. TRIPLETT: The original intent
- of this Act was to compensate sick and dying
- 16 nuclear workers for their sacrifices to this
- 17 country in a timely and fair manner.
- I had faith in this compensation
- 19 program when it was first implemented. But
- 20 the frustration that continues to escalate
- 21 from the lack of progress is overwhelming.
- There appears to be no sense of

2	families. It appears at times those
3	administering the program lose focus and often
4	forget that there are claimant survivors and
5	petitioners desperately waiting of answers
6	that they deserve. The burden of proof placed
7	on these individuals seeking compensation is
8	insurmountable and there's a lack of full
9	disclosure with Freedom of Information Act
10	requests.
11	This whole process is a vicious
12	circle, and while administering agencies are
13	battling out their differences, people are
14	dying. Thank you.
15	I fully understand that there is a
16	process and I appreciate all the hard work by
17	everyone. But there comes a time when a
18	decision has to be made.
19	This program does not have to
20	generate years of discussions to declare work
21	sites Special Exposure Cohorts. There has to
22	be accountability to getting issues addressed

urgency to pay these workers and their

_			~ ~ ' ' '	
1	ın	an	efficient	manner.

- 2 The concern about Walden Spring
- 3 hard copy records versus the CER database is
- 4 troubling. NIOSH has been unable to either
- 5 produce Walden Spring plant hard copy records
- 6 or produce validations for these records
- 7 within the CER database.
- 8 Many Weldon Spring plant records
- 9 have also been destroyed and have never been
- 10 located. As previously noted, Walden Spring
- 11 plant records from the shelf list V2161 has
- 12 never been found, because they were already
- 13 beyond the destruction date.
- 14 Furthermore, in a letter from
- 15 Belcher, Area Manager, to Roth, the Director
- 16 of Research and Developmental Division and
- 17 reference to Mallinckrodt Chemical Works
- 18 Health Protection Records from November 2nd,
- 19 1966, it was noted, quote, "in addition to the
- 20 types of records proposed in a recent letter
- 21 to Mallinckrodt Chemical Works for transfer to
- 22 Oak Ridge, the following records deserve

1	ultimate	disposal	consideration:

- 2 Medical X-ray files, film used in
- 3 dosimetry, in-plant sampling records, and
- 4 environmental sampling records," unquote.
- 5 There is no complete list of records available
- 6 for the Weldon Spring plant which leads to
- 7 huge data gaps.
- 8 And, as a result, NIOSH makes
- 9 assumptions and lacks the ability to perform
- 10 dose reconstructions with sufficient accuracy
- 11 and plausibility.
- 12 In addition to the concern of hard
- 13 copy validation, I'd like to address the memo
- 14 from Mallinckrodt's own Health and Safety
- 15 Manager, Mont Mason.
- 16 This has yet to have been
- 17 addressed. In Mason's memo, uranium and urine
- 18 report from August 1975, Mason addressed the
- 19 following:
- Number one, uranium and urine is
- 21 not an indicator of body burden and no
- 22 relationship of fixed internal deposition on

		_
1	radiation	2000
	laulation	uuse.

- 2 Numbers were controlled numbers to
- 3 take action for exposure to dust. Number two,
- 4 Mason never claimed a correlation between the
- 5 urine uranium values as a finite burden of
- 6 uranium. The title of uranium and urine on
- 7 Weldon Spring printouts as, quote, "internal
- 8 exposure," unquote, was incorrect and grossly
- 9 misleading.
- 10 Uranium and urine simply means a
- 11 milligram per liter of uranium in a spot urine
- 12 sample. Number three, there were omissions in
- the uranium and urine data on tape at CTC.
- Number four, the reading of .000
- 15 used as a "no record of exposure" is
- 16 incorrect, because it leaves the impression
- 17 that tests were made with zero results. But,
- in many cases, there were no tests made.
- 19 Number five, there was a problem
- 20 matching name information from records to
- 21 Social Security Numbers in CTC master file,
- 22 800 no match Social Security Numbers and 300

1	no	match	alphas.

- Number six, some employees'
- 3 medical jackets have been removed or lost.
- 4 And, number seven, data after shutdown has
- 5 been copied, keypunched and taped, but the
- 6 test for data shows that no match between tape
- 7 totals and totals Mason could reconstruct.
- Furthermore, a report issued to
- 9 the Advisory Board in April of 2005, with
- 10 respect to the previous Mallinckrodt
- 11 petitions, and please let us not forget that
- 12 this is Mallinckrodt, Weldon Spring plant,
- showed that the use of daily weighted averages
- is not claimant-favorable.
- 15 SC&A has already addressed that
- 16 the use of DWA cannot establish bounding
- 17 doses. Also, during the previous Mallinckrodt
- 18 petitions, Mont Mason revealed liability
- 19 concerns with data integrity for dose
- 20 reconstruction.
- In a memo dated October of '73 to
- 22 Dr. Thomas Mancuso, Mason reported significant

1 liability concern, which affected	how
-------------------------------------	-----

- 2 Mallinckrodt recorded its data on dust
- 3 studies.
- 4 A dust evaluation from 1949
- 5 resulted in the removal of 34 employees.
- 6 Mason stated in light of growing awareness and
- 7 presence of radioactive materials, carefully
- 8 drafted explanations and responses were
- 9 prepared in advance of announcing the transfer
- 10 of people.
- 11 Managers, supervisors and medical
- 12 staff and the Health Department were all
- 13 coached and coordinated. As prior caution and
- 14 upon the advice of an attorney, a formal
- 15 report was never prepared on the study.
- The company's own Health and
- 17 Safety Director cast serious doubts on the
- 18 reliability of Mallinckrodt's dust study.
- 19 This undermines the very basis for
- 20 the use of Mallinckrodt records in dose
- 21 reconstruction.
- 22 Another concern at the Weldon

1	Spring	plant	was	the	production	or	extraction
---	--------	-------	-----	-----	------------	----	------------

- of thorium during the operational period and
- 3 the lack of the appropriate monitoring.
- 4 In a review of Mallinckrodt
- 5 Chemical Works from 1965, it was stated that
- 6 the conventional bioassay techniques were not
- 7 adequate for monitoring potential thorium
- 8 exposures as a result from current
- 9 Mallinckrodt production operations.
- 10 Thorium pot denitration operations
- 11 were observed to be poorly contained and
- 12 visibly dusty. Particularly was thus noted
- 13 during a hand scooping transfer procedure,
- which was being done outside the hood.
- 15 Air movement in the vicinity was
- 16 vigorously adverse to contamination control,
- due to a partially open outside door.
- 18 Area Manager Belcher also stated
- 19 that thorium exposures were more than realized
- 20 at the Weldon Spring plant. Records also
- 21 indicate that thorium was extracted from the
- 22 raffinates during the operational period.

1	In an ORAU memo from September 16,
2	1991, a floor plant study classification of
3	radium, radon and thorium exposure indicated
4	that in 1955, Mallinckrodt was asked by the
5	AEC to extract thorium from raffinate residues
6	on a production basis.
7	During this period, health hazards
8	of thorium exposure were unknown. Hard copy
9	records document Mallinckrodt's futile efforts
10	to seek help from the AEC and government-
11	contracted laboratories for guidance on health
12	hazards for setting the permissible body
13	burden and concentrations in urine and air.
14	This sparked the AEC to begin
15	animal experiments to determine thorium
16	biological hazards.
17	Los Alamos agreed biological
18	effect of thorium should be treated
19	approximately equal to plutonium on a curie
20	basis.
21	This pilot plant work continued
22	until the shutdown of the duster site in 1958.

1	And	from	1958	to	1966,	the	process	was
---	-----	------	------	----	-------	-----	---------	-----

- 2 continued on a large-scale production basis at
- 3 the Weldon Spring plant.
- And, to the best of my knowledge
- 5 and research, NIOSH has lacked the ability to
- 6 reconstruct doses for internal thorium, and as
- 7 a result, Special Exposure Cohorts have been
- 8 granted.
- 9 There's no sufficient personnel
- 10 and work place monitoring for thorium at the
- 11 Weldon Spring plant. As a petitioner for the
- 12 plant, I am beyond discouraged in the SEC
- 13 process in the lack of communication and
- 14 progression in granting cohorts. Weldon
- 15 Spring plant workers and claimants are in
- 16 desperate need of an expedited resolution.
- 17 Thank you.
- 18 CHAIRMAN MELIUS: Thank you. Does
- 19 anybody else wish to speak? Anybody else in
- 20 the audience? Excuse me, who --
- 21 MS. JOHNSON: This is Mary
- Johnson, I would like to speak.

1	CHAIRMAN MELIUS: Okay, yes,
2	you're one of the okay, go ahead. I just
3	want to make sure the petitioners could speak
4	first.
5	MS. JOHNSON: Okay, do you want me
6	to wait?
7	CHAIRMAN MELIUS: NO, no, you can
8	go ahead. You can go ahead, I'm sorry.
9	MS. JOHNSON: Okay, first I wanted
10	to thank you for allowing me to speak today.
11	And before I begin, I would like to tell the
12	Advisory Board and NIOSH and SC&A that I have
13	the utmost respect and admiration for the
14	expertise and knowledge they bring.
15	And so the comments I make, I
16	would like to not be taken personally, because
17	my frustration is really about the
18	administrators of this program.
19	I hope today to be a voice for the
20	claimants and the workers and the survivors of
21	the workers at the Mallinckrodt Weldon Spring
22	site.

1	I've read the dose reconstruction
2	on my claim. I've read the Site Profile,
3	NIOSH's evaluation, the SC&A reviews and
4	responses, and I have listened to all of our
5	Work Group meetings.
6	Additionally I, along with my
7	daughter, [identifying information redacted],
8	and Tina Triplett, who are both petitioners
9	for the SEC on the Weldon Spring site, have
10	exhaustively searched through documents at
11	local libraries, Weldon Spring Interpretative
12	Center, K: drives, private archives, online
13	databases, employment records and various
14	other sources.
15	Our searches and FOIA requests
16	have produced virtually nothing regarding the
17	Weldon Spring site. Never has anyone searched
18	so thoroughly and obtained so little.
19	Instead, the most valuable
20	information we seem to have obtained through
21	the last ten years is through the sharing of
22	stories and facts from the workers themselves,

1	much	of	which i	NOW	is	pas	sed	on	by	their	-
2	survi	vors	because	SO	many	of	them	have	e di	ied.	

- But these workers' experiences
- 4 don't seem to quite fit into the models used
- 5 for dose reconstruction.
- Therefore, to me, the one glaring
- 7 absence in all of the science behind our
- 8 claims is the human element. The amount of
- 9 research and science in processing our claims
- 10 and the SEC petition, to me are overwhelming
- and mind-boggling to the average claimant.
- 12 It's as if our SEC is on trial,
- 13 but we have no representation. I do not
- believe in my heart that the Act of 2000 asks
- 15 for this kind of seemingly obsessive
- 16 scrutiny.
- Executive Order 13179, which was
- 18 signed by President Bill Clinton on December
- 19 the 7th, 2000, also supports fair and timely
- 20 compensation for these workers and their
- 21 survivors, and states that we should ensure
- 22 the program minimizes the administrative

burden on the workers and their survivors,	an	10
--	----	----

- 2 respects their dignity and privacy. It also
- 3 states that all pertinent and available
- 4 information for evaluating and processing
- 5 claims be shared and provided to claimants.
- 6 Believe me when I say there is
- 7 nothing, nothing timely about this program.
- 8 We are burdened and there is no dignity in
- 9 being made to beg for a pittance that will
- 10 never give back the hell that these workers or
- 11 their loved ones -- who have died.
- I urge you to remember that this
- 13 is a compensation program first, not a
- 14 research project. We're here in this
- 15 situation today because the government and
- scientists, in their quest for an atomic bomb,
- 17 forgot the human element and we are locked
- 18 here in this compensation program because of
- 19 research for answers which cannot always be
- 20 clear.
- 21 And, once again, it seems the
- 22 human element is becoming forgotten. Please

1	step	back	and	remember	the	human	elements,

- 2 these workers and their survivors who have
- 3 already waited far too long.
- 4 You know, I have attended some of
- 5 these public meetings and ceremonies that
- 6 we've had, and it's been mentioned in several
- 7 instances what brave men and women these
- 8 workers were and how they were heroes.
- 9 Maybe, but not in the usual
- 10 manner. These men and women, many very young
- 11 -- my husband was 18 -- didn't know what they
- were walking into, nor what the cost to them
- 13 would be. Nor were they told or given the
- 14 option, based on the information, of whether
- they wanted to work there or not. They didn't
- 16 know they were walking into years of great
- 17 health problems or even an early death.
- They didn't know the harm they may
- 19 have carried home to their loved ones. No
- one, no one, wants to be that kind of hero.
- You may remember, [identifying
- information redacted], she was a claimant from

1	Weldon Spring site and [identifying
2	information redacted]addressed the Board in
3	years past, once in St. Louis and again in
4	Chicago. And [identifying information
5	redacted]suffered several years from very
6	primary cancers. Two of them were quite rare.
7	[Identifying information redacted]
8	was denied, after each one of these cancers
9	were diagnosed, she was denied her claim time
10	and time again. [identifying information
11	redacted] died August the 27th, 2010. And we
12	promised [identifying information redacted]we
13	would continue pushing for this compensation,
14	and we will.
15	We need an answer. We need an
16	answer now so we can determine in which
17	direction we need to proceed. Thanks for
18	allowing me to speak.
19	CHAIRMAN MELIUS: Okay, thank you.
20	Is there anybody else in the audience that
21	would like to provide public comments?

(No response.)

1	CHAIRMAN MELIUS: Is there anybody
2	on the phone that would like to provide public
3	comments?
4	(No response.)
5	CHAIRMAN MELIUS: Okay, I guess
6	what we'll do then is we will wait until 5:30
7	and then we will continue the public comment
8	period, that's the scheduled time. So why
9	don't we break until the next ten or 15
10	minutes? Thanks.
11	(Whereupon, the above-entitled matter
12	went off the record at 5:19 p.m. and resumed
13	at 5:32 p.m.)
14	CHAIRMAN MELIUS: If we could get
15	seated we should get started again, we do have
16	some people on the line. Excuse me, Denise,
17	could we get seated, it's 5:30, we need to get
18	started again.
19	This is the Advisory Board on
20	Radiation and Work Health with a thunderstorm
21	in the background, which you may hear on the
22	microphones, and public comment period. And,

1	Ted,	do	you	want	to	give	the	introduction?
---	------	----	-----	------	----	------	-----	---------------

- MR. KATZ: Yes, good afternoon,
- 3 for folks on the phone, I don't think we have
- 4 new folks here in the room, but we've had a
- 5 few comments already.
- And we're ready for you on the
- 7 line. Just to let you all know that your
- 8 comments are being transcribed verbatim and
- 9 they will appear in the transcript to this
- 10 Board Meeting, which will be published on the
- 11 NIOSH website for this program for all the
- 12 public to see.
- So everything you say personally
- 14 about yourself will be captured in the
- 15 transcript. However, just to let you know,
- 16 anything you might say about a third party,
- another person, what you say would be redacted
- or edited to protect the privacy of that other
- 19 person.
- 20 And if you're interested in seeing
- 21 the full details of this Redaction Policy,
- they are on the NIOSH website under the Board

- 1 section of the NIOSH website.
- 2 Under "meetings," you'll see
- 3 "Redaction Policy." That's what I'm speaking
- 4 to here.
- 5 CHAIRMAN MELIUS: Okay, thanks,
- 6 Ted. Is there anybody on the line, phone
- 7 line, that would like to make public comments?
- 8 MR. FESTER: Yes, I would.
- 9 CHAIRMAN MELIUS: Can you please
- 10 identify yourself?
- 11 MR. FESTER: Yes. My name is
- 12 Thomas Fester, F-e-s-t-e-r, from Cincinnati,
- 13 Ohio.
- 14 CHAIRMAN MELIUS: Okay, thank you,
- 15 go ahead, Mr. Fester.
- 16 MR. FESTER: I worked at the GE
- facility during the case period, 1961 to 1970.
- 18 I retired and developed bone cancer and, the
- 19 bottom line is, they had to amputate my right
- 20 leg. And of course Christ Hospital decided --
- 21 they wrote letters it was radiation that
- 22 caused it.

2	this off the paper, but I didn't write it. My
3	points are, real quick, at GE, security was
4	actually the main item, not radiation
5	monitoring or any special precautions, no
6	dosimeters, no warnings.
7	I listened to a meeting that you
8	had on the GE facility and it seemed like the
9	main concern was the number of claims, not
10	anything else.
11	And I was really perturbed about
12	that. But my point is there's only, from what
13	I understand, there's only like 150 claims and
14	even that, half of them are not even going to
15	qualify for 21 cancers.
16	But what I wanted to get at was,
17	like I said, your main concern would seem like
18	the amount of claims and that shouldn't be
19	it.
20	There's a lot of inconsistency in
21	your stuff, from what I understand. I read in
22	the paper and on the internet speaking of the
	NEW P. ADAGA

It might sound like I'm reading

1

1	inconsistency.	. For	instance	, Bethlehem	Steel

- they had enough for a dose reconstruction but
- 3 they didn't, they put in a petition for a SEC
- 4 and it went right on through. Now this is
- 5 like the fourth time for GE and we ain't got
- 6 enough time.
- 7 And I'm sure that NIOSH has done
- 8 extensive research on this facility and highly
- 9 recommends this for an SEC. They cannot find
- 10 answers to very big questions, and it seems
- like a lot of hem-haw going around. My point
- is, next week, next month, you talked about
- 13 August, September, next year, will not solve
- 14 anything.
- 15 Without -- I don't know, I've
- 16 never heard of any kind of a plan of action.
- 17 I don't know if you have one or anything. My
- 18 last comment was, I wish you guys would
- 19 reconsider and make this an SEC facility, for
- 20 those who -- only for the those who qualify.
- There's a lot of people out there,
- 22 a lot of widows who lost -- right at the time

1	when	you	retire,	they	lost	their	husbands,	men
---	------	-----	---------	------	------	-------	-----------	-----

- 2 have lost their wives, their kids -- it's
- 3 always at a critical time and it can't be, the
- 4 number of claims shouldn't really have
- 5 anything to do with it.
- 6 My point is, I don't see, I didn't
- 7 hear anything about a plan of action. So
- 8 postponing it just seems very ridiculous.
- 9 That's all I wanted to say. I very appreciate
- 10 the time.
- 11 CHAIRMAN MELIUS: Thank you.
- 12 There is a plan of action. It may not have
- been spoken about in detail here, or you might
- 14 have not been on the phone at the time we
- 15 talked about it.
- But there is a plan of action, and
- as we've said, we expect it to be completed in
- 18 the next month or two.
- 19 MR. FESTER: Well, I hope my
- letter goes to heart and I appreciate the time
- 21 to speak to you. Because we don't have a lot
- 22 of time left.

1	I'm in my 70s and when you lose
2	your leg soon as you retire, I'm sure that if
3	it hit home to some of you people, you might
4	speed up the qualification a little bit, but
5	thank you very much for your time.
6	CHAIRMAN MELIUS: Okay, thank you.
7	Anyone else on the phone?
8	MS. DAVIES: Yes, my name is Lois
9	Davies. My father and I both worked at the
10	General Electric Company at Evendale, in
11	Cincinnati, Ohio.
12	We were both in the case period.
13	My dad was a stationary engineer from the day
14	General Electric opened. He took care of all
15	the heating and air conditioning for all the
16	buildings in Evendale and entered every
17	building numerous times, because of his job,
18	over the years.
19	And I was a secretary for 13 years
20	at General Electric Company, and never I
21	agree with the gentleman that just talked,
22	that there was never, ever, never, never,

1	anything	mentioned	about	toxic	waste,	any	kind
---	----------	-----------	-------	-------	--------	-----	------

- of danger to your health.
- 3 The only concern at that time was
- 4 the security, the secret security, which I
- 5 know was necessary, but because of the secret
- 6 documents and things, there were many times
- 7 that I would have to walk to numerous
- 8 buildings to deliver a document.
- 9 And I also worked in numerous
- 10 buildings because of different promotions,
- 11 which I know you mentioned, about depending on
- 12 what buildings you worked in.
- 13 And all this information was given
- 14 to them when I first submitted the
- 15 information. But there was never, never
- 16 mentioned anything about danger working in the
- 17 buildings.
- I've had breast cancer and I've
- 19 taken chemo and radiation. I now have
- 20 congestive heart failure, because of the
- 21 chemo, because of the cancer. And my dad died
- 22 of multiple myeloma.

1	This has really been a nightmare.
2	And, like I said, I've sent all the
3	information that is necessary and it's just
4	very upsetting that this has not been resolved
5	and it just seems like there's just too many
6	delays. And I do appreciate the time, thank
7	you.
8	CHAIRMAN MELIUS: Thank you. Is
9	there anyone else on the phone who would like
10	to make public comments?
11	MS. ANDERSON: Yes, this is Lois
12	Anderson. I am a widow of Ronald Anderson, he
13	worked at General Electric for 30 years until
14	he retired.

- And in June, six years ago, we
  were at a meeting in Tri-County, I think that
  was the area. But anyway, he filled out the
  claim forms and they were sent to Cleveland.
- He's gone now five years and they
  keep delaying it and delaying it and delaying
  it. My kids seem to think that this is a big
  joke, that you're all just waiting for me to

_	
7	die.
_	UTE:

- So, I agree with Lois and Mr.
- 3 Fester and I'd really appreciate if you would
- 4 get some answers on this, because I think
- 5 NIOSH has done everything they can possibly
- 6 do.
- 7 And I thank you for the time and
- 8 listening to me.
- 9 CHAIRMAN MELIUS: Thank you.
- 10 Anybody else on the phone that wishes to make
- 11 public comments?
- 12 (No response.)
- 13 CHAIRMAN MELIUS: Okay, one more
- 14 time, anybody else that wishes to make public
- 15 comments?
- 16 (No response.)
- 17 CHAIRMAN MELIUS: Okay, if not,
- 18 that then closes the public comment session
- 19 and the Board will reconvene tomorrow at 8:15
- 20 -- roughly 8:15 to 8:30 with the schedule.
- 21 And we believe Doug Daniels will
- be here, the speaker for tomorrow, and we'll

1	go from there.
2	MS. ANDERSON: Is that on the GE
3	again at 8:15 in the morning?
4	CHAIRMAN MELIUS: No, no, we'll be
5	speaking about some more general issues.
6	They'll be no further discussion of GE at this
7	meeting.
8	MS. ANDERSON: All right, thank
9	you.
10	CHAIRMAN MELIUS: Thank you.
11	(Whereupon, the above-entitled
12	matter went off the record at 5:41 p.m.)
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	

1

2